<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "JATS-journalpublishing1.dtd">
<article article-type="review-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">Neuroanatomy and Behaviour</journal-id>
      <journal-id journal-id-type="doi">10.35430/nab</journal-id>
      <journal-title-group>
        <journal-title>Neuroanatomy and Behaviour</journal-title>
        <abbrev-journal-title abbrev-type="publisher">NAB</abbrev-journal-title>
      </journal-title-group>
      <issn publication-format="electronic">2652-1768</issn>
      <publisher>
        <publisher-name>Episteme Health Inc.</publisher-name>
        <publisher-loc>
          <city>Melbourne</city>
          <state>Victoria</state>
          <country>Australia</country>
        </publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.35430/nab.2020.e10</article-id>
      <article-version article-version-type="VoR" vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="version-of-record">Version of Record</article-version>
      <article-categories>
        <subj-group subj-group-type="display-channel">
          <subject>Review</subject>
        </subj-group>
        <subj-group>
          <subject>Biological Sciences</subject>
          <subject>Neurosciences</subject>
          <subject>Pharmacology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Schizophrenia and drug addiction comorbidity: recent advances in our understanding of behavioural susceptibility and neural mechanisms</article-title>
      </title-group>
      <contrib-group content-type="author">
        <contrib contrib-type="author" equal-contrib="no" corresp="no" deceased="no">
          <name>
            <surname>Menne</surname>
            <given-names>Victoria</given-names>
          </name>
          <xref ref-type="aff" rid="affiliation-3fc6d260b7cd85a09e62848e119a9a00" />
          <xref ref-type="aff" rid="affiliation-6a0f83b11f8e930612860f2b9275c781" />
        </contrib>
        <contrib contrib-type="author" equal-contrib="no" corresp="yes" deceased="no">
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3758-9598</contrib-id>
          <name>
            <surname>Chesworth</surname>
            <given-names>Rose</given-names>
          </name>
          <xref ref-type="aff" rid="affiliation-6a0f83b11f8e930612860f2b9275c781" />
          <xref ref-type="corresp" rid="cor1">*</xref>
          <xref ref-type="award" rid="funder-2c643faf06a15401d05cf163d20456d5" />
          <xref ref-type="award" rid="funder-47b526a8e209a4377958152890eb0416" />
          <xref ref-type="award" rid="funder-ea3708e258042b915900c0f180ab301e" />
          <xref ref-type="award" rid="funder-337452df59607f6fa57b590c504717a6" />
        </contrib>
      </contrib-group>
      <aff id="affiliation-3fc6d260b7cd85a09e62848e119a9a00">
        <institution-wrap>
          <institution-id institution-id-type="ISNI">0000 0001 0481 6099</institution-id>
          <institution>Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands</institution>
        </institution-wrap>
      </aff>
      <aff id="affiliation-6a0f83b11f8e930612860f2b9275c781">
        <institution-wrap>
          <institution-id institution-id-type="ISNI">0000 0001 0746 8405</institution-id>
          <institution>School of Medicine, Western Sydney University, Campbelltown, NSW, Australia</institution>
        </institution-wrap>
      </aff>
      <author-notes>
        <corresp id="cor1">* <email>r.chesworth@westernsydney.edu.au</email></corresp>
      </author-notes>
      <pub-date date-type="pub" iso-8601-date="2020-01-16">
        <day>16</day>
        <month>01</month>
        <year>2020</year>
      </pub-date>
      <volume>2</volume>
      <elocation-id>e10</elocation-id>
      <history>
        <date date-type="accepted" iso-8601-date="2020-01-08">
          <day>08</day>
          <month>01</month>
          <year>2020</year>
        </date>
        <date date-type="received" iso-8601-date="2019-11-05">
          <day>05</day>
          <month>11</month>
          <year>2019</year>
        </date>
        <date date-type="rev-recd" iso-8601-date="2019-12-22">
          <day>22</day>
          <month>12</month>
          <year>2019</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright Â© 2020 Victoria Menne, Rose Chesworth</copyright-statement>
        <copyright-year>2020</copyright-year>
        <copyright-holder>Victoria Menne, Rose Chesworth</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>Except where otherwise noted, the content of this article is licensed under Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Schizophrenia is a severe psychiatric disorder which is worsened substantially by substance abuse/addiction. Substance abuse affects nearly 50% of individuals with schizophrenia, extends across several drug classes (e.g. nicotine, cannabinoids, ethanol, psychostimulants) and worsens overall functioning of patients. Prominent theories explaining schizophrenia and addiction comorbidity include the <italic>primary addiction hypothesis</italic> (i.e. schizophrenia susceptibility primes drug reward circuits, increasing drug addiction risk following drug exposure), the <italic>two-hit hypothesis</italic> (i.e. drug abuse and other genetic and/or environmental risk factors contribute to schizophrenia development) and the <italic>self-medication hypothesis</italic> (i.e. drug use alleviates schizophrenia symptoms). Animal models can be used to evaluate the utility and validity of these theories. Since this literature was last reviewed by Ng and colleagues in 2013 [<italic>Neurosci Biobehav Rev</italic>, <italic>37</italic>(5)], significant advances have been made to our understanding of schizophrenia and substance abuse comorbidity. Here we review advances in the field since 2013, focussing on two key questions: 1) Does schizophrenia susceptibility increase susceptibility to drug addiction (assessing the primary addiction hypothesis), and 2) Do abused drugs exacerbate or ameliorate schizophrenia symptoms (assessing the two-hit hypothesis and the self-medication hypothesis). We addressed these questions using data from several schizophrenia preclinical models (e.g. genetic, lesion, neurodevelopmental, pharmacological) across drug classes (e.g. nicotine, cannabinoids, ethanol, psychostimulants). We conclude that addiction-like behaviour is present in several preclinical schizophrenia models, and drugs of abuse can exacerbate but also ameliorate schizophrenia-relevant behaviours. These behavioural changes are associated with altered receptor system function (e.g. dopaminergic, glutamatergic, GABAergic) critically implicated in schizophrenia and addiction pathology. </p>
      </abstract>
      <kwd-group>
        <kwd>Schizophrenia</kwd>
        <kwd>Drug Addiction</kwd>
        <kwd>Drug Abuse</kwd>
        <kwd>Rodent Model</kwd>
        <kwd>Behaviour</kwd>
        <kwd>Molecular</kwd>
      </kwd-group>
      <funding-group>
        <award-group id="funder-2c643faf06a15401d05cf163d20456d5">
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">10.13039/501100001776</institution-id>
              <institution>Western Sydney University</institution>
            </institution-wrap>
          </funding-source>
          <award-id>Molecular Medicine Research Group Seed Funding 2017</award-id>
        </award-group>
        <award-group id="funder-47b526a8e209a4377958152890eb0416">
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">10.13039/501100001776</institution-id>
              <institution>Western Sydney University</institution>
            </institution-wrap>
          </funding-source>
          <award-id>Molecular Medicine Research Group Seed Funding 2018</award-id>
        </award-group>
        <award-group id="funder-ea3708e258042b915900c0f180ab301e">
          <funding-source>
            <institution-wrap>
              <institution>Ainsworth Medical Research Innovation Fund</institution>
            </institution-wrap>
          </funding-source>
        </award-group>
        <award-group id="funder-337452df59607f6fa57b590c504717a6">
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">10.13039/501100001061</institution-id>
              <institution>Rebecca Cooper Medical Research Foundation</institution>
            </institution-wrap>
          </funding-source>
        </award-group>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>1. Introduction</title>
      <p>Schizophrenia is a severe psychiatric illness affecting approximately 1% of the population worldwide <xref ref-type="bibr" rid="ref1">[1]</xref>, and is characterised by a combination of positive symptoms (e.g. delusions, hallucinations, conceptual disorganisation), negative symptoms (e.g. apathy, social withdrawal, emotional blunting) and cognitive impairment (e.g. impaired executive function, working memory and attention) <xref ref-type="bibr" rid="ref2">[2]</xref>. Sex differences are evident in schizophrenia: males have a higher incidence rate and an earlier onset of schizophrenia (although females show an increased incidence of schizophrenia following menopause), males present with worse negative symptoms and do not respond as well to antipsychotic treatment as females; several of these differences have been attributed to protective effects of estrogen in females <xref ref-type="bibr" rid="ref3">[3]</xref>. Drug abuse and addiction (used interchangeably) is very common in patients with schizophrenia, occurring up to five times more frequently than in the general population, and affecting nearly 50% of patients (excluding nicotine dependence, which affects nearly 90% of patients with schizophrenia) <xref ref-type="bibr" rid="ref4">[4</xref>,<xref ref-type="bibr" rid="ref5">5]</xref>. For example, cannabis abuse occurs in 50% of patients with schizophrenia, compared to ~1% of the general population, nicotine abuse occurs in ~29% of patients, compared to ~13% of the general population, and alcohol abuse occurs in 43-65% of patients, compared to ~5% of the general population <xref ref-type="bibr" rid="ref5">[5]</xref>. Drug abuse causes significant problems for patients by worsening symptoms, limiting treatment compliance, increasing psychotic relapse and hospitalisation, and increasing suicide risk <xref ref-type="bibr" rid="ref6">[6</xref>-<xref ref-type="bibr" rid="ref11">11]</xref>. Some drugs, such as cannabis and methamphetamine, increase risk for developing psychosis and schizophrenia; however, chronic drug abuse can also develop after disease onset, indicating a complex bidirectional relationship <xref ref-type="bibr" rid="ref12">[12]</xref>. Several drug classes are abused in schizophrenia, including cannabis, psychostimulants (e.g. methamphetamine, cocaine), alcohol and nicotine <xref ref-type="bibr" rid="ref5">[5]</xref>. To the authorsâ knowledge, sex differences in the prevalence of substance abuse in patients with schizophrenia has not been reported. Despite high rates of substance abuse in schizophrenia and the significant problems it causes, the causes of comorbidity are unclear.</p>
      <sec>
        <title>1.1 Theories of schizophrenia and drug abuse comorbidity</title>
        <p>Several theories have been developed to help explain the high rate of substance abuse in schizophrenia (see <xref ref-type="bibr" rid="ref13">[13]</xref>). The <italic>self-medication theory</italic> suggests that individuals with schizophrenia abuse substances to ameliorate symptoms of the disease <xref ref-type="bibr" rid="ref14">[14]</xref>; however, this has received limited empirical support (e.g. <xref ref-type="bibr" rid="ref15">[15</xref>,<xref ref-type="bibr" rid="ref16">16]</xref>). The <italic>primary addiction hypothesis</italic> purports that schizophrenia and drug addiction share similar pathophysiology in mesocortolimbic circuitry, and thus individuals predisposed to schizophrenia also have an elevated propensity for addiction <xref ref-type="bibr" rid="ref17">[17]</xref>. In the primary addiction hypothesis, drug addiction can occur prior to, but also after developing schizophrenia. The <italic>two-hit hypothesis</italic> claims that genetic or environmental vulnerabilities (first hit) for schizophrenia interact with additional genetic or environmental factor/s (second hit), such as substance abuse, resulting in the development of psychotic symptoms and schizophrenia <xref ref-type="bibr" rid="ref18">[18]</xref>. In the <italic>two-hit hypothesis</italic> drug abuse both contributes to and exacerbates schizophrenia symptoms. Related to this is the <italic>shared susceptibility hypothesis</italic>, which suggests that poor functioning and the presence of poverty, victimization and toxic social environments in patients with schizophrenia accumulate to increase risk for developing substance abuse <xref ref-type="bibr" rid="ref19">[19]</xref>. Due to the similarities between the two-hit hypothesis and the shared susceptibility hypothesis, we will evaluate environmental influences on substance abuse risk as part of the two-hit hypothesis. Clinical evidence mostly falls in favour of the primary addiction hypothesis and the two-hit hypothesis <xref ref-type="bibr" rid="ref12">[12]</xref>; however, determining cause and effect can often be difficult in clinical samples due to the ethical implications of administering substances which increase psychotic symptoms to individuals with schizophrenia. Preclinical rodent models can thus facilitate our understanding of causative factors for substance abuse and schizophrenia comorbidity.</p>
      </sec>
      <sec>
        <title>1.2 Rodent models of schizophrenia</title>
        <p>Preclinical rodent models of schizophrenia can be used to better understand aspects of schizophrenia aetiology, pathophysiology, symptomology and neural function. While no model can encompass the full spectrum of neurological change within this uniquely human disorder, models can help us understand how specific genetic and environmental factors contribute to, and also interact to bring about the development of schizophrenia. Furthermore, rodent models allow us to more precisely investigate different hypotheses for substance abuse comorbidity in schizophrenia. This review will examine comorbidity between drug abuse and schizophrenia in the following classes of model:</p>
        <sec>
          <title>Genetic models.</title>
          <p>Genetic models are generated by inserting, knocking down, deleting or mutating genes relevant to schizophrenia into the rodent genome <xref ref-type="bibr" rid="ref20">[20]</xref>. Many genetic risk factors for schizophrenia are cumulative and explain a small amount (e.g. 1-2% of variance) in terms of risk for schizophrenia; thus combinations of risk genes or gene-environment combinations can improve on these models. Nonetheless, these models often possess good construct validity for schizophrenia, as causal factors associated with schizophrenia risk are reproduced in these models <xref ref-type="bibr" rid="ref20">[20]</xref>.</p>
        </sec>
        <sec>
          <title>Neurodevelopmental models.</title>
          <p>Schizophrenia can be conceptualised as a neurodevelopmental disorder <xref ref-type="bibr" rid="ref21">[21]</xref>, and manipulations during gestation, birth and early postnatal development are used to produce irreversible changes in central nervous system development. Examples of manipulations include lesions, disruption of neurogenesis during critical gestational periods, post-weaning social isolation and maternal immune activation <xref ref-type="bibr" rid="ref20">[20]</xref>. Due to the high volume of data on the neonatal ventral hippocampal lesion (NVHL) model, we will address this separately to other neurodevelopmental models.</p>
        </sec>
        <sec>
          <title>Pharmacological models.</title>
          <p>In patients with schizophrenia, biochemical aberrations of the dopamine, Î³-amino-butyric acid (GABA), glutamate [e.g. abnormalities of n-methyl-d-asparate (NMDA) receptors], and nicotinic receptor systems, as well as functional and structural changes in the brain are present <xref ref-type="bibr" rid="ref22">[22]</xref>. Repeated administration of substances which disrupt these neurotransmitter systems including phencyclidine (PCP), ketamine, dizocilpine (MK-801), amphetamine and methamphetamine produces behavioural and brain abnormalities which resemble symptoms of schizophrenia <xref ref-type="bibr" rid="ref20">[20]</xref>; however, the construct validity (i.e. the relevance of these pharmacological models to schizophrenia pathology) of these models is limited.</p>
        </sec>
      </sec>
      <sec>
        <title>1.3 Schizophrenia-relevant behaviour in rodents</title>
        <p>Schizophrenia-relevant behaviour can be modelled in rodents, and below we briefly describe behaviours modelling positive, negative and cognitive symptoms, as well as sensorimotor gating. For a more detailed review of this topic, see <xref ref-type="bibr" rid="ref20">[20</xref>,<xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24]</xref>.</p>
        <p><italic>Positive symptoms of schizophrenia</italic> are modelled by tests of locomotor activity and sensitivity to effects of psychomimetic drugs on locomotion and stereotyped behaviours. Locomotor behaviour is considered a proxy measure for psychosis, as both locomotion and psychosis are elevated by increased dopamine transmission in the mesolimbic pathway, and both psychosis and hyperlocomotion in schizophrenia rodent models can be reduced by antipsychotic treatment <xref ref-type="bibr" rid="ref23">[23]</xref>. Also, patients with schizophrenia are sensitive to the psychosis-inducing effects of psychomimetic drugs (e.g. amphetamines, the NMDA antagonist MK-801) <xref ref-type="bibr" rid="ref25">[25]</xref>, and these drugs can also increase locomotor behaviour. However, locomotion is a complex and non-specific behaviour, and should be interpreted with caution, as compounds can reduce locomotor activity by mechanisms that may not be related to antipsychotic efficacy <xref ref-type="bibr" rid="ref23">[23]</xref>.</p>
        <p><italic>Negative symptoms of schizophrenia</italic>, such as anhedonia, social withdrawal and loss of motivation are measured through tests such as sucrose preference (modelling anhedonia), social interaction/social preference (modelling social withdrawal) and operant progressive ratio testing for food rewards (modelling loss of motivation) <xref ref-type="bibr" rid="ref23">[23</xref>,<xref ref-type="bibr" rid="ref24">24]</xref>. Sucrose preference measures voluntary consumption of a palatable food reinforcer (i.e. sucrose) as well as water, and a reduction in preference for sucrose over water may indicate a limited ability to feel pleasure from a normally enjoyable activity. The social interaction test measures a range of behaviours exhibited when two unfamiliar rodents interact freely (e.g. sniffing the conspecific, following, climbing over/under etc). The social preference test assesses 1) preference for investigating an unfamiliar conspecific in a cage compared to an empty cage, and 2) preference for a novel conspecific over a familiar conspecific. While these social tests assess social behaviours, as well as the preference for socialisation and social novelty, the degree to which these directly correspond with social withdrawal in schizophrenia is not clear. Operant progressive ratio testing examines the motivation to obtain a food reward. Animals engage in an operant response (e.g. lever press, nose poke) to receive a food reward (e.g. sugar pellet), and throughout the session, the response requirements for the reward are increased, requiring more effort from the animal to obtain the food reward. This test is considered a measure of avolition, which can be impaired in schizophrenia <xref ref-type="bibr" rid="ref23">[23</xref>,<xref ref-type="bibr" rid="ref24">24]</xref>.</p>
        <p><italic>Cognitive impairment in schizophrenia</italic>, for example, deficits in working memory, attention, and executive function, are modelled through an array of rodent cognitive tasks. Most cognitive behavioural tasks reported in this review assess short- and long-term memory function, using tasks such as fear conditioning (animals learn to associate a tone and/or context with a footshock), the Morris Water Maze (animals learn to locate a platform submerged in water over successive days using either egocentric or environmental cues), novel object recognition test (animals investigate a novel object more than a familiar object) and Y-maze (animals investigate a novel arm in a Y-shaped maze more than familiar arms). However, there are more complex tests of cognitive ability which may better reflect cognitive impairment in schizophrenia. These include the 5 choice serial reaction time task, where animals in an operant chamber need to identify which of five apertures has been briefly illuminated, via a nose poke, to receive a food reward; this assesses attention and inhibitory control <xref ref-type="bibr" rid="ref23">[23]</xref>. In the set shifting task, animals learn to dig for a food reward which is associated with specific cues. When tested, animals need to respond to relevant cues associated with a food reward (e.g. digging medium), and ignore cues which do not predict a food reward (e.g. odour); this assesses rule learning and discrimination <xref ref-type="bibr" rid="ref23">[23]</xref>. Rodent touchscreen technology, in which rodents need to respond to âtargetâ visual pattern stimuli and to withhold responses to ânon-targetâ stimuli, permits assessment of perceptual discrimination, object-place associative learning, attention, impulsivity, compulsivity, extinction and other domains <xref ref-type="bibr" rid="ref26">[26</xref>,<xref ref-type="bibr" rid="ref27">27]</xref>.</p>
        <p>A related domain is prepulse inhibition (PPI), a measure of sensorimotor gating, which is a pre-attentional process to facilitate stimulus filtering and limit sensory overload <xref ref-type="bibr" rid="ref28">[28]</xref>. PPI is the reduction in startle to an auditory or tactile stimulus, by the prior presentation of a non-startling stimulus <xref ref-type="bibr" rid="ref28">[28]</xref>. PPI is measured in rodents assessment of the whole body flinch to auditory (i.e. tone/white noise) or tactile (i.e. air puff) stimuli, and can be disrupted by administration of psychomimetic drugs <xref ref-type="bibr" rid="ref28">[28]</xref>. PPI is impaired in patients with schizophrenia, but PPI deficits are also observed in other disorders e.g. obsessive-compulsive disorder, Touretteâs syndrome; thus, PPI is not specific to schizophrenia alone <xref ref-type="bibr" rid="ref29">[29]</xref>.</p>
      </sec>
      <sec>
        <title>1.4 Addiction-relevant behaviour in rodents</title>
        <p>Here we briefly outline the behavioural assessment of addiction-relevant behaviour in rodents; however, further information on these tests can be found in the following reviews for conditioned place preference <xref ref-type="bibr" rid="ref28">[28</xref>-<xref ref-type="bibr" rid="ref31">31]</xref>, behavioural/locomotor sensitization <xref ref-type="bibr" rid="ref32">[32</xref>-<xref ref-type="bibr" rid="ref34">34]</xref>, and drug self-administration <xref ref-type="bibr" rid="ref35">[35</xref>,<xref ref-type="bibr" rid="ref36">36]</xref>.</p>
        <p><italic>Conditioned Place Preference (CPP)</italic>: CPP is an indirect measure of drug reward, based on context-drug associations. The CPP apparatus contains two distinct environments (i.e. drug-paired and vehicle-paired environments), created by a combination of wall patterns, floor textures and/or scent cues. Animals are tested for their baseline preference between these two compartments, in a pre-test baseline session. Then, across several days, animals are given vehicle- and drug-environment pairings (i.e. animals are given a vehicle injection and confined to the vehicle-paired environment in the morning, and then in the afternoon or the next day, animals are given a drug injection and confined to the drug-paired environment). This process is repeated several times (e.g. normally 3-5 vehicle and drug pairings for each animals). At Test, animals are given free access to both compartments, and if they spend more time in the drug-paired environment than the vehicle-paired environment, this indicates the drug was rewarding. The place preference score is often presented as the difference between pre- and post-test scores.</p>
        <p><italic>Behavioural/Locomotor Sensitization</italic>: Behavioural/locomotor sensitization is defined by the augmented motor-stimulant response that occurs with repeated, intermittent exposure to a drug, and is considered a marker of neural adaptations that can facilitate future drug taking <xref ref-type="bibr" rid="ref32">[32]</xref>. Briefly, animals are intermittently administered a drug in a specific context (e.g. an open field apparatus). Repeated administration of the same drug dose over successive days/weeks leads to an increase in the behavioural response to the drug, termed the development of sensitization. These behaviours can include locomotion and/or stereotyped behaviours (e.g. sniffing, grooming, head weaving). Expression of sensitization is evident when animals are given a low-dose drug prime and they exhibit higher levels of these behaviours than in response to vehicle treatment (i.e. the behaviours have sensitized). </p>
        <p><italic>Intravenous drug self-administration</italic>: Rodents can self-administer drugs of abuse freely within operant chambers, allowing control over the amount and frequency of the drug administered. Animals can engage in an operant response (e.g. lever press, nose poke, head movements detected by infra-red beams), which will provide a drug infusion. Drug reward can occur in the presence of cues (e.g. light, tone), and other discriminative stimuli (e.g. scents, wall and floor textures). An inactive operant response (e.g. lever press on the âinactiveâ lever or nose poke in the âinactiveâ hole) permits assessment of discrimination within the task. Rodents learn to self-administer abused drugs according to reinforcement schedules e.g. Fixed Ratio (FR) schedules require a fixed number of operant responses to obtain a drug reward (e.g. FR2 requires 2 lever presses for 1 drug reward), while a Progressive Ratio (PR) schedule requires an increasing number of operant responses to obtain a drug reward. After a period of self-administration (often 2-3 weeks), animals can be put into abstinence (e.g. kept in home cage with no exposure to operant chambers) or undergo extinction training, where the drug is no longer available in the operant chambers, and animals need to learn to inhibit their responding on the active lever. Extinction can also be conducted in a different context, mimicking the change in context which can occur in rehabilitation centres. Drug-associated cues may also be omitted during extinction. Relapse-like behaviour can be modelled in reinstatement and renewal tests, where animals are returned to the operant chambers and drug-associated cues are presented (i.e. cue-induced reinstatement), or a low dose drug-prime is administered (i.e. drug-primed reinstatement), or the animals experience a stressor (i.e. stress-induced reinstatement). Renewal of drug-seeking occurs when an animal is extinguished in a different context, but is then returned to the original drug-taking context, which facilitates drug-seeking. Resumption of drug-taking can also be modelled after extinction; this is termed reacquisition.</p>
        <p><italic>Intracranial Self-Stimulation</italic>: In the intracranial self-stimulation (ICSS) paradigm, rodents are implanted with intracranial electrodes that target specific brain regions [e.g. medial forebrain bundle of the hypothalamus, ventral tegmental area (VTA)], and performance of an operant response results in the delivery of electrical stimulation to that target <xref ref-type="bibr" rid="ref37">[37</xref>,<xref ref-type="bibr" rid="ref38">38]</xref>. ICSS is rewarding as it promotes dopamine release in nucleus accumbens, it is enhanced by drugs that increase extracellular dopamine in nucleus accumbens, and it is blocked by drugs that deplete dopamine or block dopamine receptors <xref ref-type="bibr" rid="ref37">[37</xref>,<xref ref-type="bibr" rid="ref38">38]</xref>. Rodents learn to stimulate the target brain region over several training days, and ICSS rates levels can modified by parameters such as pulse frequency, pulse amplitude, stimulus train duration and schedule of reinforcement <xref ref-type="bibr" rid="ref37">[37]</xref>. In ICSS paradigms, ICSS rates are lower at low frequencies (e.g. 56-71 Hz) and increase with higher frequencies (110 Hz+) <xref ref-type="bibr" rid="ref37">[37]</xref>. The abuse potential of drugs can be assessed in ICSS: once animals have established baseline responding, administration of an abused drug can shift their baseline ICSS responding e.g. responding at low frequencies at baseline can be elevated by drug treatment [37]. The facilitation of ICSS responding is indicative of abuse potential; this may be due to ICSS and drug administration producing additive effects on mesolimbic dopamine release and transmission, thus facilitating the operant behaviour which maintains ICSS <xref ref-type="bibr" rid="ref37">[37]</xref>.</p>
      </sec>
      <sec>
        <title>1.5 Methods and literature</title>
        <p>During the course of writing this review, we noticed that interactions between abused substances and schizophrenia rodent models tended to target two major, yet distinct research questions. One question explored how rodent models of schizophrenia respond to drugs of abuse in addiction behavioural paradigms (e.g. conditioned place preference, locomotor sensitization, self-administration). This question evaluates the primary addiction hypothesis (i.e. that schizophrenia and drug addiction share similar pathophysiology in mesocortolimbic circuitry) and investigates <italic>if addiction behaviour is elevated</italic> in rodent models of schizophrenia, suggesting that risk for schizophrenia also elevates risk for substance abuse.</p>
        <p>The other component of the literature addresses if animal models of schizophrenia <italic>are more susceptible to the effects of abused drugs on schizophrenia-relevant behaviour</italic>, including whether schizophrenia-like behaviour is exacerbated by abused drugs in rodent models of the disorder. This component addresses the two-hit hypothesis, and evidence in favour of this hypothesis suggests the development of schizophrenia may be facilitated by drug exposure. Alternatively, some studies also examine the possible therapeutic effects of some abused drugs in these models, potentially supporting the self-medication hypothesis.</p>
        <p>To provide a structured overview, each component of the review is divided into the model used and the drug investigated. In 2013, Ng and colleagues reviewed the existing literature on rodent models of schizophrenia targeting dual diagnosis <xref ref-type="bibr" rid="ref39">[39]</xref>, and we refer readers to this review for an in-depth examination of substance abuse comorbidity in rodent models of schizophrenia prior to 2013. However, since then a large body of literature has examined this topic further, providing novel insights into the behavioural and molecular underpinnings of comorbid substance abuse in schizophrenia. Here, we present literature since 2013 on this topic; yet, where relevant (e.g. when limited information is available on a topic), we refer to older studies to help inform our conclusions. Literature searches were conducted using PubMed. Our search terms are provided in <xref ref-type="table" rid="table1">Table 1</xref>.</p>
        <table-wrap id="table1">
          <label>Table 1</label>
          <caption>
            <title>Search term keywords used in PubMed.</title>
          </caption>
          <table>
            <tbody>
              <tr>
                <td>Keyword 1</td>
                <td>Boolean operator</td>
                <td>Keyword 2</td>
                <td>Boolean operator</td>
                <td>Keyword 3</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Mouse [Title/Abstract]</td>
                <td>AND</td>
                <td>Alcohol [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Mouse [Title/Abstract]</td>
                <td>AND</td>
                <td>Nicotine [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Mouse [Title/Abstract]</td>
                <td>AND</td>
                <td>Cannabis [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Mouse [Title/Abstract]</td>
                <td>AND</td>
                <td>Cocaine [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Mouse [Title/Abstract]</td>
                <td>AND</td>
                <td>Methamphetamin [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Rat [Title/Abstract]</td>
                <td>AND</td>
                <td>Cannabis [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Rat [Title/Abstract]</td>
                <td>AND</td>
                <td>Nicotine [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Rat [Title/Abstract]</td>
                <td>AND</td>
                <td>Alcohol [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Rat [Title/Abstract]</td>
                <td>AND</td>
                <td>Cocaine [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Rat [Title/Abstract]</td>
                <td>AND</td>
                <td>Methamphetamin [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Mouse [Title/Abstract]</td>
                <td>AND</td>
                <td>Addiction [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Mouse [Title/Abstract]</td>
                <td>AND</td>
                <td>Substance Abuse [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Rat [Title/Abstract]</td>
                <td>AND</td>
                <td>Addiction [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Rat [Title/Abstract]</td>
                <td>AND</td>
                <td>Substance Abuse [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Rodent [Title/Abstract]</td>
                <td>AND</td>
                <td>Addiction [Title/Abstract]</td>
              </tr>
              <tr>
                <td>Schizophrenia [Title/Abstract]</td>
                <td>AND</td>
                <td>Rodent [Title/Abstract]</td>
                <td>AND</td>
                <td>Drug abuse [Title/Abstract]</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec>
        <title>1.6 Definitions</title>
        <p>Here we outline several definitions used within this review.</p>
        <p><italic>Developmental periods</italic>: Susceptible periods of rodent development include the neonatal period [gestational day (G) 1-18/21] and postnatal period [postnatal day (PND) 1-21], as well as adolescence (PND 22-60), young adulthood (PND 60-90) and adulthood (PND 90+). While there is discussion over the duration of adolescence in rodents <xref ref-type="bibr" rid="ref40">[40]</xref>, we have adopted these broad definitions, based on a review of the rodent adolescent literature <xref ref-type="bibr" rid="ref40">[40]</xref>, to provide consistency for the reader.</p>
        <p><italic>Drug administration</italic>: Drug administration is described as acute (once-off drug administration, often within 1 hour before or after experimental manipulation), sub-chronic (3-10 days drug administration; drugs are often administered 1-2x every 24 hours) or chronic (1-2 administrations per day for more than 10 days).</p>
        <p><italic>Schizophrenia-relevant behaviour</italic>: Schizophrenia-like behaviour can be modelled in rodents using tests to assess positive and negative symptoms, as well as cognitive impairment and sensorimotor gating deficits. These are described above in section 1.3 (reviews: <xref ref-type="bibr" rid="ref23">[23</xref>,<xref ref-type="bibr" rid="ref41">41</xref>,<xref ref-type="bibr" rid="ref42">42]</xref>).</p>
        <p><italic>Addiction-relevant behaviour</italic>: We refer extensively to behavioural tests of addiction-relevant behaviour (described above in section 1.4), including conditioned place preference (CPP), behavioural/locomotor sensitization, and drug self-administration.</p>
      </sec>
    </sec>
    <sec>
      <title>2. Addiction-relevant behaviour in rodent models of schizophrenia</title>
      <p>All preclinical studies reviewed in section 2 are summarised in Tables <xref ref-type="table" rid="table2">2</xref>, <xref ref-type="table" rid="table3">3</xref> and <xref ref-type="table" rid="table4">4</xref>.</p>
      <sec>
        <title>2.1 Genetic models</title>
        <p>Addiction-like behaviour in genetic models of schizophrenia has been examined only for the psychostimulants cocaine and amphetamine, which increase dopamine release and transmission in the mesocorticolimbic pathway <xref ref-type="bibr" rid="ref43">[43</xref>,<xref ref-type="bibr" rid="ref44">44]</xref>.</p>
        <sec>
          <title>Psychostimulants: cocaine and amphetamine</title>
          <p>Dopamine metabolism and signalling are critically linked schizophrenia symptoms, whereby elevated dopamine release in the mesolimbic pathway is hypothesized to contribute to positive symptoms, whereas reduced dopamine in the mesocorticolimbic pathway appears to contribute to negative symptoms of the disorder <xref ref-type="bibr" rid="ref45">[45</xref>,<xref ref-type="bibr" rid="ref46">46]</xref>. Altered dopamine signalling may be linked to dopamine receptor expression, and several studies indicate D<sub>2</sub> receptor expression is elevated in the striatum but reduced in thalamic regions of unmedicated patients with schizophrenia (review: <xref ref-type="bibr" rid="ref47">[47]</xref>). Interestingly, mice overexpressing dopamine D<sub>2</sub> receptors in the paraventricular nucleus of the hypothalamus (PVT) (i.e. the opposite of what is observed in patients with schizophrenia) show attenuated locomotor sensitization to a cocaine challenge, compared to mice which do not overexpress PVT D<sub>2</sub> receptors <xref ref-type="bibr" rid="ref48">[48]</xref>, suggesting reduced susceptibility to cocaine-induced neural adaptations. These effects on cocaine sensitization occur in the absence of altered schizophrenia-relevant behaviours in PVT D<sub>2</sub> overexpressing mice <xref ref-type="bibr" rid="ref48">[48]</xref>. The PVT may modulate cocaine sensitization via dense projections to critical reward regions such as the medial prefrontal cortex (mPFC), nucleus accumbens (NAcc), amygdala and bed nucleus of the stria terminalis (BNST). The effects of D<sub>2</sub> receptor knockdown/knockout in the PVT have not yet been examined; however, it would be interesting to observe whether reduced PVT D<sub>2</sub> expression increases cocaine sensitization and other addiction-relevant behaviours, potentially providing a mechanism for elevated drug abuse susceptibility in patients with schizophrenia.</p>
          <p>The <italic>DISC1</italic> gene is a rare genetic risk factor for schizophrenia that codes for several proteins involved in dopamine signalling (e.g. cAMP-specific 3',5'-cyclic phosphodiesterase 4B, serine/threonine protein kinase Akt and glycogen synthasekinase-3 (GSK-3) <xref ref-type="bibr" rid="ref49">[49</xref>,<xref ref-type="bibr" rid="ref50">50]</xref>). Several lines of transgenic mice designed to model <italic>DISC1</italic> mutations have been created, many of which exhibit schizophrenia relevant behaviours, including hyperactivity, decreased social behaviours, anhedonia in the sucrose preference test and sensorimotor gating impairment (review: <xref ref-type="bibr" rid="ref51">[51]</xref>). Recent evidence suggests <italic>DISC1</italic> gene alterations can regulate addiction-relevant behaviour for cocaine in rats <xref ref-type="bibr" rid="ref52">[52]</xref>. <italic>Disc1</italic> knockdown in the NAcc of rats increases cocaine self-administration under higher reinforcement schedules [i.e. FR4-10, but not FR1-2] <xref ref-type="bibr" rid="ref52">[52]</xref>. Also, DISC1 protein levels are elevated in the NAcc of sham control rats after 12 days of cocaine self-administration, compared to sham control rats which self-administer saline <xref ref-type="bibr" rid="ref52">[52]</xref>. This suggests <italic>Disc1</italic> can regulate motivation for cocaine, and upregulation of DISC1 protein may be a compensatory mechanism following repeated cocaine self-administration. Importantly, this provides a link between genetic risk for schizophrenia and drug addiction susceptibility, supporting the primary addiction hypothesis.</p>
          <p><italic>Epidermal growth factor (EGF)</italic> is involved in cellular proliferation, differentiation, and survival, and a functional single nucleotide polymorphism (SNP) in the <italic>EGF</italic> gene which increases <italic>EGF</italic> transcription is associated with lower age of onset of schizophrenia <xref ref-type="bibr" rid="ref53">[53</xref>,<xref ref-type="bibr" rid="ref54">54]</xref>. <italic>EGF</italic> overexpression in mice facilitates acquisition of cocaine behavioural sensitization, such that cocaine sensitization is much stronger in mice overexpressing <italic>EGF</italic>, compared to wildtype-like (WT) controls where sensitization did occur but was not very prominent <xref ref-type="bibr" rid="ref55">[55]</xref>. These behavioural effects are accompanied by changes in dopamine metabolites in mice overexpressing <italic>EGF</italic>: striatal extracellular levels of tyrosine hydroxylase (TH) are decreased and catechol-O-methyl-transferase (COMT) increased, whereas dopa-decarboxylase in the NAcc and frontal cortex are increased, and extracellular dopamine and DOPAC are elevated in the NAcc <xref ref-type="bibr" rid="ref55">[55]</xref>. These findings link increased <italic>EGF</italic> function with elevated cocaine sensitivity via increased dopamine metabolism, and also supports the primary addiction hypothesis.</p>
          <p>NMDA receptors regulate glutamate signalling which appears to be dysregulated in schizophrenia, and NMDA dysfunction is observed in post mortem brain tissue of patients with schizophrenia <xref ref-type="bibr" rid="ref56">[56]</xref>. Changes to NMDA function can be modelled using glycine transporter 1 heterozygous knockout mice to model NMDA hyperfunction, and serine racemase knockout to model NMDA hypofunction <xref ref-type="bibr" rid="ref57">[57]</xref>. Glycine transporter 1 heterozygous knockout in the forebrain (i.e. forebrain NMDA hyperfunction) enhances cognitive performance in mice <xref ref-type="bibr" rid="ref58">[58</xref>,<xref ref-type="bibr" rid="ref59">59]</xref>, while serine racemase knockout mice (i.e. NMDA hypofunction) exhibit hyperlocomotion, sociability deficits and greater ventricular volumes <xref ref-type="bibr" rid="ref60">[60</xref>-<xref ref-type="bibr" rid="ref62">62]</xref>, all of which are relevant to schizophrenia. In terms of drug abuse potential, both NMDA hyper- and hypofunction mouse models express place preference for cocaine <xref ref-type="bibr" rid="ref57">[57]</xref>. However, NMDA hypofunction facilitates extinction of cocaine place preference (i.e. NMDA hypofunction reduces drug seeking), whereas NMDA hyperfunction enhances drug-primed reinstatement of cocaine place preference (i.e. NMDA hyperfunction increases drug seeking) <xref ref-type="bibr" rid="ref57">[57]</xref>. In addition, NMDA hypofunction reduces sensitivity to the threshold-lowering (i.e. rewarding) and the performance-elevating (i.e. stimulant) effects of cocaine in an intracranial self-stimulation paradigm <xref ref-type="bibr" rid="ref63">[63]</xref>. NMDA hypofunction also attenuates cocaine locomotor sensitization <xref ref-type="bibr" rid="ref57">[57]</xref>; this may be due to blunted cocaine-induced dopamine and glutamate release in the NAcc <xref ref-type="bibr" rid="ref63">[63]</xref>. Note also that a previous study reported that NMDA hypofunction reduces expression of context-specific sensitization and conditioned hyperactivity for amphetamine, while NMDA hyperfunction facilitates acquisition of amphetamine sensitization <xref ref-type="bibr" rid="ref64">[64]</xref>. Together, this suggests that NMDA receptor hypofunction decreases the rewarding responses of cocaine, and higher doses of cocaine are required to achieve a hedonic response, while NMDA hyperfunction increases cocaine reward and necessitates lower doses of cocaine for a hedonic response. Considering NMDA receptors appear downregulated in schizophrenia, particularly in reward-relevant regions such as the striatum and prefrontal cortex (review: <xref ref-type="bibr" rid="ref56">[56]</xref>), it seems that individuals with schizophrenia may require higher doses of cocaine to achieve a rewarding state, increasing the risk of developing severe physiological dependency and withdrawal <xref ref-type="bibr" rid="ref63">[63]</xref>.</p>
          <p>Together, these studies demonstrate addiction-like behaviour in genetic models of schizophrenia risk. In particular, genetic models with construct validity for schizophrenia e.g. <italic>Disc1</italic> and <italic>EGF</italic> transgenic mice, exhibit enhanced addiction-like behaviour, providing support for the primary addiction hypothesis. Furthermore, <italic>EGF</italic> transgenic mice exhibit elevated dopamine metabolism in forebrain regions, and considering the critical role of dopamine in reward signalling, these models provide a potential mechanism for elevated addiction propensity in individuals with schizophrenia. Future research will examine addiction-relevant behaviours in other genetic models of schizophrenia, to non-psychostimulant drugs.</p>
    <table-wrap id="table2">
      <label>Table 2</label>
      <caption>
        <title>Addiction-relevant behaviour in genetic and pharmacological rodent models of schizophrenia</title>
        <p>Abbreviations: CPP, conditioned place preference; DA, dopamine; Disc1; Disrupted in Schizophrenia 1; EGF, epidermal growth factor; FC, frontal cortex; HET; heterozygous; ICSS, intracranial self-stimulation; NAcc, nucleus accumbens, PCP, phencyclidine.</p>
      </caption>
      <table>
        <tbody>
          <tr>
            <td>Author, date [Reference]</td>
            <td>Model</td>
            <td>Drug</td>
            <td>Results - Behaviour (âdecrease, âincrease, ~no effect)</td>
            <td>Results - Brain (âdecrease, âincrease, ~no effect)</td>
          </tr>
          <tr>
            <td>Clark et al 2017 <xref ref-type="bibr" rid="ref48">[48]</xref></td>
            <td>DA D<sub>2</sub> receptor overexpression in the PVT of mice</td>
            <td>Cocaine</td>
            <td>âcocaine sensitization.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Gancarz et al 2016 <xref ref-type="bibr" rid="ref52">[52]</xref></td>
            <td><italic>Disc1</italic> knockdown in the Nacc of rats</td>
            <td>Cocaine</td>
            <td>â cocaine self-administration.</td>
            <td>âNacc <italic>DISC1</italic> protein levels after cocaine self-administration in shams.</td>
          </tr>
          <tr>
            <td>Eda et al 2013 <xref ref-type="bibr" rid="ref55">[55]</xref></td>
            <td><italic>EGF</italic> overexpressing mice</td>
            <td>Cocaine</td>
            <td>âcocaine sensitization.</td>
            <td>in <italic>EGF </italic>overexpressing mice: âstriatal extracellular tyrosine hydroxylase, âcatechol-O-methyl-transferase. âdopa-decarboxylase in Nacc and FC. âNacc extracellular dopamine and dopamine metabolites.</td>
          </tr>
          <tr>
            <td>Puhl et al 2015 <xref ref-type="bibr" rid="ref60">[60]</xref></td>
            <td>Glycine transporter 1 HET knockout mice</td>
            <td>Cocaine</td>
            <td>~ cocaine CPP and CPP extinction. â Cocaine-primed reinstatement.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Puhl et al 2015 <xref ref-type="bibr" rid="ref60">[60]</xref>; Puhl et al 2019 <xref ref-type="bibr" rid="ref63">[63]</xref></td>
            <td>Serine racemase knockout mice</td>
            <td>Cocaine</td>
            <td>~ cocaine CPP. âcocaine CPP extinction. âcocaine sensitization. âsensitivity to cocaine ICSS.</td>
            <td>âcocaine-induced dopamine and glutamate release in NAcc.</td>
          </tr>
          <tr>
            <td>Benneyworth et al 2012 <xref ref-type="bibr" rid="ref64">[64]</xref></td>
            <td>Glycine transporter 1 HET knockout mice</td>
            <td>Amphetamine</td>
            <td>âamphetamine sensitization. ~expression of amphetamine sensitization.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Benneyworth et al 2012 <xref ref-type="bibr" rid="ref64">[64]</xref></td>
            <td>Serine racemase knockout mice</td>
            <td>Amphetamine</td>
            <td>âAmphetamine sensitization and âexpression of amphetamine sensitization. âExtinction of amphetamine sensitization.</td>
            <td>âNAcc spine density after extinction.</td>
          </tr>
          <tr>
            <td>Fletcher et al 2018 <xref ref-type="bibr" rid="ref110">[110]</xref></td>
            <td>Chronic amphetamine treatment in rats</td>
            <td>Nicotine</td>
            <td>~Acquisition and maintenance of nicotine self-administration.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Fletcher et al 2018 <xref ref-type="bibr" rid="ref110">[110]</xref></td>
            <td>Chronic PCP treatment in rats</td>
            <td>Nicotine</td>
            <td>~Acquisition and maintenance of nicotine self-administration.</td>
            <td>n/a</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
        </sec>
      </sec>
      <sec>
        <title>2.2 Lesion models</title>
        <p>The neonatal ventral hippocampal lesion (NVHL) is a widely used neurodevelopmental animal model, in which an excitotoxin infusion is made into the ventral hippocampus during the first postnatal week, a time point roughly comparable to the third trimester of human development <xref ref-type="bibr" rid="ref65">[65]</xref>. This lesion causes neurodevelopmental interruptions hypothesised to be relevant to schizophrenia susceptibility <xref ref-type="bibr" rid="ref66">[66]</xref>. The NVHL model develops behavioural and neurobiological dysfunction relevant to schizophrenia e.g. social interaction and cognitive impairment, prepulse inhibition deficits, and an enhanced locomotor response to stress <xref ref-type="bibr" rid="ref67">[67</xref>,<xref ref-type="bibr" rid="ref68">68]</xref>.</p>
        <sec>
          <title>Psychostimulants: amphetamine and methamphetamine</title>
          <p>In a brain stimulation paradigm in young adult rats, reward thresholds following acute amphetamine are similarly elevated in NVHL and sham controls, yet this elevation drops off more rapidly in NVHL rats, indicating increased tolerance for amphetamine <xref ref-type="bibr" rid="ref69">[69]</xref>. In a drug self-administration paradigm, NVHL rats show higher motivation for methamphetamine self-administration under a progressive ratio schedule, but no differences in responding under a fixed ratio schedule of reinforcement <xref ref-type="bibr" rid="ref70">[70]</xref>.</p>
        </sec>
        <sec>
          <title>Psychostimulants: cocaine</title>
          <p>Cocaine-induced locomotor activity during sensitization, as well as locomotion following a cocaine challenge is enhanced in adult NVHL rats compared to sham controls <xref ref-type="bibr" rid="ref71">[71</xref>,<xref ref-type="bibr" rid="ref72">72]</xref>. However, when examining gene expression in the caudate-putamen and mPFC using genome-wide microarrays, there is no overlap in the direction of gene expression change induced by NVHL and cocaine sensitization i.e. NVHL mostly downregulates gene expression in these regions, whereas cocaine sensitization mostly upregulates gene expression, compared to sham controls <xref ref-type="bibr" rid="ref71">[71]</xref>. This analysis included genes associated with neuropsychiatric conditions (e.g. psychosis, bipolar disorder), such as <italic>Estrogen receptor 2, Glial fibrillary acidic protein, CD 40 molecule TNF receptor Superfamily 5,</italic> and several Zinc finger protein genes. There were a limited number of genes (17% of total genes) impacted on by NVHL-cocaine interactions, and there was no overlap in the direction of gene expression change for these interactions <xref ref-type="bibr" rid="ref71">[71]</xref>. The rarity of convergence of NVHL and cocaine sensitization effects on individual genes suggests that the NVHL model and cocaine treatment may interact on the neural network level, rather than being reducible to one or a few molecular interactions <xref ref-type="bibr" rid="ref71">[71]</xref>.</p>
          <p>Cocaine self-administration under fixed ratio responding is intact in NVHL rats, yet lesioned rats demonstrate prolonged extinction and exaggerated cue-induced reinstatement of cocaine seeking, suggesting impaired prefrontal control over cue-induced drug-seeking or a general impairment in new action-outcome learning <xref ref-type="bibr" rid="ref73">[73]</xref>. Supporting this, working memory deficits in the radial arm maze in adult NVHL rats predict subsequent cocaine behavioural sensitization, suggesting a link between cognition and addiction-relevant behaviours in this model <xref ref-type="bibr" rid="ref72">[72]</xref>. However, incubation of cocaine craving is not altered in NVHL rats, suggesting specific addiction-relevant behavioural domains are altered following NVHL lesions <xref ref-type="bibr" rid="ref73">[73]</xref>. Collectively, this suggests NVHL rats model several aspects of increased susceptibility to psychostimulant abuse observed in individuals with schizophrenia, and suggest changes in gene expression may interact at a neural network level to facilitate drug-seeking behaviour.</p>
        </sec>
        <sec>
          <title>Nicotine</title>
          <p>Nicotine abuse is very common in schizophrenia â up to 90% of patients smoke cigarettes compared to approximately 26% of the general population <xref ref-type="bibr" rid="ref5">[5]</xref>. Animal models have the potential to unravel this high level of susceptibility to nicotine.</p>
          <p>Neonatal ventral hippocampal lesions enhance the rewarding effects of nicotine. Adult NVHL rats demonstrate faster acquisition of nicotine self-administration and higher nicotine intake during self-administration (<xref ref-type="bibr" rid="ref74">[74]</xref> but see also <xref ref-type="bibr" rid="ref72">[72</xref>,<xref ref-type="bibr" rid="ref75">75]</xref>), modelling the higher levels of smoking observed in schizophrenia patients. Adult NVHL rats are also resistant to reducing nicotine use, exhibiting slower extinction of nicotine seeking and elevated drug-primed reinstatement compared to sham controls <xref ref-type="bibr" rid="ref72">[72</xref>,<xref ref-type="bibr" rid="ref74">74</xref>,<xref ref-type="bibr" rid="ref75">75]</xref>.</p>
          <p>Increased susceptibility to nicotine may be age-dependent, occurring only in adult NVHL but not adolescent NVHL rats. Nicotine sensitization in adolescence is similar between NVHL and sham controls <xref ref-type="bibr" rid="ref74">[74]</xref>. Furthermore, prior nicotine sensitization does not affect acquisition or extinction of nicotine self-administration, suggesting adolescent nicotine treatment does not facilitate later nicotine consumption <xref ref-type="bibr" rid="ref74">[74]</xref>. While nicotine sensitization increases responding for a high nicotine dose (30 Âµg/infusion, dose-response study), this is unaffected by NVHL <xref ref-type="bibr" rid="ref74">[74]</xref>. Together, this data suggests that schizophrenia pathology may precipitate vulnerability to nicotine addiction later in life, but early nicotine exposure does not modulate this relationship.</p>
          <p>Interestingly, when both ethanol and nicotine are available in a self-administration paradigm, NVHL rats display greater consumption of both ethanol and nicotine compared to sham controls <xref ref-type="bibr" rid="ref75">[75]</xref>. During extinction, when both ethanol and nicotine are unavailable, NVHL rats exhibit elevated responding for these two drugs, compared to sham controls <xref ref-type="bibr" rid="ref75">[75]</xref>. Drug-primed reinstatement of nicotine-seeking is greater in NVHL rats compared to sham controls, but this is unaffected by ethanol availability <xref ref-type="bibr" rid="ref75">[75]</xref>. These findings indicate vulnerability of NVHL rats to both substances when they are concurrently available.</p>
        </sec>
        <sec>
          <title>Ethanol</title>
          <p>Alcohol abuse is also observed at higher rates in schizophrenia (43-65% of patients experience alcohol dependence) than in the general population (approximately 5%) <xref ref-type="bibr" rid="ref5">[5]</xref>. Adolescent alcohol use is associated with elevated use in adulthood in healthy controls <xref ref-type="bibr" rid="ref76">[76]</xref>; however, susceptibility to the effects of adolescent alcohol use on brain reward dysfunction is unknown in schizophrenia. NVHL rats can be used to model this relationship. Indeed, NVHL rats are susceptible to adolescent ethanol exposure: NVHL rats given chronic voluntary ethanol access during adolescence demonstrate higher rates of ethanol consumption in two-bottle free choice in adulthood compared to sham controls given voluntary ethanol access in adolescence. NVHL rats with adolescent ethanol access also show escalation of ethanol self-administration, delayed extinction of ethanol-seeking and higher rates of drinking during reacquisition compared to sham controls with adolescent ethanol access <xref ref-type="bibr" rid="ref77">[77]</xref>. These effects occur despite similar levels of adolescent ethanol intake between NVHL and sham rats, and importantly, addiction-like phenotypes (e.g. escalation of intake, resistance to extinction) are only present in NVHL rats which experience adolescent exposure to ethanol <xref ref-type="bibr" rid="ref77">[77]</xref>. These findings indicate that NVHL lesions do not have an impact on the immediate effect of ethanol in adolescence but increase later susceptibility for addictive-like behaviour, supporting a two-hit model of addiction susceptibility i.e. early drug exposure and schizophrenia/addiction susceptibility increases risk for addiction in later life.</p>
          <p>For a natural reinforcer (e.g. sucrose), in a self-administration paradigm, NVHL rats show intact extinction learning, and reacquisition of responding is similar to controls <xref ref-type="bibr" rid="ref77">[77]</xref>. NVHL rats do however exhibit impaired acquisition and maintenance of autoshaping for a food reinforcer following latent inhibition, and impaired extinction of autoshaping behaviour <xref ref-type="bibr" rid="ref78">[78]</xref>, suggesting select cognitive deficits in this model. Interestingly, these cognitive deficits may contribute to the ethanol addiction-relevant phenotype of NVHL rats, as the degree of latent inhibition in NVHL rats predicts future ethanol drinking <xref ref-type="bibr" rid="ref78">[78]</xref>, suggesting a link between cognitive impairment and elevated ethanol consumption in this model.</p>
        </sec>
        <sec>
          <title>Cannabinoids: CB<sub>1</sub> receptor agonists WIN 55,212-2 and Î<sup>9</sup>-tetrahydrocannabinnol</title>
          <p>CB<sub>1</sub> cannabinoid receptor agonists are of particular relevance to schizophrenia because CB<sub>1</sub> receptors mediate the psychoactive and rewarding properties of cannabis <xref ref-type="bibr" rid="ref79">[79]</xref>, and there is strong evidence linking adolescent cannabis use with increased risk for schizophrenia, particularly in individuals with genetic predisposition for the disorder (reviews: <xref ref-type="bibr" rid="ref80">[80</xref>,<xref ref-type="bibr" rid="ref81">81]</xref>). In addition, cannabis abuse is 3-4x higher in patients with schizophrenia than in healthy populations <xref ref-type="bibr" rid="ref5">[5]</xref>. Assessing addiction-relevant behaviours for CB<sub>1</sub> receptor agonists in schizophrenia rodent models can provide insights into why cannabis use is so common in schizophrenia. It should be noted that in many rodent studies, CB<sub>1</sub> receptor agonists fail to produce rewarding and reinforcing effects <xref ref-type="bibr" rid="ref82">[82</xref>-<xref ref-type="bibr" rid="ref84">84]</xref>, or only do so under specific experimental conditions, which may be due to concurrently occurring aversive properties of these drugs mediated by effects of cannabinoids on other receptors (e.g. in mice, Îº-opioid receptors mediate aversive effects of THC); see discussion in <xref ref-type="bibr" rid="ref84">[84]</xref>. </p>
          <p>NVHL rats exhibit an age-specific susceptibility to the CB<sub>1</sub> receptor agonist WIN 55,212-2 (WIN) <xref ref-type="bibr" rid="ref85">[85]</xref>. While acute WIN treatment has no effect on locomotion in adolescence in NVHL rats, WIN increases locomotor activity in young adult NVHL rats, compared to sham controls <xref ref-type="bibr" rid="ref85">[85]</xref>. In addition, young adult but not adolescent NVHL rats exhibit a greater aversion to WIN in a conditioned place preference paradigm compared to controls, yet the opposite effect occurs for CB<sub>1</sub> receptor agonist Î<sup>9</sup>-tetrahydrocannabinnol (THC), where sham controls demonstrate an aversion for THC, which is not present in NVHL rats <xref ref-type="bibr" rid="ref85">[85]</xref>. These findings are mirrored in a brain stimulation reward paradigm, where THC produces a weak attenuation of reward in sham controls, but not NVHL rats, and WIN has the opposite effect, attenuating reward in NVHL rats but enhancing it in controls <xref ref-type="bibr" rid="ref69">[69]</xref>. The different effects of THC and WIN may be due to different pharmacokinetics between the two drugs (e.g. WIN has a higher CB<sub>1</sub> receptor affinity than THC <xref ref-type="bibr" rid="ref86">[86]</xref>), and/or cannabinoid receptor expression in reward regions [(e.g. striatum, VTA] in NVHL rats, but this has not been assessed. Nonetheless, together this suggests NVHL alters the sensitivity of the endocannabinoid system to reward, in a manner specific to the reinforcer used (e.g. NVHL increases sensitivity to WIN, but decreases sensitivity to THC).</p>
    <table-wrap id="table3">
      <label>Table 3</label>
      <caption>
        <title>Addiction-relevant behaviour in neonatal ventral hippocampal lesion rat models of schizophrenia</title>
        <p>Abbreviations: CPA, conditioned place aversion; CPP, conditioned place preference; ICSS, intracranial self-stimulation; mPFC, medial prefrontal cortex; NVHL, neonatal ventral hippocampal lesion; WIN, WIN 55,212-2.</p>
      </caption>
      <table>
        <tbody>
          <tr>
            <td>Author, date [Reference]</td>
            <td>Model</td>
            <td>Drug</td>
            <td>Results - Behaviour (âdecrease, âincrease, ~no effect)</td>
            <td>Results - Brain (âdecrease, âincrease, ~no effect)</td>
          </tr>
          <tr>
            <td>Gallo et al 2014 <xref ref-type="bibr" rid="ref69">[69]</xref></td>
            <td>NVHL rat</td>
            <td>Amphetamine</td>
            <td>âtolerance for amphetamine in ICSS.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Brady et al 2008 <xref ref-type="bibr" rid="ref70">[70]</xref></td>
            <td>NVHL rat</td>
            <td>Methamphetamine</td>
            <td>~ methamphetamine self-administration (dose range).</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Chambers et al 2013 <xref ref-type="bibr" rid="ref71">[71]</xref>; Rao et al 2016 <xref ref-type="bibr" rid="ref72">[72]</xref></td>
            <td>NVHL rat</td>
            <td>Cocaine</td>
            <td>âCocaine sensitization and âexpression of cocaine sensitization.</td>
            <td>~ gene expression change in striatum and mPFC after cocaine sensitization in NVHL.</td>
          </tr>
          <tr>
            <td>Karlsson et al 2013 <xref ref-type="bibr" rid="ref73">[73]</xref></td>
            <td>NVHL rat</td>
            <td>Cocaine</td>
            <td>~Cocaine self-administration. âExtinction and âcue-induced reinstatement for cocaine. ~Incubation of cocaine craving</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Rao et al 2016 <xref ref-type="bibr" rid="ref72">[72]</xref>; Berg et al 2014 <xref ref-type="bibr" rid="ref74">[74]</xref>; Sentir et al 2018 <xref ref-type="bibr" rid="ref75">[75]</xref></td>
            <td>NVHL rat</td>
            <td>Nicotine</td>
            <td>~Nicotine sensitization. ~Nicotine sensitization on acquisition or extinction of nicotine self-administration. Nicotine sensitization in NVHL â's nicotine self-administration, âextinction and ânicotine-primed reinstatement.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Sentir et al 2018 <xref ref-type="bibr" rid="ref75">[75]</xref></td>
            <td>NVHL rat</td>
            <td>Nicotine</td>
            <td>âEthanol and nicotine self-administration (when available together). âExtinction of nicotine and ethanol. âNicotine-primed reinstatement.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Jeanblanc et al 2015 <xref ref-type="bibr" rid="ref77">[77]</xref></td>
            <td>NVHL rat</td>
            <td>Ethanol</td>
            <td>Following adolescent ethanol exposure, NVHL show âethanol free consumption, âescalation of ethanol self-administration, âextinction and âreacquisition of ethanol.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Jeanblanc et al 2015 <xref ref-type="bibr" rid="ref77">[77]</xref>; Khokhar et al 2018 <xref ref-type="bibr" rid="ref78">[78]</xref></td>
            <td>NVHL rat</td>
            <td>Sucrose</td>
            <td>~Extinction and ~reacquisition for sucrose. âacquisition and maintenance of autoshaping following latent inhibition. âImpaired extinction of autoshaping behaviour for sucrose.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Gallo et al 2014 <xref ref-type="bibr" rid="ref69">[69]</xref>; Gallo et al 2014 <xref ref-type="bibr" rid="ref85">[85]</xref></td>
            <td>NVHL rat</td>
            <td>WIN</td>
            <td>In NVHL, âWIN-induced locomotion in young adulthood. âWIN CPP in young adult NVHL. WIN âICSS reward in NVHL.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Gallo et al 2014 <xref ref-type="bibr" rid="ref69">[69]</xref>; Gallo et al 2014 <xref ref-type="bibr" rid="ref85">[85]</xref></td>
            <td>NVHL rat</td>
            <td>THC</td>
            <td>âTHC CPA in early adult NVHL. ~THC CPP in adolescent NVHL. ~THC ICSS in NVHL.</td>
            <td>n/a</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
        </sec>
      </sec>
      <sec>
        <title>2.3 Non-lesion neurodevelopmental models</title>
        <p>Non-lesion neurodevelopmental models of schizophrenia induce a pre- or post-natal insult via maternal cytokine elevation [e.g. administration of mitotoxin methylazoxymethanol acetate (MAM), lipopolysaccharide (LPS), polyinosinic-citidilic acid (Poly I:C) or quinpirole], prenatal stress or rearing environment manipulations during the post-natal period. Pups tested in adolescence and/or adulthood show altered addiction-relevant behaviour to several drugs of abuse. It should be noted that the timing of maternal infection and the infectious agent chosen can influence behavioural and neurological outcomes, and the current lack of consistency across research groups in the implementation of maternal infection may cause differences in the outcomes <xref ref-type="bibr" rid="ref87">[87</xref>,<xref ref-type="bibr" rid="ref88">88]</xref>.</p>
        <sec>
          <title>Psychostimulants: amphetamine</title>
          <p>Altered dopaminergic function is observed in the Poly I:C model, where prenatal Poly I:C treatment in mice enhances locomotor sensitization and stereotyped behaviour to repeated amphetamine administration, compared to control offspring <xref ref-type="bibr" rid="ref89">[89]</xref>. Also, amphetamine CPP is greater in Poly I:C offspring compared to control offspring, suggesting heightened reward for amphetamine <xref ref-type="bibr" rid="ref89">[89]</xref>. Similarly, prenatally MAM-treated rats show a greater stereotyped behavioural response to an amphetamine challenge dose than controls, suggesting greater expression of amphetamine sensitization following prenatal MAM treatment <xref ref-type="bibr" rid="ref90">[90]</xref>. This suggests maternal infection can increase sensitivity to the rewarding and locomotor stimulating effects of psychostimulants, and may suggest heightened dopaminergic system function.</p>
        </sec>
        <sec>
          <title>Psychostimulants: cocaine</title>
          <p>Mice prenatally exposed to Poly I:C exhibit enhanced cocaine reward in CPP, indicating stronger cocaine context-reward associations <xref ref-type="bibr" rid="ref91">[91]</xref>. Despite elevated cocaine context-reward associations, Poly I:C treated mice exhibit reduced cocaine-induced locomotor activity, which may indicate lower dopamine transporter or dopamine receptor availability in brain regions such as the VTA or striatum <xref ref-type="bibr" rid="ref91">[91]</xref>. Prenatal Poly I:C treatment in rats also enhances cross-sensitization to cocaine after behavioural sensitization to amphetamine, suggesting elevated susceptibility to other stimulant drugs following repeated amphetamine administration <xref ref-type="bibr" rid="ref89">[89]</xref>. Interestingly, Poly I:C mice do not exhibit place preference for a natural reward, sucrose, where control mice do, yet learning about an aversive stimulus (i.e. fear conditioning) is intact, suggesting impaired processing of appetitive reward in this model <xref ref-type="bibr" rid="ref91">[91]</xref>. Collectively, this suggests increased susceptibility to stimulant reward in Poly I:C treated animals, but disrupted reward processing for natural rewards, which may reflect distinct neuronal changes (e.g. within the PFC-NAcc glutamate pathway and/or downstream in medium spiny neurons) that occur following exposure to drug <italic>vs</italic> natural rewards <xref ref-type="bibr" rid="ref92">[92]</xref>.</p>
          <p>In rats which experience early life adversity [i.e. limited bedding and nesting (LBN) during PND 2-9], cocaine sensitization is unaffected. However, acute cocaine administration increases c-Fos expression in reward regions such as the NAcc core, central amygdala and lateral habenula of LBN rats, compared to controls <xref ref-type="bibr" rid="ref93">[93]</xref>. c-Fos expression in orexin/hypocretin neurons following acute cocaine in LBN rats is decreased in the lateral, dorsomedial and perifornical regions of hypothalamus, suggesting reorganization of drug reward and stress circuitry following early life stress <xref ref-type="bibr" rid="ref93">[93]</xref>.</p>
          <p>Despite elevated neuronal activity in reward regions following acute cocaine <xref ref-type="bibr" rid="ref93">[93]</xref>, cocaine self-administration behaviours are mostly unaltered in neurodevelopmental models of schizophrenia. While LBN rats initially acquire cocaine self-administration faster than controls, LBN rats self-administer similar amounts of cocaine as controls after 10 days of training, and exhibit similar sensitivity to different cocaine doses <xref ref-type="bibr" rid="ref93">[93]</xref>. Cocaine extinction and reinstatement of cocaine-seeking are also unaltered in LBN rats <xref ref-type="bibr" rid="ref93">[93]</xref>. Interestingly, the hedonic set point for cocaine is reduced, such that LBN rats prefer to self-administer lower doses of cocaine under low effort conditions but demonstrated similar levels of motivation to self-administer cocaine under higher effort conditions <xref ref-type="bibr" rid="ref93">[93]</xref>. This suggests either a degree of cocaine anhedonia in LBN rats or that LBN rats reach cocaine satiety faster than controls, and suggests limited bedding and nesting does not increase cocaine addiction-like behaviours.</p>
          <p>In the MAM neurodevelopmental model of maternal infection, there are no differences in cocaine self-administration under fixed and progressive schedules of reinforcement, nor in extinction or drug-induced reinstatement for cocaine <xref ref-type="bibr" rid="ref94">[94]</xref>. Similarly, offspring of dams treated with LPS show unaltered cocaine self-administration, dose-response curves and extinction, despite working memory and sensorimotor gating impairment in this model <xref ref-type="bibr" rid="ref95">[95]</xref>. Acute locomotor activity in response to various doses of cocaine is unaltered in MAM rats, compared to controls <xref ref-type="bibr" rid="ref94">[94]</xref>.</p>
          <p>Together, this demonstrates sensitivity to cocaine addiction-relevant behaviours is highly dependent on the neurodevelopmental model used, for while Poly I:C treatment seems to increase cocaine reward and cross-sensitization, other neurodevelopmental models e.g. LBN, MAM, prenatal LPS, do not exhibit a cocaine addiction-like phenotype, or demonstrate a phenotype which suggests reduced susceptibility to cocaine (e.g. LBN show cocaine anhedonia).</p>
        </sec>
        <sec>
          <title>Psychostimulants: methamphetamine</title>
          <p>There are limited effects of prenatal MAM treatment on methamphetamine responses in offspring. Prenatal MAM treatment does not affect methamphetamine self-administration under an FR1 schedule of reinforcement, or cue-induced reinstatement after abstinence, in male or female rats <xref ref-type="bibr" rid="ref96">[96]</xref>. Dose-response, schedules of reinforcement and extinction behaviour for methamphetamine have not yet been examined in MAM rats. However, MAM offspring are less susceptible to the suppressing effects of low dose ketamine on methamphetamine self-administration than control rats, and the authors suggest this may be due to impaired PFC glutamatergic signalling in MAM rats <xref ref-type="bibr" rid="ref97">[97]</xref>. Further research into the effects of neurodevelopmental insults on addiction behaviour for methamphetamine are warranted.</p>
        </sec>
        <sec>
          <title>Nicotine</title>
          <p>Developmental stress appears to increase sensitivity to nicotine. Adult rats which experienced prenatal stress exhibit greater nicotine reward in CPP than non-stressed rats <xref ref-type="bibr" rid="ref98">[98]</xref>. Also, rats reared in isolation during adolescence show behavioural sensitization to repeated nicotine administration during adolescence, where rats reared in an enriched environment do not <xref ref-type="bibr" rid="ref99">[99]</xref>. LPS treatment during gestation facilitates intravenous nicotine self-administration at higher reinforcement schedules (i.e. FR5, not FR1/FR2), but has no  effect on dose-response responding or motivation for nicotine under a progressive ratio <xref ref-type="bibr" rid="ref100">[100]</xref>. Similarly, in the MAM rat model of schizophrenia, Weeks and colleagues found no differences between MAM rats and controls in nicotine self-administration <xref ref-type="bibr" rid="ref101">[101]</xref>. This was observed across a range of doses and schedules of reinforcement, in both standard 1-hr self-administration sessions and 23-hr extended access sessions, and this was not different between the sexes <xref ref-type="bibr" rid="ref101">[101]</xref>. Interestingly, MAM animals responded less for sucrose or reinforcing visual stimuli alone or when paired with nicotine, suggesting potential deficits in reinforcement learning in this model <xref ref-type="bibr" rid="ref101">[101]</xref>. Thus, it seems that developmental stress can increase susceptibility to nicotine addiction-like behaviour in adulthood, but this is not the case following maternal infection.</p>
    <table-wrap id="table4">
      <label>Table 4</label>
      <caption>
        <title>Addiction-relevant behaviour in neurodevelopmental rodent models of schizophrenia</title>
        <p>Abbreviations: CPP, conditioned place preference; DA, dopamine; HPC, hippocampus; LPS, lipopolysaccharide; MAM, mitotoxin methylazoxymethanol acetate; NAcc, nucleus accumbens; Poly I:C, polyinosinic-citidilic acid; VTA, ventral tegmental area.</p>
      </caption>
      <table>
        <tbody>
          <tr>
            <td>Author, date [Reference]</td>
            <td>Model</td>
            <td>Drug</td>
            <td>Results - Behaviour (âdecrease, âincrease, ~no effect)</td>
            <td>Results - Brain (âdecrease, âincrease, ~no effect)</td>
          </tr>
          <tr>
            <td>Borcoi et al 2015 <xref ref-type="bibr" rid="ref89">[89]</xref></td>
            <td>Poly I:C mice</td>
            <td>Amphetamine</td>
            <td>âAmphetamine sensitization and âAmphetamine CPP.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Chen et al 2014 <xref ref-type="bibr" rid="ref90">[90]</xref></td>
            <td>Prenatal MAM treated rats</td>
            <td>Amphetamine</td>
            <td>âAmphetamine sensitization challenge.</td>
            <td>~regulation of afferent VTA DA neurons (from HPC and pedunculopontine tegmental area).</td>
          </tr>
          <tr>
            <td>Labouesse et al 2015 <xref ref-type="bibr" rid="ref91">[91]</xref></td>
            <td>Prenatal Poly I:C treated mice</td>
            <td>Cocaine</td>
            <td>âCocaine CPP, âCocaine locomotor activity.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Borcoi et al 2015 <xref ref-type="bibr" rid="ref89">[89]</xref></td>
            <td>Prenatal Poly I:C treated mice</td>
            <td>Amphetamine then cocaine</td>
            <td>âcocaine cross-sensitization after amphetamine sensitization.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Labouesse et al 2015 <xref ref-type="bibr" rid="ref91">[91]</xref></td>
            <td>Prenatal Poly I:C treated mice</td>
            <td>Sucrose</td>
            <td>No CPP for sucrose. ~Fear conditioning.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Bolton et al 2018 <xref ref-type="bibr" rid="ref93">[93]</xref></td>
            <td>Limited bedding and nesting rats</td>
            <td>Cocaine</td>
            <td>~Cocaine sensitization. âacquisition of cocaine self-administration. ~cocaine self-administration (dose range). ~Cocaine extinction and reinstatement âcocaine hedonic set point.</td>
            <td>Cocaine â's c-Fos in NAcc core, central amygdala and lateral habenula after acute cocaine. Cocaine â's c-Fos in orexin/hypocretin neurons in the lateral, dorsomedial and perifornical hypothalamus.</td>
          </tr>
          <tr>
            <td>Featherstone et al 2009 <xref ref-type="bibr" rid="ref94">[94]</xref></td>
            <td>Prenatal MAM treated rats</td>
            <td>Cocaine</td>
            <td>~Cocaine self-administration, ~cocaine motivation, ~cocaine sensitization.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Santos-Toscano et al 2016 <xref ref-type="bibr" rid="ref95">[95]</xref></td>
            <td>Prenatal LPS treated rats</td>
            <td>Cocaine</td>
            <td>~cocaine self-administration acquisition and dose response, ~extinction of cocaine self-administration.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Ruda-Kucerova et al 2017 <xref ref-type="bibr" rid="ref96">[96]</xref>; Ruda-Kucerova et al 2017 <xref ref-type="bibr" rid="ref97">[97]</xref></td>
            <td>Prenatal MAM treated rats</td>
            <td>Methamphetamine</td>
            <td>~Methamphetamine self-administration, ~cue-induced reinstatement for methamphetamine. âKetamine suppression of methamphetamine self-administration.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Said et al 2015 <xref ref-type="bibr" rid="ref98">[98]</xref></td>
            <td>Prenatally stressed rats</td>
            <td>Nicotine</td>
            <td>âNicotine CPP</td>
            <td>âNAcc DA D<sub>2</sub> receptor mRNA expression. Nicotine âNacc D<sub>2</sub> mRNA in prenatally stressed rats.</td>
          </tr>
          <tr>
            <td>Brown et al 2018 <xref ref-type="bibr" rid="ref99">[99]</xref></td>
            <td>Isolation rearing vs environmental enrichment in rats</td>
            <td>Nicotine</td>
            <td>âNicotine sensitization. Chronic postnatal quinpirole ânicotine sensitization.</td>
            <td>Neonatal quinpirole reduces elevated Nacc glial cell line-derived neurotrophic factor levels induced by nicotine in isolation-reared rats, but not in rats reared in an enriched environment.</td>
          </tr>
          <tr>
            <td>Waterhouse et al 2018 <xref ref-type="bibr" rid="ref100">[100]</xref></td>
            <td>Prenatal LPS treated rats</td>
            <td>Nicotine</td>
            <td>âNicotine self-administration acquisition. ~Nicotine dose-response or nicotine motivation.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Weeks et al 2019 <xref ref-type="bibr" rid="ref101">[101]</xref></td>
            <td>Prenatal MAM treated rats</td>
            <td>Nicotine</td>
            <td>~Nicotine self-administration (dose range, reinforcement schedules).âsucrose responding, âresponding for reinforcing visual stimuli alone or paired with nicotine.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Ruda-Kucerova et al 2017 <xref ref-type="bibr" rid="ref96">[96]</xref></td>
            <td>Prenatal MAM treated rats</td>
            <td>Ethanol</td>
            <td>~Ethanol consumption, ~ethanol resumption after abstinence.</td>
            <td>n/a</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
          <p>NAcc dopamine D<sub>2</sub> receptor mRNA expression levels are elevated in adult rats which are prenatally stressed <xref ref-type="bibr" rid="ref98">[98]</xref>, while chronic postnatal quinpirole treatment, which increases D<sub>2</sub> receptor sensitivity, enhances sensitization during adolescence to nicotine <xref ref-type="bibr" rid="ref99">[99]</xref>. This suggests elevated D<sub>2</sub> receptor function may underlie effects of prenatal stress on nicotine reward. Importantly, elevations in D<sub>2</sub> mRNA expression induced by prenatal stress are reduced by sub-chronic (8 day) nicotine treatment during adulthood <xref ref-type="bibr" rid="ref98">[98]</xref>, suggesting this effect may be reversible and potentially supporting the self-medication hypothesis.</p>
          <p>Chronic nicotine treatment also increases glial cell line-derived neurotrophic factor (GDNF) levels in the NAcc, and neonatal quinpirole reduces elevated GDNF levels induced by nicotine in isolation-reared rats <xref ref-type="bibr" rid="ref99">[99]</xref>. Considering GDNF is critical for dopaminergic plasticity in reward-relevant brain regions <xref ref-type="bibr" rid="ref102">[102]</xref>, it is possible that elevated sensitivity to nicotine in neurodevelopmental rodent models of schizophrenia may be due to altered dopamine receptor function in reward regions (e.g. NAcc).</p>
        </sec>
        <sec>
          <title>Ethanol</title>
          <p>Recently, Ruda-Kucerova and colleagues found no differences in ethanol consumption using a voluntary consumption procedure or resumption of ethanol drinking after abstinence in male or female rats exposed to MAM prenatally <xref ref-type="bibr" rid="ref96">[96]</xref>. However, other preclinical studies (pre-2013) have shown that early life stress (e.g. social isolation stress, chronic variable stress) can increase adult ethanol intake (e.g. <xref ref-type="bibr" rid="ref103">[103</xref>-<xref ref-type="bibr" rid="ref107">107]</xref>, see also reviews: <xref ref-type="bibr" rid="ref108">[108</xref>,<xref ref-type="bibr" rid="ref109">109]</xref>). Elevated ethanol intake in other neurodevelopmental models may be linked to molecular changes such as decreased firing of dopaminergic VTA neurons in an LPS model <xref ref-type="bibr" rid="ref103">[103]</xref>, and may be related to altered anxiety-like states, as ethanol consumption in two-bottle free choice can be reduced by administration of anxiolytic adrenergic drugs <xref ref-type="bibr" rid="ref105">[105]</xref>. Together, this suggests a critical role of the schizophrenia-relevant model on ethanol intake and ethanol-seeking behaviour.</p>
        </sec>
      </sec>
      <sec>
        <title>2.4 Pharmacological models</title>
        <p>Nicotine</p>
        <p>Only one study has examined how pharmacological models of schizophrenia respond to nicotine addiction-relevant behaviours. In models of reduced dopamine sensitivity (i.e. chronic adult amphetamine treatment) or glutamatergic dysfunction (i.e. chronic adult PCP treatment), acquisition and maintenance of intravenous nicotine self-administration is unaffected <xref ref-type="bibr" rid="ref110">[110]</xref>. It should be noted that prior research demonstrates reduced brain stimulation reward and sucrose consumption in chronic PCP models, suggesting altered addiction-like phenotypes in this model <xref ref-type="bibr" rid="ref111">[111</xref>,<xref ref-type="bibr" rid="ref112">112]</xref>. Considering this, further investigation into how pharmacological schizophrenia models respond in addiction behavioural paradigms is warranted.</p>
      </sec>
      <sec>
        <title>2.5 Interim summary</title>
        <p>From the literature reviewed, it is clear that susceptibility to addiction-like behaviour depends on the model assessed and also the drug tested. The NVHL rat in particular exhibits elevated addiction-like behaviours to many abused drugs, including psychostimulants, nicotine, ethanol and cannabinoids. Some genetic models (e.g. <italic>Disc1</italic> knockdown rats and <italic>EGF</italic> transgenic mice) also exhibit addiction-relevant behaviour for psychostimulants; however, other drugs of abuse have not been assessed in these models, and this is an area of critical further study. Similarly, pharmacological models of schizophrenia remain practically unexplored in their addiction-like behaviour. In non-lesion neurodevelopmental models, addiction-like phenotypes appear dependent on the drug tested, with several models showing elevated addiction-like behaviour for nicotine, but not methamphetamine or ethanol, and only one model exhibiting addiction-like behaviour for cocaine. Cannabinoids have not been assessed in non-lesion neurodevelopmental models. Addiction-like behaviours for opioids have not yet been assessed in any rodent model of schizophrenia, and this is an interesting area of future research, as recent research suggests patients with schizophrenia abuse opioids less than the general population <xref ref-type="bibr" rid="ref113">[113]</xref>. The reasons for why some models show addiction-like phenotypes and some do not is currently unclear; however, there appear links to altered dopaminergic signalling in models which do show addiction-like phenotypes e.g. in <italic>EGF</italic> overexpressing mice and prenatally stressed rats. The mechanisms driving the presence of addiction-like phenotypes in different models is an area of critical further research. </p>
        <p>The type of research reviewed above is critical for understanding which genetic and environmental schizophrenia risk factors influence addiction susceptibility. This is particularly important for genetic risk factors e.g. <italic>DISC1</italic>, <italic>EGF</italic>, as this could facilitate future genetic counselling for patients carrying these mutations about their elevated risk for addiction, providing a personalised medicine approach. Furthermore, these studies have started to shed light on molecular changes linked to elevated addiction propensity in schizophrenia models e.g. changes in dopamine metabolism and D<sub>2</sub> receptor function, increasing our understanding of potential mechanisms of comorbidity between these disorders. So far, the examination of mechanisms underlying addiction propensity in schizophrenia models has been limited, and has focused mostly on dopaminergic function; future research can examine other changes to other addiction-relevant neurotransmitter systems (e.g. glutamatergic, serotonergic) as well as plastic and epigenetic changes in mesocorticolimbic regions.</p>
      </sec>
    </sec>
    <sec>
      <title>3. Susceptibility of schizophrenia rodent models to effects of drugs on schizophrenia-relevant behaviour and brain function</title>
      <p>All preclinical studies reviewed in section 3 are summarised in Tables <xref ref-type="table" rid="table5">5</xref> - <xref ref-type="table" rid="table9">9</xref>.</p>
      <sec>
        <title>3.1 Genetic models</title>
        <sec>
          <title>Psychostimulants â amphetamine, methamphetamine, dopamine agonists</title>
          <p>Brain derived neurotropic factor (BDNF) is critical for hippocampal synaptic plasticity and the regulation of learning and memory <xref ref-type="bibr" rid="ref114">[114</xref>,<xref ref-type="bibr" rid="ref115">115]</xref>. BDNF protein is reduced in first episode, drug naÃ¯ve patients with schizophrenia <xref ref-type="bibr" rid="ref116">[116</xref>,<xref ref-type="bibr" rid="ref117">117]</xref> and is increased after antipsychotic treatment <xref ref-type="bibr" rid="ref118">[118]</xref>. BDNF mRNA expression is reduced in post-mortem PFC tissue from patients with schizophrenia <xref ref-type="bibr" rid="ref119">[119]</xref>, and BDNF is implicated in neural responses to psychostimulants <xref ref-type="bibr" rid="ref120">[120]</xref>. Heterozygous <italic>BDNF</italic> mice (i.e. <italic>BDNF</italic> HET mice) exhibit prepulse inhibition deficits at baseline <xref ref-type="bibr" rid="ref121">[121]</xref>, similar to that observed in patients with schizophrenia <xref ref-type="bibr" rid="ref122">[122]</xref>.</p>
          <p>Adult male <italic>BDNF</italic> HET mice are more sensitive to the disruptive effects of acute amphetamine on PPI compared to WT mice, but this sensitivity is not observed in female <italic>BDNF</italic> HET mice <xref ref-type="bibr" rid="ref121">[121]</xref>. However, adult male or female <italic>BDNF</italic> HET mice do not exhibit differential sensitivity to the disruptive effects of acute apomorphine, a dopamine D<sub>1</sub> and D<sub>2</sub> partial agonist on PPI, suggesting drug-specific effects on PPI disruption, which may be linked to the pharmacodynamics of each dopaminergic drug (e.g. amphetamine reverses monoamine transporters, while apomorphine is a dopamine D<sub>1</sub> and D<sub>2</sub> partial agonist) <xref ref-type="bibr" rid="ref121">[121]</xref>.</p>
          <p>In <italic>BDNF</italic> HET mice (sexes collapsed), chronic adolescent methamphetamine administration reduces cross-sensitization of locomotion to acute amphetamine, suggesting an attenuation of behaviours relevant to psychosis in methamphetamine-treated <italic>BDNF</italic> HET mice <xref ref-type="bibr" rid="ref123">[123]</xref>. However, chronic adolescent methamphetamine administration does not alter other schizophrenia-relevant behaviours, such as social preference, social novelty, baseline prepulse inhibition or short-term memory in the Y-maze in <italic>BDNF</italic> HET males or females, compared to WT littermate controls <xref ref-type="bibr" rid="ref121">[121</xref>,<xref ref-type="bibr" rid="ref124">124]</xref>. Methamphetamine-induced locomotion during the adolescent administration period is also similar between <italic>BDNF</italic> HET and WT mice, in both sexes <xref ref-type="bibr" rid="ref121">[121]</xref>. This suggests that chronic adolescent methamphetamine in <italic>BDNF</italic> HET mice affects cross-sensitization to amphetamine, but has no effect on some schizophrenia-relevant social and cognitive behaviours.</p>
          <p>In a mouse model of <italic>DISC1</italic> with the L100P amino acid substitution in exon 2 in <italic>Disc1</italic>, acute methamphetamine-induced locomotion is not different to WT controls <xref ref-type="bibr" rid="ref125">[125]</xref>. The effect of methamphetamine on other schizophrenia-relevant behaviours in this model has not been assessed. Considering other <italic>Disc1</italic> models (e.g. <italic>Disc1</italic> knockdown, <italic>Disc1 dominant negative</italic> mutation, discussed below) exhibit greater susceptibility to addiction-like behaviour for cocaine and the cognitive impairing effects of THC, further work on this mouse model is warranted.</p>
          <p>Together, these data suggest a limited effect of psychostimulants on schizophrenia-relevant behaviour in genetic models; however, PPI is disrupted by amphetamine and cross-sensitization to methamphetamine is reduced in <italic>BDNF</italic> HET mice.</p>
        </sec>
        <sec>
          <title>Nicotine</title>
          <p>A schizophrenia genetic susceptibility model, the <italic>Snap-25</italic> KO mouse, has a heterozygous deletion of the presynaptic protein SNAP-25, which is a critical component of the SNARE protein-protein complex responsible for action-potential triggered release of neurotransmitters <xref ref-type="bibr" rid="ref126">[126]</xref>. <italic>Snap-25</italic> KO mice do not exhibit schizophrenia-relevant behaviours in adolescence at baseline e.g. locomotor hyperactivity, social withdrawal; however, there is a gene * <italic>in utero</italic> interaction, whereby locomotor hyperactivity and social withdrawal in adolescence are evident following prenatal nicotine exposure in <italic>Snap-25</italic> KO mice, but not WT controls <xref ref-type="bibr" rid="ref126">[126]</xref>. Prenatal nicotine treatment in <italic>Snap-25</italic> KO mice also impairs striatal D<sub>2</sub> receptor dependent long-term depression (LTD) and reduces striatal D<sub>2</sub> receptor affinity, but leaves striatal CB<sub>1</sub> receptor regulated plasticity intact, compared to <italic>Snap-25</italic> KO mice without prenatal nicotine exposure <xref ref-type="bibr" rid="ref126">[126]</xref>. This suggests that intact expression and function of <italic>Snap-25</italic> may be protective against the effects of prenatal nicotine on schizophrenia-like behaviour, as well as striatal D<sub>2</sub> receptor expression and function.</p>
          <p>SNPs in the human <italic>CHRNA5</italic> gene, which encodes the Î±5 nicotinic acetylcholine (nACh) receptor subunit, increases risk for both smoking and schizophrenia <xref ref-type="bibr" rid="ref127">[127]</xref>. Mice which express a human Î±5 SNP (i.e. Î±5-SNP-expressing mice) show impaired social behaviour and sensorimotor gating, as well as lower activity of vasoactive intestinal polypeptide (VIP) interneurons, which results in increased somatostatin interneuron inhibitory drive over layer II/III pyramidal neurons <xref ref-type="bibr" rid="ref128">[128]</xref>. Importantly, the decreased activity observed in Î±5-SNP-expressing mice resembles the hypofrontality observed in patients with schizophrenia and addiction <xref ref-type="bibr" rid="ref128">[128]</xref>. Chronic nicotine administration reverses this hypofrontality, supporting the self-medication hypothesis when alterations to nACh subunit Î±5 are present <xref ref-type="bibr" rid="ref128">[128]</xref>.</p>
          <p><italic>G72</italic> is a gene from schizophrenia-associated genetic region <italic>SCZD7</italic> on chromosome 13q32-q33, and elevated <italic>G72</italic> transcript levels are observed in forebrain structures in post-mortem tissue of patients with schizophrenia <xref ref-type="bibr" rid="ref129">[129]</xref>. In transgenic mice overexpressing <italic>G72</italic>, chronic adult nicotine administration reverses impairments in social memory, working memory and PPI, compared to vehicle <italic>G72</italic> transgenic mice <xref ref-type="bibr" rid="ref130">[130]</xref>. Chronic nicotine also reverses the upregulation of oxytocin receptor binding in the central amygdala observed in vehicle treated <italic>G72</italic> transgenic mice, which may relate to improvements in social memory in nicotine-treated <italic>G72</italic> transgenic mice <xref ref-type="bibr" rid="ref131">[131]</xref>. The <italic>G72</italic> mutation is also protective against operant associative memory deficits caused by chronic nicotine, but long-term spatial learning in the Morris Water Maze is worsened by chronic nicotine treatment in <italic>G72</italic> mice <xref ref-type="bibr" rid="ref130">[130]</xref>, suggesting domain-specific effects of chronic nicotine in this model.</p>
          <p>Reelin is a large extracellular matrix protein critically involved in brain development and neural plasticity. Reelin deficits have been observed in schizophrenia <xref ref-type="bibr" rid="ref132">[132]</xref>, and heterozygous <italic>reeler</italic> mice exhibit hyperlocomotion, PPI and cognitive deficits, and perseverative behaviour <xref ref-type="bibr" rid="ref133">[133</xref>-<xref ref-type="bibr" rid="ref135">135]</xref>, as well as a loss of Purkinje cells of the cerebellum, which is also observed in patients with schizophrenia <xref ref-type="bibr" rid="ref136">[136</xref>,<xref ref-type="bibr" rid="ref137">137]</xref>. In adolescent heterozygous <italic>reeler</italic> mice, subchronic (6 day) nicotine free choice drinking ameliorates hyperlocomotion, perseverative behaviour and cognitive impairment <xref ref-type="bibr" rid="ref138">[138</xref>,<xref ref-type="bibr" rid="ref139">139]</xref>. Furthermore, in heterozygous <italic>reeler</italic> mice, subchronic nicotine restores mRNA levels of reelin and GAD67 in the cortex, hippocampus, striatum and cerebellum to WT-like levels <xref ref-type="bibr" rid="ref138">[138</xref>,<xref ref-type="bibr" rid="ref139">139]</xref>. Together, this suggests protective effects of subchronic nicotine in the heterozygous <italic>reeler</italic> mouse.</p>
          <p><italic>Neuregulin 1</italic> is a well-established risk gene for schizophrenia, involved in processes such as axon guidance, synapse formation and synaptic plasticity, as well as excitatory glutamatergic and inhibitory GABAergic transmission <xref ref-type="bibr" rid="ref140">[140</xref>,<xref ref-type="bibr" rid="ref141">141]</xref>. Alternative splicing leads to &gt;30 NRG1 isoforms, and several mouse models have been developed to study altered Nrg1 function with reference to schizophrenia. <italic>Type III Neuregulin 1</italic> heterozygous knockout (<italic>Type III Nrg1</italic> HET) mice exhibit social interaction impairment and PPI deficits at baseline. <italic>Type III Nrg1</italic> HET mice are also less sensitive to the effects of acute nicotine on theta-burst stimulation elicited long-term potentiation (LTP) in cortical-basolateral amygdala (BLA) synapses, such that in WT mice, nicotine reduces the threshold for the activation of LTP in cortical-BLA synapses, but this effect is absent in <italic>Type III Nrg1</italic> mutant mice <xref ref-type="bibr" rid="ref142">[142]</xref>. This effect in <italic>Type III Nrg1</italic> HET animals is dependent on Î±7 nicotinic receptors <xref ref-type="bibr" rid="ref142">[142]</xref>. Interestingly, chronic (6 weeks) nicotine consumption in drinking water improves PPI in <italic>Type III Nrg1</italic> transgenic mice <xref ref-type="bibr" rid="ref143">[143]</xref>. Considering that the ameliorative effects of nicotine on PPI deficits involve Î±7 nicotinic receptors <xref ref-type="bibr" rid="ref144">[144]</xref>, and type III NRG1 backsignalling regulates Î±7 nicotinic receptor surface expression <xref ref-type="bibr" rid="ref145">[145]</xref>, it is possible that chronic nicotine treatment in <italic>Type III Nrg1</italic> mutant mice may restore Î±7 nicotinic receptor surface expression in the cortex and BLA to WT levels.</p>
    <table-wrap id="table5">
      <label>Table 5</label>
      <caption>
        <title>Susceptibility of schizophrenia genetic rodent models to effects of psychostimulant drugs (including nicotine) on schizophrenia-relevant behaviour and brain function</title>
        <p>Abbreviations: BDNF, brain derived neurotrophic factor; BLA, basolateral amygdala; CB, cerebellum; DA, dopamine; FC, frontal cortex; HET, heterozygous; HPC, hippocampus; KO, knockout; LTD, long-term depression; PPI, prepulse inhibition; VIP, vasoactive intestinal polypeptide.</p>
      </caption>
      <table>
        <tbody>
          <tr>
            <td>Author, date [reference]</td>
            <td>Model</td>
            <td>Drug administration</td>
            <td>Age at Drug Treatment / Age at Behavioural Testing</td>
            <td>Results - Behaviour (âdecrease, âincrease, ~no effect)</td>
            <td>Results - Brain (âdecrease, âincrease, ~no effect)</td>
          </tr>
          <tr>
            <td>Manning et al 2013 <xref ref-type="bibr" rid="ref121">[121]</xref></td>
            <td><italic>BDNF</italic> HET mice</td>
            <td>Acute amphetamine</td>
            <td>Adult / Adult</td>
            <td>âsensitivity to amphetamine-induced PPI disruption in male but not female <italic>BDNF</italic> HET mice.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Manning et al 2013 <xref ref-type="bibr" rid="ref121">[121]</xref></td>
            <td><italic>BDNF</italic> HET mice</td>
            <td>Acute apomorphine</td>
            <td>Adult / Adult</td>
            <td>~sensitivity to apomorphine-induced PPI disruption in male or female <italic>BDNF</italic> HET mice.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Manning et al 2013 <xref ref-type="bibr" rid="ref123">[123]</xref></td>
            <td><italic>BDNF</italic> HET mice</td>
            <td>Chronic methamphetamine</td>
            <td>Adolescence / Adult</td>
            <td>âCross-sensitization to amphetamine after methamphetamine in adolescence.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Arime et al 2014 <xref ref-type="bibr" rid="ref125">[125]</xref></td>
            <td><italic>DISC1</italic> L100P mouse model</td>
            <td>Acute methamphetamine</td>
            <td>Adult / Adult</td>
            <td>~Methamphetamine-induced locomotion</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Baca et al 2013 <xref ref-type="bibr" rid="ref126">[126]</xref></td>
            <td><italic>Snap-25</italic> HET mice</td>
            <td>Chronic nicotine given to dams during gestation and after birth</td>
            <td>Prenatal / Adult</td>
            <td>âLocomotor hyperactivity and social withdrawal after prenatal nicotine exposure <italic>Snap-25</italic> KO mice.</td>
            <td>âDA D<sub>2</sub> receptor-dependent LTD in nicotine-exposed <italic>Snap-25</italic> HET mice. Prenatal nicotine exposure altered affinity and/or receptor coupling of DA D<sub>2</sub> receptors in <italic>Snap-25</italic> HET mice.</td>
          </tr>
          <tr>
            <td>Koukouli et al 2017 <xref ref-type="bibr" rid="ref128">[128]</xref></td>
            <td>Î±5-SNP-expressing mice</td>
            <td>Chronic nicotine</td>
            <td>Adult / Adult</td>
            <td>n/a</td>
            <td>âActivity of VIP interneurons, reversed by chronic nicotine administration.</td>
          </tr>
          <tr>
            <td>Hambsch et al 2041 <xref ref-type="bibr" rid="ref130">[130]</xref></td>
            <td><italic>G72</italic> overexpressing mice</td>
            <td>Chronic nicotine</td>
            <td>Adult / Adult</td>
            <td>Chronic nicotine âsocial recognition memory, âPPI and âY-maze working memory in <italic>G72</italic> transgenic mice. Chronic nicotine â MWM spatial memory in <italic>G72</italic> mice. <italic>G72</italic> mutation protects against nicotine-induced associative memory   deficits.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Zanos et al 2018 <xref ref-type="bibr" rid="ref131">[131]</xref></td>
            <td><italic>G72</italic> overexpressing mice</td>
            <td>Chronic nicotine</td>
            <td>Adult / Adult</td>
            <td>n/a</td>
            <td>âoxytocin receptor binding in CeA after chronic nicotine in <italic>G72</italic> mice.</td>
          </tr>
          <tr>
            <td>Romano et al 2013 <xref ref-type="bibr" rid="ref138">[138]</xref></td>
            <td><italic>Reeler</italic> HET mice</td>
            <td>Subchronic nicotine</td>
            <td>Adolescence / Adolescence</td>
            <td>Nicotine âhomecage locomotion in <italic>Reeler</italic> HET mice.</td>
            <td>Nicotine âReelin and GAD67 gene expression in FC, HPC, CB not striatum.</td>
          </tr>
          <tr>
            <td>Romano et al 2014 <xref ref-type="bibr" rid="ref139">[139]</xref></td>
            <td><italic>Reeler</italic> HET mice</td>
            <td>Subchronic nicotine</td>
            <td>Adolescence / Early adulthood</td>
            <td>Nicotine âhyperlocomotion, âholeboard exploration, âT-maze acquisition in <italic>Reeler</italic> HET mice. ~Nicotine on anxiety in either genotype.</td>
            <td>Nicotine âReelin and GAD67 cDNA levels in FC and HPC in <italic>Reeler</italic> HET mice.</td>
          </tr>
          <tr>
            <td>Jiang et al 2013 <xref ref-type="bibr" rid="ref142">[142]</xref></td>
            <td><italic>Type III Nrg1</italic> HET mice</td>
            <td>Acute nicotine applied to brain slices</td>
            <td>Pre-weaning / Pre-weaning</td>
            <td>n/a</td>
            <td><italic>Type III Nrg1</italic> HET mice less sensitive to nicotine effects on theta-burst stimulation elicited LTP in cortical-BLA synapses, such that in WT mice; this effect is dependent on Î±7 nicotinic receptors.</td>
          </tr>
          <tr>
            <td>Chen et al 2008 <xref ref-type="bibr" rid="ref143">[143]</xref></td>
            <td><italic>Type III Nrg1</italic> HET mice</td>
            <td>Chronic nicotine</td>
            <td>Adult / Adult</td>
            <td>Nicotine âPPI in <italic>Type III Nrg1</italic> HET mice.</td>
            <td>n/a</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
          <p>Together, these studies indicate that sensitivity to the effects of nicotine on schizophrenia-relevant behaviour and brain function depends on the model used, with most models showing protective or ameliorative effects of nicotine (e.g. <italic>G72</italic> transgenic, heterozygous <italic>reeler</italic>, <italic>Type III Nrg1</italic> transgenic mice), but some models showing development of schizophrenia-relevant behaviours only following nicotine administration (e.g. <italic>Snap-25</italic> KO mice). Considering several models show ameliorative effects of nicotine, this provides support for the self-medication hypothesis, whereby nicotine improves schizophrenia-relevant behaviour and brain function, which may help explain high usage rates in patients. Nicotine administration is accompanied by a range of neural changes, including reduced striatal LTD, increased oxytocin receptor binding in the central amygdala, increased reelin and GAD67 mRNA expression in the hippocampus, striatum, cortex and cerebellum, and a reduced threshold for LTP activation in cortical-BLA synapses, The timing of nicotine administration (e.g. neonatal <italic>vs</italic> adolescence <italic>vs</italic> adulthood) may impact on potential ameliorative effects of nicotine, but this has not yet been investigated.</p>
        </sec>
        <sec>
          <title>NMDA antagonists</title>
          <p>A novel <italic>Type III Nrg1</italic> overexpression mouse (i.e. <italic>Nrg1 III tg</italic>), which models the elevated Type III NRG1 mRNA detected in postmortem dorsolateral PFC tissue of patients with schizophrenia <xref ref-type="bibr" rid="ref146">[146]</xref>, exhibits sex-specific cognitive, social and prepulse inhibition impairment, but no changes to locomotor activity in either sex <xref ref-type="bibr" rid="ref147">[147]</xref>. However, acute hyperlocomotor activity in response to the NMDA antagonist MK-801 is blunted in adult female <italic>Nrg1 III tg</italic> mice <xref ref-type="bibr" rid="ref147">[147]</xref>. Interestingly, this effect is not observed in adult male <italic>Nrg1 III tg</italic> mice, where hyperlocomotion following MK-801 is similar to WT mice <xref ref-type="bibr" rid="ref148">[148]</xref>. This may suggest a reduced number of available NMDA receptors in <italic>Nrg1 III tg</italic> female mice, in alignment with the NMDA receptor hypofunction theory of schizophrenia <xref ref-type="bibr" rid="ref56">[56]</xref>. However, in <italic>BDNF</italic> HET mice, acute MK-801 does not differentially affect prepulse inhibition in male or female <italic>BDNF</italic> HETs compared to WT mice <xref ref-type="bibr" rid="ref121">[121]</xref>, indicating model-specific effects of MK-801 on schizophrenia-relevant behaviour.</p>
        </sec>
        <sec>
          <title>Cannabinoids: Cannabidiol</title>
          <p>Spontaneously hypertensive rats (SHR) are a model of schizophrenia, exhibiting behaviours including hyperlocomotion, sensorimotor gating deficits, associative memory impairment and reduced social behaviour <xref ref-type="bibr" rid="ref149">[149]</xref>. Cannabidiol (CBD) is a non-intoxicating cannabis plant compound which is a weak CB<sub>1</sub> receptor negative allosteric modulator <xref ref-type="bibr" rid="ref150">[150]</xref>, and is being investigated as a potential anti-psychotic <xref ref-type="bibr" rid="ref151">[151]</xref>. In SHR, acute CBD treatment does not reverse hyperlocomotion and social withdrawal <xref ref-type="bibr" rid="ref152">[152]</xref>. However, chronic low dose (i.e. 0.5 â 5 mg/kg) CBD treatment during adolescence dose-dependently reverses locomotor hyperactivity, sensorimotor gating deficits and fear-associated cognitive impairment in SHR <xref ref-type="bibr" rid="ref153">[153]</xref>. Chronic adolescent CBD treatment also increases the ratio of 5-HIAA/serotonin tissue levels in the PFC in adulthood in both SHR and controls, but CBD has no effect on serotonin levels in the dorsal striatum or BDNF levels in the PFC or dorsal striatum <xref ref-type="bibr" rid="ref153">[153]</xref>, suggesting that CBD ameliorates schizophrenia-relevant behaviours in SHR by a different mechanism (e.g. increasing anandamide levels <xref ref-type="bibr" rid="ref154">[154]</xref>).</p>
          <p>Similarly, in a different <italic>Neuregulin 1</italic> mouse model of schizophrenia (i.e. the <italic>Neuregulin 1 transmembrane domain</italic> heterozygous mouse, <italic>Nrg1 TM</italic> HET), which exhibits hyperlocomotion, impaired social behaviour and PPI deficits at baseline <xref ref-type="bibr" rid="ref155">[155</xref>,<xref ref-type="bibr" rid="ref156">156]</xref>, acute treatment with higher doses of CBD (i.e. 50 - 100 mg/kg) reverses PPI deficits, compared to vehicle treated <italic>Nrg1</italic> mutants <xref ref-type="bibr" rid="ref157">[157]</xref>. Also, chronic treatment in this dose range increases social behaviour and increases GABA-A receptor binding in the granular retrosplenial cortex in adult <italic>Nrg1 TM</italic> HET mice <xref ref-type="bibr" rid="ref157">[157]</xref>. However, chronic CBD does not reverse locomotor hyperactivity, sensorimotor gating deficits or reduced 5-HT<sub>2A</sub> receptor binding density in the substantia nigra of these mice <xref ref-type="bibr" rid="ref157">[157]</xref>. While this indicates CBD can have ameliorative effects on schizophrenia-relevant behaviours, it also shows that the effects of CBD can depend on the model used, the age targeted (e.g. adolescence <italic>vs</italic> adulthood) and the dose used.</p>
        </sec>
        <sec>
          <title>Cannabinoids: Î<sup>9</sup>-Tetrahydrocannabinol</title>
          <p>Several models of genetic risk for schizophrenia are more sensitive to behavioural and neural effects of THC. The dominant negative <italic>Disc1</italic> (<italic>DN-Disc1</italic>) mutant mouse is more susceptible to the effects of adolescent THC treatment than WT controls <xref ref-type="bibr" rid="ref158">[158]</xref>. Chronic THC in adolescence increases anxiolytic behaviour and impairs short-term memory in <italic>DN-Disc1</italic> mutant mice, where these effects are not apparent in WT controls <xref ref-type="bibr" rid="ref158">[158]</xref>. The cognitive impairment induced by THC in <italic>DN-Disc1</italic> mice may be linked to hippocampal CB<sub>1</sub> receptor and BDNF levels, as chronic THC selectively increases hippocampal CB<sub>1</sub> receptor and BDNF protein levels in WT mice but not in <italic>DN-Disc1</italic> mice <xref ref-type="bibr" rid="ref158">[158]</xref>. Interestingly, overexpression of hippocampal BDNF in <italic>DN-Disc1</italic> mice prevents THC-induced cognitive impairment in these mice, suggesting that BDNF upregulation may be a homeostatic response designed to maintain proper cognitive function following exogenous insult <xref ref-type="bibr" rid="ref158">[158]</xref>.</p>
          <p>In the <italic>Nrg1 TM</italic> HET model of genetic risk for schizophrenia, <italic>Nrg1 TM</italic> HET males are more sensitive to the locomotor suppressing and PPI enhancing effects of acute THC than are THCâtreated WT controls <xref ref-type="bibr" rid="ref159">[159]</xref>. Female <italic>Nrg1 TM</italic> HET mice do not exhibit this elevated sensitivity to THC in terms of locomotion and PPI, and are even less susceptible than WTs to the supressing effects of THC on some social behaviours <xref ref-type="bibr" rid="ref160">[160]</xref>. The <italic>Nrg1</italic> gene mutation assessed also impacts on susceptibility to THC, as male mice from a different <italic>Nrg1</italic> mutant model, i.e. <italic>Nrg1 III tg</italic> mice do not exhibit altered THC-induced locomotion, social behaviour or prepulse inhibition, compared to THC-treated WT controls <xref ref-type="bibr" rid="ref161">[161]</xref>.</p>
          <p>In adolescence, the <italic>Nrg1 TM</italic> HET mutation protects against inhibiting effects of chronic THC on investigative social behaviours in male mice <xref ref-type="bibr" rid="ref162">[162]</xref>. However, adolescent <italic>Nrg1 TM</italic> HET mice continue to demonstrate locomotor suppression after 2 days washout from THC where WTs do not, suggesting increased susceptibility to locomotor, but not social effects of THC in adolescent <italic>Nrg1 TM</italic> mutants <xref ref-type="bibr" rid="ref162">[162]</xref>.</p>
          <p>There are complex effects of chronic adolescent THC treatment on receptor expression across the brain in <italic>Nrg1 TM</italic> HET mice. Chronic adolescent THC increases CB<sub>1</sub> receptor binding in the substantia nigra in <italic>Nrg1</italic> but not WT mice <xref ref-type="bibr" rid="ref162">[162]</xref>. Considering the role of CB<sub>1</sub> receptors in controlling dopamine release in the basal ganglia direct pathway, this elevation in CB<sub>1</sub> receptor binding may reflect continued suppression of locomotion following chronic THC in adolescent <italic>Nrg1</italic> mutant mice <xref ref-type="bibr" rid="ref162">[162]</xref>. In addition, the elevation in NMDA receptor binding in the hippocampus, auditory cortex and cingulate cortex in THC-treated adolescent <italic>Nrg1 TM</italic> HET but not WT mice may also contribute to the continued locomotor suppression in <italic>Nrg1</italic> mutants, as NMDA receptor antagonism induces hyperlocomotion, and increased NMDA receptor binding may reflect reduced locomotion (<xref ref-type="bibr" rid="ref162">[162]</xref> see also <xref ref-type="bibr" rid="ref163">[163]</xref>). Finally, adolescent THC treatment increases 5-HT<sub>2A</sub> receptor binding in the agranular insular cortex in <italic>Nrg1</italic> mutants, whereas in WTs, THC treatment reduces 5-HT<sub>2A</sub> binding in the agranular insular cortex, ventral pallidum and cingulate cortex, and increases 5-HT<sub>2A</sub> binding in the caudate-putamen <xref ref-type="bibr" rid="ref162">[162]</xref>. In patients with schizophrenia, reduced 5-HT<sub>2A</sub>R density is observed post-mortem in prefrontal and other cortical regions <xref ref-type="bibr" rid="ref164">[164</xref>,<xref ref-type="bibr" rid="ref165">165]</xref>, and may relate to social withdrawal and social anxiety observed in patients. The elevation of 5-HT<sub>2A</sub> receptor binding in <italic>Nrg1</italic> mutants may reflect the protective effect of the <italic>Nrg1</italic> genotype on the social behaviour-suppressing effects of THC <xref ref-type="bibr" rid="ref162">[162]</xref>.</p>
          <p>Using a proteomics approach, Spencer and colleagues <xref ref-type="bibr" rid="ref163">[163]</xref> demonstrated that adolescent <italic>Nrg1 TM</italic> mutants chronically treated with THC show an altered profile of proteins which affect synapse formation and dendritic spine dynamics <xref ref-type="bibr" rid="ref163">[163]</xref>. Chronic adolescent THC in <italic>Nrg1</italic> mutants induces changes in several proteins involved in intracellular trafficking and stabilization of NMDA receptors at the synapse (e.g. FLOT1, APOA1, GPSM2) <xref ref-type="bibr" rid="ref163">[163]</xref>. Interestingly, THC treatment caused proteomic changes in WT mice suggestive of greater oxidative stress and neurodegeneration than in <italic>Nrg1</italic> mutant mice, again suggesting a degree of protection against some effects of THC in <italic>Nrg1 TM</italic> HET mice <xref ref-type="bibr" rid="ref163">[163]</xref>. These findings may help to explain the altered behavioural responses of <italic>Nrg1 TM</italic> HET mice to cannabinoid treatment.</p>
    <table-wrap id="table6">
      <label>Table 6</label>
      <caption>
        <title>Susceptibility of schizophrenia genetic rodent models to effects of drugs (NMDA antagonists and cannabinoids) on schizophrenia-relevant behaviour and brain function</title>
        <p>Abbreviations: 5-HT, serotonin; CB<sub>1</sub>, cannabinoid receptor 1; CBD, cannabidiol; Disc1, disrupted in schizophrenia 1; GABA; Gamma Aminobutyric Acid; NMDA; N-methyl-d-aspartate; Nrg1, Neuregulin 1; PFC; prefrontal cortex; PPI, prepulse inhibition; SHR, spontaneously hypertensive rats; SN, substantia nigra; THC, Î9-tetrahydrocannabinol; tg, transgenic; WT, wild-type like.</p>
      </caption>
      <table>
        <tbody>
          <tr>
            <td>Author, date [reference]</td>
            <td>Model</td>
            <td>Drug administration</td>
            <td>Age at Drug Treatment / Age at Behavioural Testing</td>
            <td>Results - Behaviour (âdecrease, âincrease, ~no effect)</td>
            <td>Results - Brain (âdecrease, âincrease, ~no effect)</td>
          </tr>
          <tr>
            <td>Olaya et al 2018 <xref ref-type="bibr" rid="ref147">[147]</xref>; Olaya et al 2017 <xref ref-type="bibr" rid="ref148">[148]</xref></td>
            <td><italic>Type III Nrg1</italic> overexpressing mice</td>
            <td>Acute MK-801</td>
            <td>Adult / Adult</td>
            <td>âMK-801-induced locomotion in female <italic>Nrg1 III tg</italic> mice (vs WT). ~MK-801-induced locomotion in male <italic>Nrg1 III tg</italic> mice (vs WT).</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Manning et al 2013 <xref ref-type="bibr" rid="ref121">[121]</xref></td>
            <td><italic>BDNF</italic> HET mice</td>
            <td>Chronic methamphetamine, acute MK-801</td>
            <td>Adult / Adult</td>
            <td>~MK-801-induced PPI disruption in <italic>BDNF</italic> HET mice (vs WT). ~Chronic methamphetamine on MK-801-induced PPI disruption in <italic>BDNF</italic> HET (vs WT).</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Almeida et al 2013 <xref ref-type="bibr" rid="ref152">[152]</xref></td>
            <td>SHR</td>
            <td>Acute CBD</td>
            <td>Adult / Adult</td>
            <td>~CBD on hyperlocomotion and social withdrawal in SHR.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Peres et al 2018 <xref ref-type="bibr" rid="ref153">[153]</xref></td>
            <td>SHR</td>
            <td>Chronic CBD</td>
            <td>Adolescence / Adult</td>
            <td>CBD âhyperlocomotion âPPI and âcognitive impairment in SHR.</td>
            <td>~CBD on ratio of PFC 5-HIAA/serotonin levels between SHR and controls. ~CBD on serotonin levels in dorsal striatum or <italic>BDNF</italic> levels in PFC or dorsal striatum.</td>
          </tr>
          <tr>
            <td>Long et al 2012 <xref ref-type="bibr" rid="ref157">[157]</xref></td>
            <td><italic>Nrg1 TM</italic> HET mice</td>
            <td>Acute and chronic CBD</td>
            <td>Adult / Adult</td>
            <td>Acute CBD âPPI in <italic>Nrg1 TM</italic> HET mice. Chronic CBD âsocial behaviour in <italic>Nrg1 TM</italic> HET mice. ~Chronic CBD on hyperlocomotion or PPI deficits in <italic>Nrg1 TM</italic> HET mice.</td>
            <td>CBD âGABA-A receptor binding in the granular retrosplenial cortex in <italic>Nrg1 TM</italic> HET mice. ~CBD on CB<sub>1</sub> receptor, NMDA or 5-HT1A receptor binding across several forebrain regions in WT or <italic>Nrg1 TM</italic> HET mice.</td>
          </tr>
          <tr>
            <td>Segal-Gavish et al 2017 <xref ref-type="bibr" rid="ref158">[158]</xref></td>
            <td>Dominant negative <italic>Disc1</italic> mice</td>
            <td>Chronic THC</td>
            <td>Adolescence / Early adulthood</td>
            <td>THC âanxiolytic behaviour and âshort-term memory in <italic>Disc1</italic> mutant mice,. ~THC on locomotion in <italic>Disc1</italic> mutant mice. HPC <italic>BDNF</italic> overexpression in DIsc1 mutant   mice âcognition.</td>
            <td>THC âHPC CB<sub>1</sub> receptor and <italic>BDNF</italic> protein levels in WT but not <italic>Disc1</italic> mice.</td>
          </tr>
          <tr>
            <td>Boucher et al 2007 <xref ref-type="bibr" rid="ref159">[159]</xref></td>
            <td><italic>Nrg1 TM</italic> HET mice</td>
            <td>Acute THC</td>
            <td>Adult / Adult</td>
            <td>THC âlocomotion, âanxiety and âPPI in <italic>Nrg1 TM</italic> HET mice.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Long et al 2010 <xref ref-type="bibr" rid="ref160">[160]</xref></td>
            <td><italic>Nrg1 TM</italic> HET mice</td>
            <td>Acute THC</td>
            <td>Adult / Adult</td>
            <td>~THC-induced locomotion, PPI, anxiety, cognition between <italic>Nrg1 TM</italic> HET vs WT. THC âsocial behaviours in WT but not <italic>Nrg1 TM</italic> HET mice</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Lloyd et al 2018 <xref ref-type="bibr" rid="ref161">[161]</xref></td>
            <td><italic>Nrg1 TM</italic> HET mice</td>
            <td>Acute THC</td>
            <td>Adult / Adult</td>
            <td>~THC-induced locomotion, social behaviour or PPI between Nrg1 type III overexpressing mice vs THC-treated WT controls.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Long et al 2013 <xref ref-type="bibr" rid="ref162">[162]</xref></td>
            <td><italic>Nrg1 TM</italic> HET mice</td>
            <td>Acute and chronic THC</td>
            <td>Adolescence / Early adulthood</td>
            <td><italic>Nrg1 TM</italic> HET mutation protects against THC-induced âin social behaviour. âLocomotion in <italic>Nrg1 TM</italic> HET mice after THC washout. ~THC-induced anxiety or PPI between <italic>Nrg1 TM</italic> HET vs WT.</td>
            <td>THC âCB1 receptor binding in SN of <italic>Nrg1 TM</italic> HET mice, THC âNMDA receptor binding in the HPC, auditory cortex and cingulate cortex in <italic>Nrg1 TM</italic> HET mice. THC â5-HT2A receptor binding in the agranular insular cortex in <italic>Nrg1</italic> mutants. THC â5-HT2A binding in the agranular insular cortex, VP and cingulate cortex, and â5-HT2A binding in the striatum.</td>
          </tr>
          <tr>
            <td>Spencer et al 2013 <xref ref-type="bibr" rid="ref163">[163]</xref></td>
            <td><italic>Nrg1 TM</italic> HET mice</td>
            <td>Acute and chronic THC</td>
            <td>Adolescence / Early adulthood</td>
            <td>n/a</td>
            <td>THC alters profile of proteins which affect synapse formation and dendritic spine dynamics in <italic>Nrg1 TM</italic> mutants.</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
          <p>Clinical data indicates a complex relationship between cannabis use and schizophrenia susceptibility between the sexes <xref ref-type="bibr" rid="ref166">[166</xref>-<xref ref-type="bibr" rid="ref169">169]</xref>. It is possible risk genes modulate this relationship, e.g. BDNF Val66Met genotype when coupled with cannabis abuse modulates risk for psychosis onset in females, but not males <xref ref-type="bibr" rid="ref167">[167]</xref>. The preclinical data presented above suggests complex interactions between cannabinoid treatment, schizophrenia genetic susceptibility and sex, where cannabinoids can both protect against and worsen schizophrenia-like behaviour. Further investigation into sex differences in these cannabis-gene interactions is warranted.</p>
        </sec>
      </sec>
      <sec>
        <title>3.2 Lesion models</title>
        <sec>
          <title>Psychostimulants: amphetamine</title>
          <p>In NVHL rats, acute amphetamine-induced locomotion is enhanced compared to sham controls <xref ref-type="bibr" rid="ref72">[72</xref>,<xref ref-type="bibr" rid="ref77">77</xref>,<xref ref-type="bibr" rid="ref85">85]</xref>. The effects of NVHL on amphetamine-induced locomotion may be age-dependent, as rats in early adolescence (i.e. PND 35) do not exhibit altered acute amphetamine-induced locomotion compared to controls, where NVHL rats in late adolescence/young adulthood (PND 56) do <xref ref-type="bibr" rid="ref85">[85]</xref>. This indicate an age * drug interaction in NVHL rats, potentially reflecting late adolescent developmental changes in the mesolimbic pathway, relevant to the development of schizophrenia at this age.</p>
        </sec>
        <sec>
          <title>Nicotine</title>
          <p>NVHL rats exhibit deficits in learning and memory in the radial arm maze <xref ref-type="bibr" rid="ref72">[72</xref>,<xref ref-type="bibr" rid="ref74">74</xref>,<xref ref-type="bibr" rid="ref170">170]</xref>. Unlike some genetic models (e.g. <italic>G72</italic> transgenic mice, reeler mice, <italic>Type III Nrg1</italic> HET mice, detailed above), chronic nicotine treatment in adolescence or adulthood does not reverse cognitive impairment in the radial arm maze in NVHL rats <xref ref-type="bibr" rid="ref74">[74</xref>,<xref ref-type="bibr" rid="ref170">170]</xref>. Chronic adolescent or adult nicotine treatment also does not differentially affect nACh receptor binding in mPFC or ventral striatum in NVHL rats compared to sham controls <xref ref-type="bibr" rid="ref170">[170]</xref>. These studies suggest limited effects of nicotine on learning and memory, as well as nACh receptor binding in NVHL rats. The effects of nicotine on other schizophrenia-relevant domains e.g. hyperlocomotion, social behaviour, sensorimotor gating are yet to be examined.</p>
        </sec>
      </sec>
      <sec>
        <title>3.3 Non-lesion neurodevelopmental models</title>
        <sec>
          <title>Psychostimulants: amphetamine</title>
          <p>Offspring of maternal LPS-treated rats are more sensitive to amphetamine in early adulthood, displaying a reduced breakpoint for a food reinforcer under amphetamine treatment, and greater amphetamine-induced locomotion than controls <xref ref-type="bibr" rid="ref171">[171]</xref>. However, these effects depend on the gestational day (G12 vs G16) at which LPS is administered, suggesting age-specific effects of LPS on brain development and subsequent drug reward susceptibility <xref ref-type="bibr" rid="ref171">[171]</xref>. Embryonic midbrain dopaminergic neurons are reduced 48 hr after LPS treatment at E16 but this recovers by adolescence, while midbrain dopaminergic neurons are unaffected by LPS treatment at E12 <xref ref-type="bibr" rid="ref171">[171]</xref>. This suggests altered dopaminergic function following maternal LPS treatment, which is protocol dependent and shows a degree of recovery with time. Considering the recovery of dopaminergic midbrain neurons following LPS treatment, it is possible sensitivity to amphetamine in LPS rats is mediated by dopaminergic neurons in a different brain region e.g. forebrain regions such as the dorsal and ventral striatum.</p>
        </sec>
        <sec>
          <title>Nicotine</title>
          <p>Cognitive deficits in rats prenatally treated with LPS are ameliorated by chronic nicotine self-administration, compared to LPS rats which self-administer saline <xref ref-type="bibr" rid="ref100">[100]</xref>. This may indicate a restoration of deficits in nicotinergic Î±7 and Î±4Î²2 receptor subtype function in LPS treated rats; however, this has not been assessed experimentally <xref ref-type="bibr" rid="ref100">[100]</xref>. The effects of acute or chronic nicotine in neurodevelopmental models (e.g. MAM, Poly I:C, LBN) have not yet been assessed. However, considering interactions between the immune system and nicotine <xref ref-type="bibr" rid="ref172">[172</xref>,<xref ref-type="bibr" rid="ref173">173]</xref>, this is an interesting area of future research.</p>
        </sec>
        <sec>
          <title>Cannabinoids: CBD, WIN, fatty acid amide hydrolase inhibitors</title>
          <p>Osborne and colleagues examined the effects of CBD in a rat Poly I:C model of maternal infection, which exhibit cognitive deficits and social interaction impairment <xref ref-type="bibr" rid="ref174">[174]</xref>. In males, chronic CBD treatment in early adulthood rescued deficits in short term working memory in the novel object recognition test and rewarded t-maze, as well as social interaction deficits in Poly I:C rats, with no effects of CBD in non-Poly I:C treated rats <xref ref-type="bibr" rid="ref174">[174]</xref>. Chronic CBD treatment in early adulthood attenuated Poly I:C-induced deficits in CB<sub>1</sub> receptor binding in the PFC as well as GAD67 binding in the hippocampus <xref ref-type="bibr" rid="ref175">[175]</xref>. CBD also increased protein levels of the interneuron marker parvalbumin in the hippocampus, irrespective of maternal infection, but did not affect NMDA or GABA-A receptor binding or protein levels of fatty acid amide hydrolase (FAAH), the enzyme which degrades anandamide, in the PFC or hippocampus. Overall, these findings suggest that in male rats, CBD may reverse schizophrenia-relevant negative and cognitive behaviours by restoring cannabinoid/GABAergic signalling deficits.</p>
          <p>Similarly, in female Poly I:C rats, chronic CBD in early adulthood attenuates recognition memory and social interaction deficits, and reverses the Poly I:C induced reduction in NMDA receptor binding in the PFC <xref ref-type="bibr" rid="ref176">[176]</xref>. Poly I:C also increases GAD67 and parvalbumin interneuron protein levels in the hippocampus <xref ref-type="bibr" rid="ref176">[176]</xref>. Interestingly, CBD administration control rats (i.e. no Poly I:C treatment) reduces social interaction, as well as cannabinoid CB<sub>1</sub> receptor and NMDA receptor binding in the PFC, suggesting that CBD administration to healthy rats may have negative consequences on social behaviour and brain maturation in adulthood <xref ref-type="bibr" rid="ref176">[176]</xref>. Together, this supports the antipsychotic potential of CBD for the treatment of cognitive and negative symptoms in schizophrenia but not healthy controls (review: <xref ref-type="bibr" rid="ref151">[151]</xref>), and suggests CBD could be acting by reversing PFC CB<sub>1</sub> and NMDA receptor dysfunction and increasing GABA receptor function in the hippocampus, in a sex-specific manner.</p>
          <p>In another model of maternal infection, the MAM model, chronic adolescent treatment with the CB<sub>1</sub> receptor agonist WIN prevents amphetamine-induced hyperlocomotion, but does not reverse deficits in a set-shifting task in MAM treated rats <xref ref-type="bibr" rid="ref177">[177]</xref>. Interestingly, the effect of WIN on amphetamine-induced locomotion in MAM rats occurs in the absence of changes to dopaminergic neuron firing in the VTA <xref ref-type="bibr" rid="ref177">[177]</xref>, although cell activity in other brain regions relevant to locomotor sensitization (e.g. NAcc) were not assessed in this study. These findings are surprising as CB<sub>1</sub> receptor agonists often exacerbate schizophrenia symptoms <xref ref-type="bibr" rid="ref178">[178]</xref>. The authors suggest that pubertal exposure to WIN may have changed the expression of components of the endocannabinoid system in brain structures related to motivation and motor control, thus limiting amphetamine-induced hyperlocomotion in MAM rats <xref ref-type="bibr" rid="ref177">[177]</xref>.</p>
          <p>In a novel rodent model of schizophrenia susceptibility, the F2 methylazoxymethanol acetate (F2 MAM) rat, where only a proportion (~40%) of rats display a schizophrenia-relevant phenotype (i.e. hyperdopaminergic phenotype characterized by increased dopamine neuron activity in the VTA), subchronic adolescent WIN treatment increases the proportion of F2 MAM rats with a schizophrenia-like phenotype (i.e. hyperdopaminergia) in early adulthood (i.e. from 36% to 71%), with no corresponding increase in schizophrenia-like phenotypes in WT controls <xref ref-type="bibr" rid="ref179">[179]</xref>. Adolescent WIN treatment also increases sensitivity to acute amphetamine locomotor activity in early adulthood in F2 MAM rats, compared to WT controls <xref ref-type="bibr" rid="ref179">[179]</xref>. Similarly, increasing endogenous cannabinoid signalling via the FAAH inhibitor URB597 also increases the proportion of F2 MAM rats with a schizophrenia-like phenotype in early adulthood (i.e. from 40% to 80%), but unlike WIN treatment, has no effect on amphetamine sensitivity <xref ref-type="bibr" rid="ref179">[179]</xref>. This data mirrors clinical observations of increased risk for developing schizophrenia following cannabis abuse in individuals with genetic risk for the disorder <xref ref-type="bibr" rid="ref180">[180</xref>-<xref ref-type="bibr" rid="ref182">182]</xref>, and will facilitate further investigation of the molecular and genetic mechanisms driving this susceptibility.</p>
    <table-wrap id="table7">
      <label>Table 7</label>
      <caption>
        <title>Susceptibility of schizophrenia neurodevelopmental rodent models to effects of drugs on schizophrenia-relevant behaviour and brain function</title>
        <p>Abbreviations: CB<sub>1</sub>, cannabinoid receptor 1; CBD, cannabidiol; E, embryonic day; FAAH, fatty acid amide hydrolase; GAD67, glutamate decarboxylase 67; HPC, hippocampus; LPS; lipopolysaccharide; MAM, mitotoxin methylazoxymethanol acetate; NACh, nicotine acetylchloline; NMDA; N-methyl-d-aspartate; NORT, novel object recognition; NVHL, neonatal ventral hippocampal lesion; PFC, prefrontal cortex; RAM, radial arm maze; VTA; ventral tegmental area; WIN; WIN 55,212-2.</p>
      </caption>
      <table>
        <tbody>
          <tr>
            <td>Author, date [reference]</td>
            <td>Model</td>
            <td>Drug administration</td>
            <td>Age at Drug Treatment / Age at Behavioural Testing</td>
            <td>Results - Behaviour (âdecrease, âincrease, ~no effect)</td>
            <td>Results - Brain (âdecrease, âincrease, ~no effect)</td>
          </tr>
          <tr>
            <td>Gallo et al 2014 Behav Brain Res <xref ref-type="bibr" rid="ref85">[85]</xref>; see also Rao et al 2016 <xref ref-type="bibr" rid="ref72">[72]</xref>, Jean-Blanc et al 2016 <xref ref-type="bibr" rid="ref77">[77]</xref></td>
            <td>NVHL rat</td>
            <td>Acute amphetamine</td>
            <td>Early and late adolescence / Early and late adolescence</td>
            <td>~Amphetamine-induced locomotion in early adolescence between NVHL and controls. âAmphetamine-induced locomotion in late adolescence in NVHL vs controls.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Berg et al 2014 <xref ref-type="bibr" rid="ref74">[74]</xref></td>
            <td>NVHL rat</td>
            <td>Chronic nicotine</td>
            <td>Adolescence / Adult</td>
            <td>~Chronic nicotine on cognitive impairment in the RAM in NVHL rats. Chronic nicotine âcognition in the RAM in WTs.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Berg et al 2015 <xref ref-type="bibr" rid="ref170">[170]</xref></td>
            <td>NVHL rat</td>
            <td>Chronic nicotine</td>
            <td>Adolescence or adulthood / Late adolescence or adulthood</td>
            <td>~Chronic nicotine on cognitive impairment in NVHL rats. Chronic nicotine âfood reward consumption in RAM in NVHL.</td>
            <td>Nicotine âNACh receptor binding in mPFC not striatum in NVHL rats.</td>
          </tr>
          <tr>
            <td>Straley et al 2017 <xref ref-type="bibr" rid="ref171">[171]</xref></td>
            <td>Prenatal LPS-treated rats</td>
            <td>Acute amphetamine</td>
            <td>Early adulthood / Adolescence and early adulthood</td>
            <td>âBreakpoint for food under amphetamine in LPS rats. âAmphetamine-induced locomotion in LPS rats.</td>
            <td>âEmbryonic midbrain dopaminergic neurons 48 hr after LPS treatment at E16; this recovers by adolescence. ~LPS at E12 on midbrain dopaminergic neurons.</td>
          </tr>
          <tr>
            <td>Waterhouse et al 2018 <xref ref-type="bibr" rid="ref100">[100]</xref></td>
            <td>Prenatal LPS treated rats</td>
            <td>Chronic nicotine</td>
            <td>Adult / Adult</td>
            <td>Nicotine â cognitive impairment in latent inhibition and delayed non-matching to sample tasks in LPS rats.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Osbourne et al 2017 <xref ref-type="bibr" rid="ref174">[174]</xref>; Osbourne et al 2019 <xref ref-type="bibr" rid="ref175">[175]</xref></td>
            <td>Prenatal Poly I:C treated rats</td>
            <td>Chronic CBD</td>
            <td>Late adolescence / Early adulthood</td>
            <td>CBD âshort term working memory in NORT and T-maze, and âsocial interaction in Poly I:C rats</td>
            <td>In Poly I:C rats, CBD âCB<sub>1</sub> receptor binding in PFC and âGAD67 receptor binding in HPC. CBD âparvalbumin protein levels in HPC in Poly I:C rats and controls. ~CBD on NMDA, GABA-A or FAAH protein in PFC or HPC.</td>
          </tr>
          <tr>
            <td>Osbourne et al 2019 <xref ref-type="bibr" rid="ref176">[176]</xref></td>
            <td>Prenatal Poly I:C treated rats</td>
            <td>Chronic CBD</td>
            <td>Late adolescence / Early adulthood</td>
            <td>CBD âsocial recognition memory and social interaction in female Poly I:C rats, but âsocial interaction in control rats.</td>
            <td>CBD âNMDA binding in PFC in Poly I:C rats. CBD reduced CB1 and NMDA binding in PFC in controls.</td>
          </tr>
          <tr>
            <td>Gomes et al 2014 <xref ref-type="bibr" rid="ref177">[177]</xref></td>
            <td>Prenatal MAM treated rats</td>
            <td>Chronic WIN</td>
            <td>Adolescence / Adult</td>
            <td>WIN âamphetamine-induced hyperlocomotion in MAM rats. ~WIN on set-shifting task deficits in MAM rats.</td>
            <td>âSpontaneous dopaminergic cell firing in the VTA in MAM rats. ~WIN on dopaminergic cell firing in VTA in MAM rats.</td>
          </tr>
          <tr>
            <td>Aguilar et al 2018 <xref ref-type="bibr" rid="ref179">[179]</xref></td>
            <td>F2 methylazoxymethanol acetate (F2 MAM) rat</td>
            <td>Chronic WIN or FAAH inhibitor URB597</td>
            <td>Adolescence / Adult</td>
            <td>WIN âamphetamine-induced locomotion in F2 MAM rats. ~FAAH inhibitor URB597 on amphetamine-induced locomotion in F2 MAM rats.</td>
            <td>WIN and FAAH inhibitor URB597 âproportion of F2 MAM rats with hyperdopaminergic phenotype in VTA.</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
        </sec>
      </sec>
      <sec>
        <title>3.4 Pharmacological models</title>
        <sec>
          <title>Psychostimulants: amphetamine</title>
          <p>In a rat model of dopamine supersensitivity (i.e. withdrawal from chronic haloperidol), amphetamine treatment increases the pursuit of food-based reward cues more vigorously in dopamine supersensitive rats than control rats <xref ref-type="bibr" rid="ref183">[183</xref>-<xref ref-type="bibr" rid="ref185">185]</xref>. This effect does not appear mediated by NAcc function, as intra-NAcc amphetamine injections or NAcc inhibition via GABA receptor agonists does not alter pursuit of food-based cues <xref ref-type="bibr" rid="ref185">[185]</xref>. Baseline food-seeking, however, is unaltered by dopamine supersensitivity <xref ref-type="bibr" rid="ref183">[183]</xref>. Amphetamine-induced locomotion as well as c-fos mRNA in the caudate putamen is also elevated following chronic haloperidol, compared to vehicle-treated controls <xref ref-type="bibr" rid="ref184">[184]</xref>. While further research needs to be conducted in this field, these results suggest altered reward could be present in schizophrenia-relevant pharmacological models of altered dopamine function.</p>
        </sec>
        <sec>
          <title>Nicotine</title>
          <p>Information processing, in particular 40 Hz steady-state auditory evoked responses, is deficient in patients with schizophrenia <xref ref-type="bibr" rid="ref186">[186]</xref>, and assessment of auditory evoked responses in rodents can be used to model this in the laboratory. Acute MK-801 impairs auditory-evoked neural responses in anaesthetised rats <xref ref-type="bibr" rid="ref187">[187]</xref>, and MK-801 also exacerbates psychotic symptoms in patients with schizophrenia <xref ref-type="bibr" rid="ref188">[188]</xref>. Interestingly, MK-801 induced impairment in auditory-evoked responses is ameliorated by acute nicotine administration <xref ref-type="bibr" rid="ref187">[187]</xref>. Similarly, acute MK-801-induced memory impairments in mice are improved by acute nicotine administration <xref ref-type="bibr" rid="ref189">[189]</xref>, while chronic nicotine reverses heightened impulsivity in a mouse chronic PCP model <xref ref-type="bibr" rid="ref190">[190]</xref>. Finally, systemic and intra-orbitofrontal cortex administration of nicotine or the nAChR agonist ABT-418 dose-dependently ameliorates chronic ketamine-induced impairments in a multisensory integration task, and this effect is blocked by GABA-A receptor antagonism <xref ref-type="bibr" rid="ref191">[191]</xref>. These effects appear dependent on parvalbumin interneurons in the orbitofrontal cortex, as silencing parvalbumin interneurons impairs multisensory integration task performance, and this is reversed by ABT-418 administration <xref ref-type="bibr" rid="ref191">[191]</xref>. Collectively, this suggests acute and chronic nicotine can improve cognitive impairment in an MK-801 schizophrenia rodent model, an effect which may depend on parvalbumin interneuron function in the PFC.</p>
        </sec>
        <sec>
          <title>Cannabinoids: THC, WIN, FAAH inhibitors</title>
          <p>PCP treatment, either neonatally or in adulthood, increases behavioural and brain responses to cannabinoids. A single neonatal PCP administration at G7 increases vulnerability to chronic adolescent THC-induced deficits in memory performance and sensorimotor gating <xref ref-type="bibr" rid="ref192">[192]</xref>. Neonatal PCP also induces hyperlocomotion in adult mice which are chronically treated with THC (n.b. mice were tested for locomotor activity after at least 27 days of THC treatment, reducing the sedative effects of THC <xref ref-type="bibr" rid="ref192">[192]</xref>). These behavioural effects are associated with reduced NMDA NR1 receptor protein in the cortex, reflecting a reduction in glutamatergic signalling which is hypothesised to contribute to schizophrenia pathophysiology <xref ref-type="bibr" rid="ref192">[192]</xref>.</p>
    <table-wrap id="table8">
      <label>Table 8</label>
      <caption>
        <title>Susceptibility of schizophrenia pharmacological rodent models to effects of psychostimulant and antipsychotic drugs on schizophrenia-relevant behaviour and brain function</title>
        <p>Abbreviations: GABA; Gamma Aminobutyric Acid; OFC, orbitofrontal cortex; NAcc, nucleus accumbens; PCP, phencyclidine.</p>
      </caption>
        <table>
          <tbody>
            <tr>
              <td>Author, date [reference]</td>
              <td>Model</td>
              <td>Drug administration</td>
              <td>Age at Drug Treatment / Age at Behavioural Testing</td>
              <td>Results - Behaviour (âdecrease, âincrease, ~no effect)</td>
              <td>Results - Brain (âdecrease, âincrease, ~no effect)</td>
            </tr>
            <tr>
              <td>BÃ©dard et al 2011 <xref ref-type="bibr" rid="ref183">[183]</xref>, BÃ©dard et al 2013 <xref ref-type="bibr" rid="ref184">[184]</xref>, El Hage et al 2015 <xref ref-type="bibr" rid="ref185">[185]</xref></td>
              <td>Adult rat model of dopamine supersensitivity (i.e. withdrawal from chronic haloperidol). Rat model of chronic olanzapine treatment.</td>
              <td>Acute amphetamine</td>
              <td>Adult / Adult</td>
              <td>Amphetamine âpursuit of food reward cues in dopamine supersensitive rats. ~NAcc amphetamine or NAcc GABA agonist on pursuit of food cues. âAmphetamine-induced locomotion in dopamine supersensitive rats. ~Olanzapine on amphetamine-induced locomotion or cue-seeking.</td>
              <td>âAmphetamine-induced c-fos mRNA in striatum in dopamine supersensitive rats. ~Olanzapine on amphetamine-induced c-fos mRNA in striatum.</td>
            </tr>
            <tr>
              <td>Sivarao et al 2013 <xref ref-type="bibr" rid="ref187">[187]</xref></td>
              <td>MK-801 induced impairment in auditory-evoked responses in rats</td>
              <td>Acute nicotine</td>
              <td>Adult / Adult</td>
              <td>n/a</td>
              <td>Nicotine âauditory-evoked neural responses, after MK-801 administration.</td>
            </tr>
            <tr>
              <td>Brown et al 2014 <xref ref-type="bibr" rid="ref188">[188]</xref></td>
              <td>Acute MK-801 in mice</td>
              <td>Atypical antipsychotics: clozapine, risperidone, olanzapine. Sodium channel blockers: lamotrigine, carbamazepine. Cognitive enhancers: nicotine, donepezil, modafinil, and xanomeline. All drugs acutely administered.</td>
              <td>Adult / Adult</td>
              <td>Nicotine, donepezil, modafinil, carbamazepine and xanomeline attenuated MK-801-induced memory impairment. ~Clozapine, risperidone and olanzapine on MK-801-induced memory impairment.</td>
              <td>n/a</td>
            </tr>
            <tr>
              <td>Scott et al 2014 <xref ref-type="bibr" rid="ref189">[189]</xref></td>
              <td>Chronic PCP in adult mice</td>
              <td>Acute or chronic nicotine</td>
              <td>Adult / Adult</td>
              <td>Chronic, not acute nicotine âimpulsivity in a mouse PCP model. ~Nicotine on locomotor activity in PCP mice.</td>
              <td>n/a</td>
            </tr>
            <tr>
              <td>Cloke et al 2016 <xref ref-type="bibr" rid="ref191">[191]</xref></td>
              <td>Chronic ketamine in rats</td>
              <td>Acute nicotine or ABT-418 (Î±4-Î²2-nicotinic-acetylcholine receptor agonist)</td>
              <td>Adult / Adult</td>
              <td>Nicotine or ABT-418 âcognition in ketamine rats; this effect was blocked by GABA-A receptor antagonism. Silencing OFC parvalbumin interneurons âcognitive performance; reversed by ABT-418.</td>
              <td>âOFC GABAergic currents in ketamine rats, normalized by ABT-418. Parvalbumin OFC immunoreactivity decreased in ketamine rats.</td>
            </tr>
        </tbody>
      </table>
    </table-wrap>
          <p>When rats are treated subchronically in adulthood with PCP, this increases mPFC firing rates in response to the FAAH inhibitor URB597, suggesting increased susceptibility to elevated levels of endocannabinoids in PCP-treated rats compared to vehicle-treated controls <xref ref-type="bibr" rid="ref193">[193]</xref>. Conversely, PCP-treated animals are unaffected by THC, where THC treatment decreases mPFC firing rates in saline treated animals <xref ref-type="bibr" rid="ref193">[193]</xref>. Subchronic PCP treatment does not modulate firing rates in response to URB597 or THC in the ventral hippocampus, suggesting an mPFC-specific effect <xref ref-type="bibr" rid="ref193">[193]</xref>. Considering neural oscillations are disrupted in schizophrenia, and cannabinoids can acutely decrease the power of neural oscillations <xref ref-type="bibr" rid="ref194">[194]</xref>, these findings can start to shed light on how cannabinoids affect mPFC neural firing in schizophrenia. </p>
          <p>Interestingly, cannabinoids may have protective effects when administered prior to PCP. In rats which either self-administer or are treated chronically with the CB<sub>1</sub> receptor agonist WIN, the sensitized locomotor response to a PCP challenge is decreased in WIN-treated animals, compared to vehicle controls <xref ref-type="bibr" rid="ref195">[195]</xref>. WIN self-administration also increases exploratory behaviour (i.e. rearing) and reduces anxiety-like behaviour in an open field arena in response to acute PCP administration <xref ref-type="bibr" rid="ref195">[195]</xref>. Interestingly, PCP-induced social withdrawal and reduced anandamide levels in the PFC and amygdala can be reversed by elevating endogenous cannabinoids via the FAAH inhibitor URB597, or by increasing cannabinoid signalling via the cannabinoid agonist CP55,940 <xref ref-type="bibr" rid="ref196">[196</xref>,<xref ref-type="bibr" rid="ref197">197]</xref>. This suggests PCP-induced social withdrawal and sensitized locomotor activity may result from deficient endocannabinoid transmission <xref ref-type="bibr" rid="ref196">[196]</xref>.</p>
          <p>In a rat model selectively bred following social isolation housing and ketamine treatment in adolescence, WIN-induced G-protein activation is reduced in the cerebellum, cortex and in subcortical regions <xref ref-type="bibr" rid="ref198">[198]</xref>. CB<sub>1</sub> receptor binding is also reduced in the cerebellum, cortex and subcortical regions in this rat model of schizophrenia, compared to controls <xref ref-type="bibr" rid="ref198">[198]</xref>. These reductions in cannabinoid receptor binding and function correspond with similar endocannabinoid system changes and elevated susceptibility to cannabinoids in patients with schizophrenia (e.g. <xref ref-type="bibr" rid="ref199">[199</xref>-<xref ref-type="bibr" rid="ref201">201]</xref>).</p>
    <table-wrap id="table9">
      <label>Table 9</label>
      <caption>
        <title>Susceptibility of schizophrenia pharmacological rodent models to effects of cannabinoid drugs on schizophrenia-relevant behaviour and brain function</title>
        <p>Abbreviations: CB, cerebellum; CeA, central amygdala; FAAH, fatty acid amide hydrolase; FC , frontal cortex; G, gestational day; HPC, hippocampus; mPFC, medial prefrontal cortex; NMDA, N-methyl-d-aspartate; PCP, phencyclidine; PPI, prepulse inhibition; THC, Î9-tetrahydrocannabinol; WIN; WIN 55,212-2.</p>
      </caption>
      <table>
        <tbody>
          <tr>
            <td>Author, date [reference]</td>
            <td>Model</td>
            <td>Drug administration</td>
            <td>Age at Drug Treatment / Age at Behavioural Testing</td>
            <td>Results - Behaviour (âdecrease, âincrease, ~no effect)</td>
            <td>Results - Brain (âdecrease, âincrease, ~no effect)</td>
          </tr>
          <tr>
            <td>Rodriguez et al 2017 <xref ref-type="bibr" rid="ref192">[192]</xref></td>
            <td>Single neonatal PCP administration at G7 in mice</td>
            <td>Chronic THC</td>
            <td>Early adulthood / Adult</td>
            <td>Chronic THC âlocomotion in neonatal PCP mice. THC âcognition in PCP mice. ~THC on PPI deficits in PCP mice.</td>
            <td>THC âCB<sub>1</sub> receptor binding in FC of PCP mice. PCP âNMDA NR1 receptor binding in FC. THC âNMDA NR1 receptor binding in the FC in PCP mice and controls.</td>
          </tr>
          <tr>
            <td>Aguilar et al 2016 <xref ref-type="bibr" rid="ref193">[193]</xref></td>
            <td>Subchronic adult PCP treatment in rats</td>
            <td>Acute FAAH inhibitor URB597 or THC</td>
            <td>Adult / Adult</td>
            <td>n/a</td>
            <td>FAAH inhibitor URB597 âmPFC firing rates in PCP rats. ~THC on mPFC firing in PCP rats, where THC âmPFC firing in control rats. ~PCP on URB597 or THC-induced firing rates in ventral HPC.</td>
          </tr>
          <tr>
            <td>Spano et al 2013 <xref ref-type="bibr" rid="ref195">[195]</xref></td>
            <td>Chronic WIN treatment or WIN self-administration in rats</td>
            <td>Acute or chronic PCP</td>
            <td>Adult / Adult</td>
            <td>âPCP-sensitized locomotion in WIN-treated and WIN self-administering rats. WIN self-administration âexploration and âanxiety in PCP rats.</td>
            <td>n/a</td>
          </tr>
          <tr>
            <td>Seillier et al 2013 <xref ref-type="bibr" rid="ref196">[196]</xref>; Matricon et al 206 <xref ref-type="bibr" rid="ref197">[197]</xref></td>
            <td>Subchronic adult PCP treatment in rats</td>
            <td>Acute FAAH inhibitor URB597, cannabinoid agonist CP55,940, CB<sub>1</sub> antagonists AM251 and SR141716, TRPV1 antagonist capsazepine CPZ, cholecystokinin antagonist LY225910 LY</td>
            <td>Adult / Adult</td>
            <td>URB597 âsocial behaviour in PCP rats; this is CB<sub>1</sub> receptor but not TRPV1 receptor dependent. URB597 âsocial interaction in vehicle controls; this is CB<sub>1</sub> receptor dependent. LY225910 blocks acute PCP- and AM251-induced social withdrawal, but not URB597-induced social withdrawal.</td>
            <td>Subchronic PCP âanandamide levels in amygdala and PFC; reversed by URB597. URB597 âc-fos protein expression in OFC, CeA and dorsomedial bed nucleus of the stria terminalis in PCP rats.</td>
          </tr>
          <tr>
            <td>SzÅ±cs et al 2016 <xref ref-type="bibr" rid="ref198">[198]</xref></td>
            <td>27th generation of selectively bred male rats with social isolation and ketamine treatment</td>
            <td>Chronic ketamine</td>
            <td>Adult / Adult</td>
            <td>n/a</td>
            <td>âWIN-induced G-protein activation and âCB<sub>1</sub> receptor binding in CB, FC, subcortical regions in ketamine-treated isolated rat model.</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
          <p>Together, these results suggest cannabinoids generally worsen positive-like and cognitive behaviours, and cause altered receptor binding (e.g. cannabinoid, glutamatergic) and mPFC firing in pharmacological models of schizophrenia. This reflects clinical data, which demonstrates cannabis use can worsen symptoms in patients with schizophrenia, and in first episode patients, recent cannabis use is associated with decreased grey matter volume in the posterior cingulate cortex (review: <xref ref-type="bibr" rid="ref202">[202]</xref>). Interestingly, in rodent models, the timing of cannabinoid administration can modulate this effect; cannabinoid administration prior to PCP treatment appears protective against schizophrenia-relevant behaviours.</p>
        </sec>
      </sec>
      <sec>
        <title>3.5 Interim summary</title>
        <p>In Section 3, we summarised how abused drugs can exacerbate or alleviate schizophrenia-relevant behaviours in several rodent models of schizophrenia. Interestingly, there are some fairly consistent findings across models and drug classes. Nicotine, for example, often ameliorates schizophrenia-relevant behaviours, as observed in most genetic models, one neurodevelopmental model and one pharmacological model. Cannabinoids have bidirectional effects on schizophrenia-relevant behaviours, with CB<sub>1</sub> agonists (e.g. THC, WIN) mostly worsening these behaviours in genetic, neurodevelopmental and pharmacological models (although there are some exceptions), and CBD ameliorating schizophrenia-like behaviours in genetic and neurodevelopmental models. There is limited data available on the effects of psychostimulants on schizophrenia-relevant behaviour; however, lesion and pharmacological models show elevated sensitivity to psychostimulants, which can be age-dependent. The effects of nicotine, cannabinoids and psychostimulants mirrors what is observed in clinical literature, e.g. nicotine improves attention and processing speed in individuals with schizophrenia <xref ref-type="bibr" rid="ref203">[203</xref>,<xref ref-type="bibr" rid="ref204">204]</xref>, cannabis worsens schizophrenia symptoms and clinical prognosis <xref ref-type="bibr" rid="ref205">[205]</xref>, CBD has antipsychotic-like effects <xref ref-type="bibr" rid="ref206">[206]</xref>, and there is recent evidence of increased susceptibility to effects of amphetamine on sensorimotor gating in schizophrenia <xref ref-type="bibr" rid="ref207">[207]</xref>. Importantly, this provides predictive validity to these models, and facilitates the use of these models to better understand brain changes associated with drug susceptibility.</p>
        <p>The research reviewed above indicates that chronic nicotine has a range of effects on the brain in schizophrenia models, including reducing striatal D<sub>2</sub> receptor mediated LTD in <italic>Snap-25</italic> KO mice, increasing GAD67 and reelin mRNA in the cortex, hippocampus, striatum and cerebellum of <italic>reeler</italic> mice, and differential theta burst stimulated LTP in cortico-BLA synapses in <italic>Type III Nrg1</italic> HET mice. Chronic THC alters CB<sub>1</sub> receptor binding in the substantia nigra and CB<sub>1</sub> protein levels in the hippocampus in genetic models (i.e. <italic>Nrg1 TM</italic> HET and <italic>DN-Disc1</italic>). Chronic THC also alters protein binding of NMDA and 5-HT<sub>2A</sub> receptors in the cortex and hippocampus of <italic>Nrg1 TM</italic> HET mice, potentially reflecting genotype-specific effects of THC on locomotion and social behaviour. Endocannabinoid signalling (e.g. firing rates following FAAH inhibitor administration, WIN-induced g-protein activation or anandamide levels) are also altered in the PFC and amygdala and cerebellum in pharmacological (e.g. PCP) and two-hit models (e.g. ketamine and social isolation), suggesting changes to endocannabinoid function potentially reminiscent of endocannabinoid system changes in patients with schizophrenia <xref ref-type="bibr" rid="ref199">[199</xref>-<xref ref-type="bibr" rid="ref201">201]</xref>. The antipsychotic-like effects of CBD may be mediated by reversing changes to PFC CB<sub>1</sub> and NMDA receptor dysfunction and increasing GABA receptor binding in the hippocampus and PFC in schizophrenia models. Finally, while there has been limited examination of how psychostimulants affect neural function in schizophrenia models, elevated c-fos mRNA expression in the caudate-putamen following chronic haloperidol suggests sensitized dopaminergic function in reward regions and may also contribute to drug-seeking susceptibility.</p>
      </sec>
    </sec>
    <sec>
      <title>4. Conclusions</title>
      <p>There has been a vast addition to the preclinical literature investigating schizophrenia and drug abuse comorbidity since 2013, and it is becoming increasingly apparent that drug addiction behaviours and susceptibility to effects of abused drugs exist in many schizophrenia models. This is an exciting development, and suggests a burgeoning new field which could lead to breakthroughs in our understanding of comorbidity between schizophrenia and addiction. Importantly, in this review we have highlighted how <italic>often</italic> addiction-like behaviour is observed in different models of schizophrenia, particularly in genetic and neurodevelopmental models. We also found significant support for each hypothesis to explain drug susceptibility in schizophrenia: neurodevelopmental and some genetic models support the primary addiction hypothesis; genetic, neurodevelopmental and pharmacological models support the two-hit hypothesis, particularly for cannabinoids and nicotine, while genetic models often support the self-medication hypothesis for nicotine. Interestingly, this review found that the susceptibility of schizophrenia models to drug abuse appears to often implicate altered dopaminergic function (e.g. increased dopamine D<sub>2</sub> receptor expression and dopamine metabolism), particularly in reward relevant regions such as the PFC and NAcc. This is relevant as changes in dopamine receptor expression are observed in drug abuse patients <xref ref-type="bibr" rid="ref5">[5]</xref>, and alterations to the dopaminergic system is consistent finding in schizophrenia, suggesting that schizophrenia susceptibility may alter drug reward pathways to elevate risk for drug abuse. It is interesting to note that cognitive impairment in some models (e.g. NVHL model) correlates with drug abuse susceptibility; investigating this in other models would be of considerable interest.</p>
      <p>Furthermore, when examining susceptibility of schizophrenia models to abused drugs, there are effects on several neurotransmitter systems highly relevant to schizophrenia and addiction, primarily in mesocorticolimbic structures. Nicotine treatment has ameliorative effects on schizophrenia relevant behaviour in several models (e.g. genetic and pharmacological models, but not the NVHL model), and this may be dependent on actions at Î±7 nicotinergic receptors. Several models are more susceptible to the effects of cannabinoids such as THC and CBD on schizophrenia-relevant behaviours, and this is accompanied by complex changes in cannabinoid, glutamatergic, serotonergic and GABAergic receptor systems. Considering changes to these systems have all been reported in schizophrenia <xref ref-type="bibr" rid="ref208">[208</xref>-<xref ref-type="bibr" rid="ref211">211]</xref>, these findings not only validate the models used, but indicate how changes in these systems are relevant to both schizophrenia and drug susceptibility. Changes to specific receptor systems and subunits indicates which targets are specifically affected by drug exposure in schizophrenia, increasing our understanding of interactions between these disorders and potentially providing targets for future pharmacotherapies specifically designed to treat addiction in schizophrenia.</p>
      <p>However, there are still several gaps in the literature which need to be addressed. To date, there has been very limited investigation into the molecular correlates of susceptibility to abused drugs. Also, most research has examined the response of schizophrenia models to effects of nicotine and cannabinoids on schizophrenia-like behaviours, yet behavioural and neural responses to other drugs of abuse (e.g. alcohol, psychostimulants, opioids), remains mostly unexplored. Other critical areas of future research include investigating addiction-like behaviour for non-psychostimulant drugs in genetic and pharmacological models of schizophrenia, as well as investigating potential sex-specific effects in terms of addiction-relevant behaviour. Poly-drug use has rarely been examined (but see a recent example: <xref ref-type="bibr" rid="ref75">[75]</xref>), yet considering that poly-drug use is common in schizophrenia <xref ref-type="bibr" rid="ref212">[212</xref>,<xref ref-type="bibr" rid="ref213">213]</xref>, this is another research area with incredible potential. Addressing these gaps in the literature will thoroughly advance our understanding of the complex relationship between schizophrenia and drug abuse, and eventually help to better treat addiction in schizophrenia.</p>
    </sec>
    <sec>
      <title>Declarations</title>
      <sec>
        <title>Author's Contributions</title>
        <p>RC conceptualised the review scope, VM and RC researched the topic and wrote the review, VM, JCO and RC edited the review, VM and RC approved the review prior to submission.</p>
      </sec>
      <sec>
        <title>Acknowledgements</title>
        <p>We would like to thank Dr Juan Olaya for his helpful comments on the manuscript.</p>
      </sec>
      <sec>
        <title>Funding</title>
        <p>RC is supported by the Molecular Medicine Research Group (Seed Funding 2017 and 2018, Western Sydney University) as well as the Ainsworth Medical Research Innovation Fund. In addition, RC is supported by the Rebecca Cooper Medical Research Foundation.</p>
      </sec>
      <sec>
        <title>Conflict of Interest Declaration</title>
        <p>This review was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
      </sec>
    </sec>
    <sec>
      <title>Editorial Notes</title>
      <sec>
        <title>History</title>
        <list list-type="bullet">
          <list-item>
            <p>Received: 2019-11-05</p>
          </list-item>
          <list-item>
            <p>Revised: 2019-12-22</p>
          </list-item>
          <list-item>
            <p>Accepted: 2020-01-08</p>
          </list-item>
        </list>
      </sec>
      <sec>
        <title>Editorial Checks</title>
        <list list-type="bullet">
          <list-item>
            <p>Plagiarism: Plagiarism detection software found no evidence of plagiarism.</p>
          </list-item>
          <list-item>
            <p>References: Zotero did not identify any references in the <ext-link xlink:href="https://retractionwatch.com">RetractionWatch</ext-link> database.</p>
          </list-item>
        </list>
      </sec>
      <sec>
        <title>Peer Review</title>
        <p>The review process for this paper was conducted double-blind because one of the authors is a member of the committee of management of the publisher, Episteme Health Inc. During review, neither the authors nor the reviewers were aware of each other's identities.</p>
        <p>For the benefit of readers, reviewers are asked to write a public summary of their review to highlight the key strengths and weaknesses of the paper. Signing of reviews is optional.</p>
      </sec>
      <sec>
        <title>Reviewer 1 (Anonymous)</title>
        <p>This review aims to update the field on recent advances in our understanding of co-occurring schizophrenia and substance use disorders. The review focuses heavily on preclinical findings
that have been published after 2013, and aims to address important questions related to how schizophrenia impacts vulnerability to substance use and how substance use alters the course of schizophrenia. The review is thorough (for the timepoints assessed), but sometimes the language is not specific.</p>
      </sec>
      <sec>
        <title>Reviewer 2 (Steven Simmons, Childrens Hospital of Philadelphia, United States. <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-6982-4740">https://orcid.org/0000-0002-6982-4740</ext-link>)</title>
        <p>This well-written and scholarly review discusses the complex interactions between substance use disorders (SUDs) and schizophrenia. It provides a major update to the field since a prior review published in 2013. Contained within are thorough descriptions of behavioral tests and measures used in animal studies that model both psychiatric conditions. The review frames studies through the lens of multiple theories attempting to account for the high comorbidity between SUDs and schiophrenia, including the "self-medication theory" (individuals with schizophrenia use drugs to manage symptoms of schizophrenia), the "primary addiction hypothesis" (predisposition to both psychiatric conditions are linked by common pathophysiology), and the "two-hit hypothesis" (genetic/environmental factors [first hit] initially predispose an individual to develop schizophrenia, and substance use [second hit] enables the manifestation of schizophrenia symptomatology). The review considers the underlying neurotransmitter systems and circuits that underlie behaviors associated with each disorder.</p>
      </sec>
      <sec>
        <title>Reviewer 3 (Anonymous)</title>
        <p>The authors of the review aim to summarise the literature surrounding the relationship between drugs of abuse and schizophrenia, in particular focusing on various rodent models, concentrating on studies published since 2013.</p>
	<p>Drug addiction and abuse rates in the schizophrenia population is much higher than that of the general population, adding burden to an already highly burdensome disease. Given that both schizophrenia and drug addiction are complex disorders, many fundamental understanding is in flux. The review organises itself with two important and fundamental questions in mind - 1) whether schizophrenia primes individuals towards drug addiction and/or 2) whether drugs of abuse cause/exacerbate schizophrenia. The authors systematically review various types of rodent models and studies examining different drugs and molecular pathways, highlighting inconsistencies and areas that require further clarification.</p>
	<p>The review is well constructed and laid out. It is a thorough summary and critique of the area of research. The review is well written and clear in its expression and offers a useful guide towards the future research in this field.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>19</page-range>
          <volume>64</volume>
          <year>2007</year>
          <pub-id pub-id-type="doi">10.1001/archpsyc.64.1.19</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>PerÃ¤lÃ¤</surname>
              <given-names>Jonna</given-names>
            </name>
            <name>
              <surname>Suvisaari</surname>
              <given-names>Jaana</given-names>
            </name>
            <name>
              <surname>Saarni</surname>
              <given-names>Samuli I.</given-names>
            </name>
            <name>
              <surname>Kuoppasalmi</surname>
              <given-names>Kimmo</given-names>
            </name>
            <name>
              <surname>IsometsÃ¤</surname>
              <given-names>Erkki</given-names>
            </name>
            <name>
              <surname>Pirkola</surname>
              <given-names>Sami</given-names>
            </name>
            <name>
              <surname>Partonen</surname>
              <given-names>Timo</given-names>
            </name>
            <name>
              <surname>Tuulio-Henriksson</surname>
              <given-names>Annamari</given-names>
            </name>
            <name>
              <surname>Hintikka</surname>
              <given-names>Jukka</given-names>
            </name>
            <name>
              <surname>KieseppÃ¤</surname>
              <given-names>Tuula</given-names>
            </name>
            <name>
              <surname>HÃ¤rkÃ¤nen</surname>
              <given-names>Tommi</given-names>
            </name>
            <name>
              <surname>Koskinen</surname>
              <given-names>Seppo</given-names>
            </name>
            <name>
              <surname>LÃ¶nnqvist</surname>
              <given-names>Jouko</given-names>
            </name>
          </person-group>
          <source>Archives of General Psychiatry</source>
          <article-title>Lifetime Prevalence of Psychotic and Bipolar I Disorders in a General Population</article-title>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <issue>8973</issue>
          <page-range>477-481</page-range>
          <volume>346</volume>
          <year>1995</year>
          <pub-id pub-id-type="doi">10.1016/s0140-6736(95)91325-4</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Andreasen</surname>
              <given-names>Nancy C.</given-names>
            </name>
          </person-group>
          <source>The Lancet</source>
          <article-title>Symptoms, signs, and diagnosis of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <issue>5</issue>
          <page-range>417-428</page-range>
          <volume>22</volume>
          <year>2010</year>
          <pub-id pub-id-type="doi">10.3109/09540261.2010.515205</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Abel</surname>
              <given-names>Kathryn M.</given-names>
            </name>
            <name>
              <surname>Drake</surname>
              <given-names>Richard</given-names>
            </name>
            <name>
              <surname>Goldstein</surname>
              <given-names>Jill M.</given-names>
            </name>
          </person-group>
          <source>International Review of Psychiatry</source>
          <article-title>Sex differences in schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <page-range>234-258</page-range>
          <volume>191</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.07.011</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Hunt</surname>
              <given-names>Glenn E.</given-names>
            </name>
            <name>
              <surname>Large</surname>
              <given-names>Matthew M.</given-names>
            </name>
            <name>
              <surname>Cleary</surname>
              <given-names>Michelle</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>Harry Man Xiong</given-names>
            </name>
            <name>
              <surname>Saunders</surname>
              <given-names>John B.</given-names>
            </name>
          </person-group>
          <source>Drug and Alcohol Dependence</source>
          <article-title>Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990â2017: Systematic review and meta-analysis</article-title>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>469-472</page-range>
          <volume>35</volume>
          <year>2009</year>
          <pub-id pub-id-type="doi">10.1093/schbul/sbp016</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Volkow</surname>
              <given-names>N. D.</given-names>
            </name>
          </person-group>
          <source>Schizophrenia Bulletin</source>
          <article-title>Substance Use Disorders in Schizophrenia--Clinical Implications of Comorbidity</article-title>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>195-201</page-range>
          <volume>23</volume>
          <year>1997</year>
          <pub-id pub-id-type="doi">10.1093/schbul/23.2.195</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Kovasznay</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Fleischer</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Tanenberg-Karant</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Jandorf</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>A. D.</given-names>
            </name>
            <name>
              <surname>Bromet</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <source>Schizophrenia Bulletin</source>
          <article-title>Substance Use Disorder and the Early Course of Illness in Schizophrenia and Affective Psychosis</article-title>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal">
          <fpage>99</fpage>
          <issue>2</issue>
          <lpage>104</lpage>
          <page-range>99-104</page-range>
          <volume>22</volume>
          <year>1997</year>
          <person-group person-group-type="author">
            <name>
              <surname>Addington</surname>
              <given-names>Jean</given-names>
            </name>
            <name>
              <surname>Addington</surname>
              <given-names>Donald</given-names>
            </name>
          </person-group>
          <source>Journal of Psychiatry &amp; Neuroscience</source>
          <article-title>Substance abuse and cognitive functioning in schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>253-264</page-range>
          <volume>54</volume>
          <year>2002</year>
          <pub-id pub-id-type="doi">10.1016/s0920-9964(01)00261-4</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Hunt</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <source>Schizophrenia Research</source>
          <article-title>Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse</article-title>
        </element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>164-172</page-range>
          <volume>194</volume>
          <year>2006</year>
          <pub-id pub-id-type="doi">10.1097/01.nmd.0000202575.79453.6e</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Swartz</surname>
              <given-names>Marvin S.</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>H Ryan</given-names>
            </name>
            <name>
              <surname>Swanson</surname>
              <given-names>Jeffrey W.</given-names>
            </name>
            <name>
              <surname>Stroup</surname>
              <given-names>T Scott</given-names>
            </name>
            <name>
              <surname>McEvoy</surname>
              <given-names>Joseph P.</given-names>
            </name>
            <name>
              <surname>Canive</surname>
              <given-names>Jose M.</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>Del D.</given-names>
            </name>
            <name>
              <surname>Reimherr</surname>
              <given-names>Fred</given-names>
            </name>
            <name>
              <surname>McGee</surname>
              <given-names>Mark</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>Ahsan</given-names>
            </name>
            <name>
              <surname>Van Dorn</surname>
              <given-names>Richard</given-names>
            </name>
            <name>
              <surname>Rosenheck</surname>
              <given-names>Robert A.</given-names>
            </name>
            <name>
              <surname>Lieberman</surname>
              <given-names>Jeffrey A.</given-names>
            </name>
          </person-group>
          <source>The Journal of Nervous and Mental Disease</source>
          <article-title>Substance Use in Persons With Schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal">
          <issue>1-3</issue>
          <page-range>228-233</page-range>
          <volume>130</volume>
          <year>2011</year>
          <pub-id pub-id-type="doi">10.1016/j.schres.2011.04.011</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Schmidt</surname>
              <given-names>Lasse M.</given-names>
            </name>
            <name>
              <surname>Hesse</surname>
              <given-names>Moten</given-names>
            </name>
            <name>
              <surname>Lykke</surname>
              <given-names>JÃ¸rn</given-names>
            </name>
          </person-group>
          <source>Schizophrenia Research</source>
          <article-title>The impact of substance use disorders on the course of schizophreniaâA 15-year follow-up study</article-title>
        </element-citation>
      </ref>
      <ref id="ref11">
        <label>11</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>229-236</page-range>
          <volume>187</volume>
          <year>2006</year>
          <pub-id pub-id-type="doi">10.1007/s00213-006-0413-4</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Janssen</surname>
              <given-names>Birgit</given-names>
            </name>
            <name>
              <surname>Gaebel</surname>
              <given-names>Wolfgang</given-names>
            </name>
            <name>
              <surname>Haerter</surname>
              <given-names>Martin</given-names>
            </name>
            <name>
              <surname>Komaharadi</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Lindel</surname>
              <given-names>Birgit</given-names>
            </name>
            <name>
              <surname>Weinmann</surname>
              <given-names>Stefan</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders</article-title>
        </element-citation>
      </ref>
      <ref id="ref12">
        <label>12</label>
        <element-citation publication-type="journal">
          <page-range>78-85</page-range>
          <volume>194</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.schres.2017.04.016</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Khokhar</surname>
              <given-names>Jibran Y.</given-names>
            </name>
            <name>
              <surname>Dwiel</surname>
              <given-names>Lucas L.</given-names>
            </name>
            <name>
              <surname>Henricks</surname>
              <given-names>Angela M.</given-names>
            </name>
            <name>
              <surname>Doucette</surname>
              <given-names>Wilder T.</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>Alan I.</given-names>
            </name>
          </person-group>
          <source>Schizophrenia Research</source>
          <article-title>The link between schizophrenia and substance use disorder: A unifying hypothesis</article-title>
        </element-citation>
      </ref>
      <ref id="ref13">
        <label>13</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>402-408</page-range>
          <volume>164</volume>
          <year>2007</year>
          <pub-id pub-id-type="doi">10.1176/ajp.2007.164.3.402</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Green</surname>
              <given-names>Alan I.</given-names>
            </name>
            <name>
              <surname>Drake</surname>
              <given-names>Robert E.</given-names>
            </name>
            <name>
              <surname>Brunette</surname>
              <given-names>Mary F.</given-names>
            </name>
            <name>
              <surname>Noordsy</surname>
              <given-names>Douglas L.</given-names>
            </name>
          </person-group>
          <source>American Journal of Psychiatry</source>
          <article-title>Schizophrenia and Co-Occurring Substance Use Disorder</article-title>
        </element-citation>
      </ref>
      <ref id="ref14">
        <label>14</label>
        <element-citation publication-type="journal">
          <issue>5</issue>
          <page-range>231-244</page-range>
          <volume>4</volume>
          <year>1997</year>
          <pub-id pub-id-type="doi">10.3109/10673229709030550</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Khantzian</surname>
              <given-names>Edward J.</given-names>
            </name>
          </person-group>
          <source>Harvard Review of Psychiatry</source>
          <article-title>The Self-Medication Hypothesis of Substance Use Disorders: A Reconsideration and Recent Applications</article-title>
        </element-citation>
      </ref>
      <ref id="ref15">
        <label>15</label>
        <element-citation publication-type="journal">
          <page-range>62-69</page-range>
          <volume>194</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.schres.2017.03.047</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Boggs</surname>
              <given-names>Douglas L.</given-names>
            </name>
            <name>
              <surname>Surti</surname>
              <given-names>Toral S.</given-names>
            </name>
            <name>
              <surname>Esterlis</surname>
              <given-names>Irina</given-names>
            </name>
            <name>
              <surname>Pittman</surname>
              <given-names>Brian</given-names>
            </name>
            <name>
              <surname>Cosgrove</surname>
              <given-names>Kelly</given-names>
            </name>
            <name>
              <surname>Sewell</surname>
              <given-names>R. Andrew</given-names>
            </name>
            <name>
              <surname>Ranganathan</surname>
              <given-names>Mohini</given-names>
            </name>
            <name>
              <surname>D'Souza</surname>
              <given-names>Deepak Cyril</given-names>
            </name>
          </person-group>
          <source>Schizophrenia Research</source>
          <article-title>Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the âself-medicationâ hypothesis in schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref16">
        <label>16</label>
        <element-citation publication-type="journal">
          <page-range>55-61</page-range>
          <volume>194</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.schres.2017.03.010</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Rabin</surname>
              <given-names>Rachel A.</given-names>
            </name>
            <name>
              <surname>Kozak</surname>
              <given-names>Karolina</given-names>
            </name>
            <name>
              <surname>Zakzanis</surname>
              <given-names>Konstantine K.</given-names>
            </name>
            <name>
              <surname>Remington</surname>
              <given-names>Gary</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>Tony P.</given-names>
            </name>
          </person-group>
          <source>Schizophrenia Research</source>
          <article-title>Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls</article-title>
        </element-citation>
      </ref>
      <ref id="ref17">
        <label>17</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>71-83</page-range>
          <volume>50</volume>
          <year>2001</year>
          <pub-id pub-id-type="doi">10.1016/s0006-3223(01)01134-9</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Chambers</surname>
              <given-names>R.Andrew</given-names>
            </name>
            <name>
              <surname>Krystal</surname>
              <given-names>John H</given-names>
            </name>
            <name>
              <surname>Self</surname>
              <given-names>David W</given-names>
            </name>
          </person-group>
          <source>Biological Psychiatry</source>
          <article-title>A neurobiological basis for substance abuse comorbidity in schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref18">
        <label>18</label>
        <element-citation publication-type="journal">
          <issue>6</issue>
          <page-range>543-548</page-range>
          <volume>33</volume>
          <year>1999</year>
          <pub-id pub-id-type="doi">10.1016/s0022-3956(99)00039-4</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Bayer</surname>
              <given-names>Thomas A</given-names>
            </name>
            <name>
              <surname>Falkai</surname>
              <given-names>Peter</given-names>
            </name>
            <name>
              <surname>Maier</surname>
              <given-names>Wolfgang</given-names>
            </name>
          </person-group>
          <source>Journal of Psychiatric Research</source>
          <article-title>Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the âTwo hit hypothesisâ</article-title>
        </element-citation>
      </ref>
      <ref id="ref19">
        <label>19</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>31-56</page-range>
          <volume>16</volume>
          <year>1990</year>
          <pub-id pub-id-type="doi">10.1093/schbul/16.1.31</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Mueser</surname>
              <given-names>K. T.</given-names>
            </name>
            <name>
              <surname>Yarnold</surname>
              <given-names>P. R.</given-names>
            </name>
            <name>
              <surname>Levinson</surname>
              <given-names>D. F.</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bellack</surname>
              <given-names>A. S.</given-names>
            </name>
            <name>
              <surname>Kee</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Morisson</surname>
              <given-names>R. L.</given-names>
            </name>
            <name>
              <surname>Yadalam</surname>
              <given-names>K. G.</given-names>
            </name>
          </person-group>
          <source>Schizophrenia Bulletin</source>
          <article-title>Prevalence of Substance Abuse in Schizophrenia: Demographic and Clinical Correlates</article-title>
        </element-citation>
      </ref>
      <ref id="ref20">
        <label>20</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>1162-1194</page-range>
          <volume>164</volume>
          <year>2011</year>
          <pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01386.x</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Watson</surname>
              <given-names>DJG</given-names>
            </name>
            <name>
              <surname>Fone</surname>
              <given-names>KCF</given-names>
            </name>
          </person-group>
          <source>British Journal of Pharmacology</source>
          <article-title>Animal models of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref21">
        <label>21</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>409-432</page-range>
          <volume>25</volume>
          <year>2002</year>
          <pub-id pub-id-type="doi">10.1146/annurev.neuro.25.112701.142754</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Lewis</surname>
              <given-names>David A.</given-names>
            </name>
            <name>
              <surname>Levitt</surname>
              <given-names>Pat</given-names>
            </name>
          </person-group>
          <source>Annual Review of Neuroscience</source>
          <article-title>Schizophrenia as a Disorder of Neurodevelopment</article-title>
        </element-citation>
      </ref>
      <ref id="ref22">
        <label>22</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>556-566</page-range>
          <volume>48</volume>
          <year>2000</year>
          <pub-id pub-id-type="doi">10.1002/1531-8249(200010)48:4&lt;556::aid-ana2&gt;3.0.co;2-2</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Pearlson</surname>
              <given-names>Godfrey D.</given-names>
            </name>
          </person-group>
          <source>Annals of Neurology</source>
          <article-title>Neurobiology of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref23">
        <label>23</label>
        <element-citation publication-type="journal">
          <issue>7</issue>
          <page-range>560-579</page-range>
          <volume>11</volume>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.1038/nrd3649</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Pratt</surname>
              <given-names>Judith</given-names>
            </name>
            <name>
              <surname>Winchester</surname>
              <given-names>Catherine</given-names>
            </name>
            <name>
              <surname>Dawson</surname>
              <given-names>Neil</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>Brian</given-names>
            </name>
          </person-group>
          <source>Nature Reviews Drug Discovery</source>
          <article-title>Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap</article-title>
        </element-citation>
      </ref>
      <ref id="ref24">
        <label>24</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>116-126</page-range>
          <volume>29</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1177/0269881114562092</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Foussias</surname>
              <given-names>George</given-names>
            </name>
            <name>
              <surname>Siddiqui</surname>
              <given-names>Ishraq</given-names>
            </name>
            <name>
              <surname>Fervaha</surname>
              <given-names>Gagan</given-names>
            </name>
            <name>
              <surname>Agid</surname>
              <given-names>Ofer</given-names>
            </name>
            <name>
              <surname>Remington</surname>
              <given-names>Gary</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Pratt</surname>
              <given-names>Judith</given-names>
            </name>
          </person-group>
          <source>Journal of Psychopharmacology</source>
          <article-title>Dissecting negative symptoms in schizophrenia: Opportunities for translation into new treatments</article-title>
        </element-citation>
      </ref>
      <ref id="ref25">
        <label>25</label>
        <element-citation publication-type="journal">
          <fpage>69</fpage>
          <lpage>108</lpage>
          <page-range>69-108</page-range>
          <volume>78</volume>
          <year>2007</year>
          <pub-id pub-id-type="doi">10.1016/S0074-7742(06)78003-5</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Javitt</surname>
              <given-names>Daniel C.</given-names>
            </name>
          </person-group>
          <source>International Review of Neurobiology</source>
          <article-title>Glutamate and Schizophrenia: Phencyclidine, NâMethylâdâAspartate Receptors, and DopamineâGlutamate Interactions</article-title>
        </element-citation>
      </ref>
      <ref id="ref26">
        <label>26</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>1191-1203</page-range>
          <volume>62</volume>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.04.011</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Bussey</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lyon</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Mar</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>McAllister</surname>
              <given-names>K.A.L.</given-names>
            </name>
            <name>
              <surname>Nithianantharajah</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Oomen</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Saksida</surname>
              <given-names>L.M.</given-names>
            </name>
          </person-group>
          <source>Neuropharmacology</source>
          <article-title>New translational assays for preclinical modelling of cognition in schizophrenia: The touchscreen testing method for mice and rats</article-title>
        </element-citation>
      </ref>
      <ref id="ref27">
        <label>27</label>
        <element-citation publication-type="journal">
          <issue>21-22</issue>
          <page-range>3947-3966</page-range>
          <volume>232</volume>
          <year>2015</year>
          <pub-id pub-id-type="doi">10.1007/s00213-015-4081-0</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>Chi Hun</given-names>
            </name>
            <name>
              <surname>Hvoslef-Eide</surname>
              <given-names>Martha</given-names>
            </name>
            <name>
              <surname>Nilsson</surname>
              <given-names>Simon R. O.</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>Mark R.</given-names>
            </name>
            <name>
              <surname>Herbert</surname>
              <given-names>Bronwen R.</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>Trevor W.</given-names>
            </name>
            <name>
              <surname>Saksida</surname>
              <given-names>Lisa M.</given-names>
            </name>
            <name>
              <surname>Bussey</surname>
              <given-names>Timothy J.</given-names>
            </name>
            <name>
              <surname>Mar</surname>
              <given-names>Adam C.</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>The continuous performance test (rCPT) for mice: a novel operant touchscreen test of attentional function</article-title>
        </element-citation>
      </ref>
      <ref id="ref28">
        <label>28</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>31-43</page-range>
          <volume>153</volume>
          <year>2000</year>
          <pub-id pub-id-type="doi">10.1007/s002130000569</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Bardo</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Bevins</surname>
              <given-names>R.A.</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>Conditioned place preference: what does it add to our preclinical understanding of drug reward?</article-title>
        </element-citation>
      </ref>
      <ref id="ref29">
        <label>29</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>162-166</page-range>
          <volume>34</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1016/j.tips.2013.01.004</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Huston</surname>
              <given-names>Joseph P.</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>Maria A. de Souza</given-names>
            </name>
            <name>
              <surname>Topic</surname>
              <given-names>Bianca</given-names>
            </name>
            <name>
              <surname>MÃ¼ller</surname>
              <given-names>Christian P.</given-names>
            </name>
          </person-group>
          <source>Trends in Pharmacological Sciences</source>
          <article-title>What's conditioned in conditioned place preference?</article-title>
        </element-citation>
      </ref>
      <ref id="ref30">
        <label>30</label>
        <element-citation publication-type="journal">
          <issue>6</issue>
          <page-range>613-672</page-range>
          <volume>56</volume>
          <year>1998</year>
          <pub-id pub-id-type="doi">10.1016/s0301-0082(98)00060-4</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Tzschentke</surname>
              <given-names>Thomas M.</given-names>
            </name>
          </person-group>
          <source>Progress in Neurobiology</source>
          <article-title>Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues</article-title>
        </element-citation>
      </ref>
      <ref id="ref31">
        <label>31</label>
        <element-citation publication-type="journal">
          <issue>3-4</issue>
          <page-range>227-462</page-range>
          <volume>12</volume>
          <year>2007</year>
          <pub-id pub-id-type="doi">10.1111/j.1369-1600.2007.00070.x</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Tzschentke</surname>
              <given-names>Thomas M.</given-names>
            </name>
          </person-group>
          <source>Addiction Biology</source>
          <article-title>Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade</article-title>
        </element-citation>
      </ref>
      <ref id="ref32">
        <label>32</label>
        <element-citation publication-type="journal">
          <issue>8</issue>
          <page-range>91-117</page-range>
          <volume>95</volume>
          <year>2000</year>
          <pub-id pub-id-type="doi">10.1080/09652140050111681</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Robinson</surname>
              <given-names>Terry E.</given-names>
            </name>
            <name>
              <surname>Berridge</surname>
              <given-names>Kent C.</given-names>
            </name>
          </person-group>
          <source>Addiction</source>
          <article-title>The psychology and neurobiology of addiction: an incentiveâsensitization view</article-title>
        </element-citation>
      </ref>
      <ref id="ref33">
        <label>33</label>
        <element-citation publication-type="journal">
          <page-range>160-168</page-range>
          <volume>56</volume>
          <year>2009</year>
          <pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.06.070</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Vezina</surname>
              <given-names>Paul</given-names>
            </name>
            <name>
              <surname>Leyton</surname>
              <given-names>Marco</given-names>
            </name>
          </person-group>
          <source>Neuropharmacology</source>
          <article-title>Conditioned cues and the expression of stimulant sensitization in animals and humans</article-title>
        </element-citation>
      </ref>
      <ref id="ref34">
        <label>34</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>348-365</page-range>
          <volume>63</volume>
          <year>2011</year>
          <pub-id pub-id-type="doi">10.1124/pr.109.001933</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Steketee</surname>
              <given-names>Jeffery D.</given-names>
            </name>
            <name>
              <surname>Kalivas</surname>
              <given-names>Peter W.</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Sibley</surname>
              <given-names>David R.</given-names>
            </name>
          </person-group>
          <source>Pharmacological Reviews</source>
          <article-title>Drug Wanting: Behavioral Sensitization and Relapse to Drug-Seeking Behavior</article-title>
        </element-citation>
      </ref>
      <ref id="ref35">
        <label>35</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>101-118</page-range>
          <volume>37</volume>
          <year>2006</year>
          <pub-id pub-id-type="doi">10.1007/s10519-006-9097-0</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Thomsen</surname>
              <given-names>Morgane</given-names>
            </name>
            <name>
              <surname>Caine</surname>
              <given-names>S. Barak</given-names>
            </name>
          </person-group>
          <source>Behavior Genetics</source>
          <article-title>Intravenous Drug Self-administration in Mice: Practical Considerations</article-title>
        </element-citation>
      </ref>
      <ref id="ref36">
        <label>36</label>
        <element-citation publication-type="journal">
          <page-range>33-47</page-range>
          <volume>87</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.pnpbp.2018.01.002</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Farrell</surname>
              <given-names>Mitchell R.</given-names>
            </name>
            <name>
              <surname>Schoch</surname>
              <given-names>Hannah</given-names>
            </name>
            <name>
              <surname>Mahler</surname>
              <given-names>Stephen V.</given-names>
            </name>
          </person-group>
          <source>Progress in Neuro-Psychopharmacology and Biological Psychiatry</source>
          <article-title>Modeling cocaine relapse in rodents: Behavioral considerations and circuit mechanisms</article-title>
        </element-citation>
      </ref>
      <ref id="ref37">
        <label>37</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>869-917</page-range>
          <volume>66</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1124/pr.112.007419</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Negus</surname>
              <given-names>S. Stevens</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>Laurence L.</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Nader</surname>
              <given-names>Michael A.</given-names>
            </name>
          </person-group>
          <source>Pharmacological Reviews</source>
          <article-title>Intracranial Self-Stimulation to Evaluate Abuse Potential of Drugs</article-title>
        </element-citation>
      </ref>
      <ref id="ref38">
        <label>38</label>
        <element-citation publication-type="journal">
          <issue>11</issue>
          <page-range>2987-2995</page-range>
          <volume>2</volume>
          <year>2007</year>
          <pub-id pub-id-type="doi">10.1038/nprot.2007.441</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Carlezon</surname>
              <given-names>William A</given-names>
            </name>
            <name>
              <surname>Chartoff</surname>
              <given-names>Elena H</given-names>
            </name>
          </person-group>
          <source>Nature Protocols</source>
          <article-title>Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation</article-title>
        </element-citation>
      </ref>
      <ref id="ref39">
        <label>39</label>
        <element-citation publication-type="journal">
          <issue>5</issue>
          <page-range>896-910</page-range>
          <volume>37</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1016/j.neubiorev.2013.03.025</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Ng</surname>
              <given-names>Enoch</given-names>
            </name>
            <name>
              <surname>McGirr</surname>
              <given-names>Alexander</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>Albert H.C.</given-names>
            </name>
            <name>
              <surname>Roder</surname>
              <given-names>John C.</given-names>
            </name>
          </person-group>
          <source>Neuroscience &amp; Biobehavioral Reviews</source>
          <article-title>Using rodents to model schizophrenia and substance use comorbidity</article-title>
        </element-citation>
      </ref>
      <ref id="ref40">
        <label>40</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>99-106</page-range>
          <volume>354</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1007/s00441-013-1581-2</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Schneider</surname>
              <given-names>Miriam</given-names>
            </name>
          </person-group>
          <source>Cell and Tissue Research</source>
          <article-title>Adolescence as a vulnerable period to alter rodent behavior</article-title>
        </element-citation>
      </ref>
      <ref id="ref41">
        <label>41</label>
        <element-citation publication-type="journal">
          <issue>10</issue>
          <page-range>1161-1169</page-range>
          <volume>13</volume>
          <year>2010</year>
          <pub-id pub-id-type="doi">10.1038/nn.2647</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Nestler</surname>
              <given-names>Eric J</given-names>
            </name>
            <name>
              <surname>Hyman</surname>
              <given-names>Steven E</given-names>
            </name>
          </person-group>
          <source>Nature Neuroscience</source>
          <article-title>Animal models of neuropsychiatric disorders</article-title>
        </element-citation>
      </ref>
      <ref id="ref42">
        <label>42</label>
        <element-citation publication-type="journal">
          <issue>7</issue>
          <page-range>865-877</page-range>
          <volume>8</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1517/17460441.2013.797959</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Hoffman</surname>
              <given-names>Kurt Leroy</given-names>
            </name>
          </person-group>
          <source>Expert Opinion on Drug Discovery</source>
          <article-title>Role of murine models in psychiatric illness drug discovery: a dimensional view</article-title>
        </element-citation>
      </ref>
      <ref id="ref43">
        <label>43</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>28-34</page-range>
          <volume>11</volume>
          <year>1992</year>
          <pub-id pub-id-type="doi">10.1002/syn.890110105</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Keller</surname>
              <given-names>Richard W.</given-names>
            </name>
            <name>
              <surname>Maisonneuve</surname>
              <given-names>Isabelle M.</given-names>
            </name>
            <name>
              <surname>Carlson</surname>
              <given-names>Jeffrey N.</given-names>
            </name>
            <name>
              <surname>Glick</surname>
              <given-names>Stanley D.</given-names>
            </name>
          </person-group>
          <source>Synapse</source>
          <article-title>Within-subject sensitization of striatal dopamine release after a single injection of cocaine: An in vivo microdialysis study</article-title>
        </element-citation>
      </ref>
      <ref id="ref44">
        <label>44</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>677-680</page-range>
          <volume>45</volume>
          <year>1991</year>
          <pub-id pub-id-type="doi">10.1111/j.1440-1819.1991.tb01190.x</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Kashihara</surname>
              <given-names>Kenichi</given-names>
            </name>
            <name>
              <surname>Hamamura</surname>
              <given-names>Takashi</given-names>
            </name>
            <name>
              <surname>Okumura</surname>
              <given-names>Kazuya</given-names>
            </name>
            <name>
              <surname>Otsuki</surname>
              <given-names>Saburo</given-names>
            </name>
          </person-group>
          <source>Psychiatry and Clinical Neurosciences</source>
          <article-title>Methamphetamine-Induced Dopamine Release in the Medial Frontal Cortex of Freely Moving Rats</article-title>
        </element-citation>
      </ref>
      <ref id="ref45">
        <label>45</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>589-607</page-range>
          <volume>11</volume>
          <year>2011</year>
          <pub-id pub-id-type="doi">10.1586/ern.10.191</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Remington</surname>
              <given-names>Gary</given-names>
            </name>
            <name>
              <surname>Agid</surname>
              <given-names>Ofer</given-names>
            </name>
            <name>
              <surname>Foussias</surname>
              <given-names>George</given-names>
            </name>
          </person-group>
          <source>Expert Review of Neurotherapeutics</source>
          <article-title>Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment</article-title>
        </element-citation>
      </ref>
      <ref id="ref46">
        <label>46</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>397-404</page-range>
          <volume>20</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.2174/0929867311320030011</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Brunelin</surname>
              <given-names>Jerome</given-names>
            </name>
            <name>
              <surname>Fecteau</surname>
              <given-names>Shirley</given-names>
            </name>
            <name>
              <surname>Suaud-Chagny</surname>
              <given-names>Marie-Francoise</given-names>
            </name>
          </person-group>
          <source>Current Medicinal Chemistry</source>
          <article-title>Abnormal Striatal Dopamine Transmission in Schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref47">
        <label>47</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>175-180</page-range>
          <volume>214</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1016/j.pscychresns.2013.09.013</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Seeman</surname>
              <given-names>Philip</given-names>
            </name>
          </person-group>
          <source>Psychiatry Research: Neuroimaging</source>
          <article-title>Schizophrenia thalamus imaging: Low benzamide binding to dopamine D2 receptors suggests fewer D2Short receptors and fewer presynaptic terminals</article-title>
        </element-citation>
      </ref>
      <ref id="ref48">
        <label>48</label>
        <element-citation publication-type="journal">
          <issue>5</issue>
          <page-range>ENEURO.0227-17.2017</page-range>
          <volume>4</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1523/eneuro.0227-17.2017</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Clark</surname>
              <given-names>Abigail M.</given-names>
            </name>
            <name>
              <surname>Leroy</surname>
              <given-names>Felix</given-names>
            </name>
            <name>
              <surname>Martyniuk</surname>
              <given-names>Kelly M.</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>Wendy</given-names>
            </name>
            <name>
              <surname>McManus</surname>
              <given-names>Erika</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>Matthew R.</given-names>
            </name>
            <name>
              <surname>Javitch</surname>
              <given-names>Jonathan A.</given-names>
            </name>
            <name>
              <surname>Balsam</surname>
              <given-names>Peter D.</given-names>
            </name>
            <name>
              <surname>Kellendonk</surname>
              <given-names>Christoph</given-names>
            </name>
          </person-group>
          <source>eneuro</source>
          <article-title>Dopamine D2 Receptors in the Paraventricular Thalamus Attenuate Cocaine Locomotor Sensitization</article-title>
        </element-citation>
      </ref>
      <ref id="ref49">
        <label>49</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>e1015-e1015</page-range>
          <volume>7</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1038/tp.2016.282</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Dahoun</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Trossbach</surname>
              <given-names>S V</given-names>
            </name>
            <name>
              <surname>Brandon</surname>
              <given-names>N J</given-names>
            </name>
            <name>
              <surname>Korth</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Howes</surname>
              <given-names>O D</given-names>
            </name>
          </person-group>
          <source>Translational Psychiatry</source>
          <article-title>The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review</article-title>
        </element-citation>
      </ref>
      <ref id="ref50">
        <label>50</label>
        <element-citation publication-type="journal">
          <issue>12</issue>
          <page-range>707-722</page-range>
          <volume>12</volume>
          <year>2011</year>
          <pub-id pub-id-type="doi">10.1038/nrn3120</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Brandon</surname>
              <given-names>Nicholas J.</given-names>
            </name>
            <name>
              <surname>Sawa</surname>
              <given-names>Akira</given-names>
            </name>
          </person-group>
          <source>Nature Reviews Neuroscience</source>
          <article-title>Linking neurodevelopmental and synaptic theories of mental illness through DISC1</article-title>
        </element-citation>
      </ref>
      <ref id="ref51">
        <label>51</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>32-38</page-range>
          <volume>79</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.04.023</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Wong</surname>
              <given-names>Albert H.C.</given-names>
            </name>
            <name>
              <surname>Josselyn</surname>
              <given-names>Sheena A.</given-names>
            </name>
          </person-group>
          <source>Biological Psychiatry</source>
          <article-title>Caution When Diagnosing Your Mouse With Schizophrenia: The Use and Misuse of Model Animals for Understanding Psychiatric Disorders</article-title>
        </element-citation>
      </ref>
      <ref id="ref52">
        <label>52</label>
        <element-citation publication-type="journal">
          <page-range>70-74</page-range>
          <volume>105</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1016/j.neures.2015.09.001</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Gancarz</surname>
              <given-names>Amy</given-names>
            </name>
            <name>
              <surname>Jouroukhin</surname>
              <given-names>Yan</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>Atsushi</given-names>
            </name>
            <name>
              <surname>Shevelkin</surname>
              <given-names>Alexey</given-names>
            </name>
            <name>
              <surname>Mueller</surname>
              <given-names>Lauren E.</given-names>
            </name>
            <name>
              <surname>Kamiya</surname>
              <given-names>Atsushi</given-names>
            </name>
            <name>
              <surname>Dietz</surname>
              <given-names>David M.</given-names>
            </name>
            <name>
              <surname>Pletnikov</surname>
              <given-names>Mikhail V.</given-names>
            </name>
          </person-group>
          <source>Neuroscience Research</source>
          <article-title>DISC1 signaling in cocaine addiction: Towards molecular mechanisms of co-morbidity</article-title>
        </element-citation>
      </ref>
      <ref id="ref53">
        <label>53</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>356-362</page-range>
          <volume>56</volume>
          <year>2006</year>
          <pub-id pub-id-type="doi">10.1016/j.neures.2006.08.004</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>Kyu Young</given-names>
            </name>
            <name>
              <surname>Ahn</surname>
              <given-names>Yong Min</given-names>
            </name>
            <name>
              <surname>Joo</surname>
              <given-names>Eun-Jeong</given-names>
            </name>
            <name>
              <surname>Joo</surname>
              <given-names>Yeon Ho</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>Jae Seung</given-names>
            </name>
            <name>
              <surname>Yoo</surname>
              <given-names>Han Young</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>Yong Sik</given-names>
            </name>
          </person-group>
          <source>Neuroscience Research</source>
          <article-title>Partial evidence of an association between epidermal growth factor A61G polymorphism and age at onset in male schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref54">
        <label>54</label>
        <element-citation publication-type="journal">
          <issue>1-2</issue>
          <page-range>8-14</page-range>
          <volume>41</volume>
          <year>2007</year>
          <pub-id pub-id-type="doi">10.1016/j.jpsychires.2005.07.001</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Hanninen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Katila</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Anttila</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rontu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Maaskola</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hurme</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lehtimaki</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <source>Journal of Psychiatric Research</source>
          <article-title>Epidermal growth factor a61g polymorphism is associated with the age of onset of schizophrenia in male patients</article-title>
        </element-citation>
      </ref>
      <ref id="ref55">
        <label>55</label>
        <element-citation publication-type="journal">
          <page-range>21-25</page-range>
          <volume>547</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1016/j.neulet.2013.04.055</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Eda</surname>
              <given-names>Takeyoshi</given-names>
            </name>
            <name>
              <surname>Mizuno</surname>
              <given-names>Makoto</given-names>
            </name>
            <name>
              <surname>Araki</surname>
              <given-names>Kazuaki</given-names>
            </name>
            <name>
              <surname>Iwakura</surname>
              <given-names>Yuriko</given-names>
            </name>
            <name>
              <surname>Namba</surname>
              <given-names>Hisaaki</given-names>
            </name>
            <name>
              <surname>Sotoyama</surname>
              <given-names>Hidekazu</given-names>
            </name>
            <name>
              <surname>Kakita</surname>
              <given-names>Akiyoshi</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>Hitoshi</given-names>
            </name>
            <name>
              <surname>Satoh</surname>
              <given-names>Hiroshi</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>Siu-Yuen</given-names>
            </name>
            <name>
              <surname>Nawa</surname>
              <given-names>Hiroyuki</given-names>
            </name>
          </person-group>
          <source>Neuroscience Letters</source>
          <article-title>Neurobehavioral deficits of epidermal growth factor-overexpressing transgenic mice: Impact on dopamine metabolism</article-title>
        </element-citation>
      </ref>
      <ref id="ref56">
        <label>56</label>
        <element-citation publication-type="chapter">
          <fpage>351</fpage>
          <lpage>382</lpage>
          <publisher-loc>Amsterdam</publisher-loc>
          <publisher-name>Academic Press</publisher-name>
          <volume>76</volume>
          <year>2016</year>
          <pub-id pub-id-type="isbn">9780128097458</pub-id>
          <pub-id pub-id-type="doi">10.1016/bs.apha.2016.01.006</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Balu</surname>
              <given-names>D. T.</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Schwarcz</surname>
              <given-names>Robert</given-names>
            </name>
            <name>
              <surname>Coyle</surname>
              <given-names>Joseph T.</given-names>
            </name>
          </person-group>
          <source>Neuropsychopharmacology: a tribute to Joseph T. Coyle</source>
          <chapter-title>The NMDA receptor and schizophrenia: From pathophysiology to treatment</chapter-title>
        </element-citation>
      </ref>
      <ref id="ref57">
        <label>57</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>465-470</page-range>
          <volume>353</volume>
          <year>2015</year>
          <pub-id pub-id-type="doi">10.1124/jpet.115.223099</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Puhl</surname>
              <given-names>Matthew D.</given-names>
            </name>
            <name>
              <surname>Berg</surname>
              <given-names>Alexandra R.</given-names>
            </name>
            <name>
              <surname>Bechtholt</surname>
              <given-names>Anita J.</given-names>
            </name>
            <name>
              <surname>Coyle</surname>
              <given-names>Joseph T.</given-names>
            </name>
          </person-group>
          <source>Journal of Pharmacology and Experimental Therapeutics</source>
          <article-title>Availability of N-Methyl-d-Aspartate Receptor Coagonists Affects Cocaine-Induced Conditioned Place Preference and Locomotor Sensitization: Implications for Comorbid Schizophrenia and Substance Abuse</article-title>
        </element-citation>
      </ref>
      <ref id="ref58">
        <label>58</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>635-654</page-range>
          <volume>161</volume>
          <year>2009</year>
          <pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.03.056</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Singer</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Yee</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Feldon</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Iwasato</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Itohara</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Grampp</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Prenosil</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Benke</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>MÃ¶hler</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Boison</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <source>Neuroscience</source>
          <article-title>Altered mnemonic functions and resistance to N-METHYL-d-Aspartate receptor antagonism by forebrain conditional knockout of glycine transporter 1</article-title>
        </element-citation>
      </ref>
      <ref id="ref59">
        <label>59</label>
        <element-citation publication-type="journal">
          <issue>12</issue>
          <page-range>3169-3181</page-range>
          <volume>26</volume>
          <year>2006</year>
          <pub-id pub-id-type="doi">10.1523/jneurosci.5120-05.2006</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Yee</surname>
              <given-names>B. K.</given-names>
            </name>
          </person-group>
          <source>Journal of Neuroscience</source>
          <article-title>Disruption of Glycine Transporter 1 Restricted to Forebrain Neurons Is Associated with a Procognitive and Antipsychotic Phenotypic Profile</article-title>
        </element-citation>
      </ref>
      <ref id="ref60">
        <label>60</label>
        <element-citation publication-type="journal">
          <page-range>269-274</page-range>
          <volume>73</volume>
          <year>2015</year>
          <pub-id pub-id-type="doi">10.1016/j.nbd.2014.10.009</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Puhl</surname>
              <given-names>Matthew D.</given-names>
            </name>
            <name>
              <surname>Mintzopoulos</surname>
              <given-names>Dionyssios</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>J. Eric</given-names>
            </name>
            <name>
              <surname>Gillis</surname>
              <given-names>Timothy E.</given-names>
            </name>
            <name>
              <surname>Konopaske</surname>
              <given-names>Glenn T.</given-names>
            </name>
            <name>
              <surname>Kaufman</surname>
              <given-names>Marc J.</given-names>
            </name>
            <name>
              <surname>Coyle</surname>
              <given-names>Joseph T.</given-names>
            </name>
          </person-group>
          <source>Neurobiology of Disease</source>
          <article-title>In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnormalities in the serine racemase knockout mouse model of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref61">
        <label>61</label>
        <element-citation publication-type="journal">
          <issue>10</issue>
          <volume>9</volume>
          <year>2019</year>
          <pub-id pub-id-type="doi">10.1002/brb3.1383</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Matveeva</surname>
              <given-names>Tatyana M.</given-names>
            </name>
            <name>
              <surname>Pisansky</surname>
              <given-names>Marc T.</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>Amy</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>Robert F.</given-names>
            </name>
            <name>
              <surname>Gewirtz</surname>
              <given-names>Jonathan C.</given-names>
            </name>
          </person-group>
          <source>Brain and Behavior</source>
          <article-title>Sociality deficits in serine racemase knockout mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref62">
        <label>62</label>
        <element-citation publication-type="journal">
          <issue>7</issue>
          <page-range>719-727</page-range>
          <volume>14</volume>
          <year>2008</year>
          <pub-id pub-id-type="doi">10.1038/mp.2008.130</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Basu</surname>
              <given-names>A C</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>G E</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>C-L</given-names>
            </name>
            <name>
              <surname>Ehmsen</surname>
              <given-names>J T</given-names>
            </name>
            <name>
              <surname>Mustafa</surname>
              <given-names>A K</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>Z I</given-names>
            </name>
            <name>
              <surname>Benneyworth</surname>
              <given-names>M A</given-names>
            </name>
            <name>
              <surname>Froimowitz</surname>
              <given-names>M P</given-names>
            </name>
            <name>
              <surname>Lange</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Snyder</surname>
              <given-names>S H</given-names>
            </name>
            <name>
              <surname>Bergeron</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Coyle</surname>
              <given-names>J T</given-names>
            </name>
          </person-group>
          <source>Molecular Psychiatry</source>
          <article-title>Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior</article-title>
        </element-citation>
      </ref>
      <ref id="ref63">
        <label>63</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>40-50</page-range>
          <volume>24</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1111/adb.12577</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Puhl</surname>
              <given-names>Matthew D.</given-names>
            </name>
            <name>
              <surname>Desai</surname>
              <given-names>Rajeev I.</given-names>
            </name>
            <name>
              <surname>Takagi</surname>
              <given-names>Shunsuke</given-names>
            </name>
            <name>
              <surname>Presti</surname>
              <given-names>Kendall T.</given-names>
            </name>
            <name>
              <surname>Doyle</surname>
              <given-names>Michelle R.</given-names>
            </name>
            <name>
              <surname>Donahue</surname>
              <given-names>Rachel J.</given-names>
            </name>
            <name>
              <surname>Landino</surname>
              <given-names>Samantha M.</given-names>
            </name>
            <name>
              <surname>Bergman</surname>
              <given-names>Jack</given-names>
            </name>
            <name>
              <surname>Carlezon</surname>
              <given-names>William A.</given-names>
            </name>
            <name>
              <surname>Coyle</surname>
              <given-names>Joseph T.</given-names>
            </name>
          </person-group>
          <source>Addiction Biology</source>
          <article-title>N
-Methyl-d
-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse</article-title>
        </element-citation>
      </ref>
      <ref id="ref64">
        <label>64</label>
        <element-citation publication-type="journal">
          <issue>11</issue>
          <page-range>2496-2504</page-range>
          <volume>37</volume>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.1038/npp.2012.108</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Benneyworth</surname>
              <given-names>Michael A</given-names>
            </name>
            <name>
              <surname>Coyle</surname>
              <given-names>Joseph T</given-names>
            </name>
          </person-group>
          <source>Neuropsychopharmacology</source>
          <article-title>Altered Acquisition and Extinction of Amphetamine-Paired Context Conditioning in Genetic Mouse Models of Altered NMDA Receptor Function</article-title>
        </element-citation>
      </ref>
      <ref id="ref65">
        <label>65</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>9.55.1-9.55.17</page-range>
          <volume>77</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1002/cpns.15</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Brady</surname>
              <given-names>Anne Marie</given-names>
            </name>
          </person-group>
          <source>Current Protocols in Neuroscience</source>
          <article-title>The Neonatal Ventral Hippocampal Lesion (NVHL) Rodent Model of Schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref66">
        <label>66</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>295-305</page-range>
          <volume>204</volume>
          <year>2009</year>
          <pub-id pub-id-type="doi">10.1016/j.bbr.2008.11.039</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Tseng</surname>
              <given-names>Kuei Y.</given-names>
            </name>
            <name>
              <surname>Chambers</surname>
              <given-names>R. Andrew</given-names>
            </name>
            <name>
              <surname>Lipska</surname>
              <given-names>Barbara K.</given-names>
            </name>
          </person-group>
          <source>Behavioural Brain Research</source>
          <article-title>The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref67">
        <label>67</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>223-239</page-range>
          <volume>23</volume>
          <year>2000</year>
          <pub-id pub-id-type="doi">10.1016/s0893-133x(00)00137-8</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Lipska</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <source>Neuropsychopharmacology</source>
          <article-title>To Model a Psychiatric Disorder in Animals Schizophrenia As a Reality Test</article-title>
        </element-citation>
      </ref>
      <ref id="ref68">
        <label>68</label>
        <element-citation publication-type="journal">
          <issue>5-6</issue>
          <page-range>469-475</page-range>
          <volume>4</volume>
          <year>2002</year>
          <pub-id pub-id-type="doi">10.1080/1029842021000022089</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Lipska</surname>
              <given-names>Barbara K.</given-names>
            </name>
            <name>
              <surname>Weinberger</surname>
              <given-names>Daniel R.</given-names>
            </name>
          </person-group>
          <source>Neurotoxicity Research</source>
          <article-title>A neurodevelopmental model of schizophrenia: Neonatal disconnection of the hippocampus</article-title>
        </element-citation>
      </ref>
      <ref id="ref69">
        <label>69</label>
        <element-citation publication-type="journal">
          <issue>9</issue>
          <page-range>1534-1545</page-range>
          <volume>24</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1016/j.euroneuro.2014.07.003</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Gallo</surname>
              <given-names>Alexandra</given-names>
            </name>
            <name>
              <surname>Bouchard</surname>
              <given-names>Claude</given-names>
            </name>
            <name>
              <surname>Fortier</surname>
              <given-names>Emmanuel</given-names>
            </name>
            <name>
              <surname>Ducrot</surname>
              <given-names>Charles</given-names>
            </name>
            <name>
              <surname>RomprÃ©</surname>
              <given-names>Pierre-Paul</given-names>
            </name>
          </person-group>
          <source>European Neuropsychopharmacology</source>
          <article-title>Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: A brain stimulation reward study</article-title>
        </element-citation>
      </ref>
      <ref id="ref70">
        <label>70</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>205-215</page-range>
          <volume>200</volume>
          <year>2008</year>
          <pub-id pub-id-type="doi">10.1007/s00213-008-1195-7</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Brady</surname>
              <given-names>Anne Marie</given-names>
            </name>
            <name>
              <surname>McCallum</surname>
              <given-names>Sarah E.</given-names>
            </name>
            <name>
              <surname>Glick</surname>
              <given-names>Stanley D.</given-names>
            </name>
            <name>
              <surname>OâDonnell</surname>
              <given-names>Patricio</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>Enhanced methamphetamine self-administration in a neurodevelopmental rat model of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref71">
        <label>71</label>
        <element-citation publication-type="journal">
          <issue>5</issue>
          <page-range>564-575</page-range>
          <volume>12</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1111/gbb.12051</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Chambers</surname>
              <given-names>R. A.</given-names>
            </name>
            <name>
              <surname>McClintick</surname>
              <given-names>J. N.</given-names>
            </name>
            <name>
              <surname>Sentir</surname>
              <given-names>A. M.</given-names>
            </name>
            <name>
              <surname>Berg</surname>
              <given-names>S. A.</given-names>
            </name>
            <name>
              <surname>Runyan</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>K. H.</given-names>
            </name>
            <name>
              <surname>Edenberg</surname>
              <given-names>H. J.</given-names>
            </name>
          </person-group>
          <source>Genes, Brain and Behavior</source>
          <article-title>Cortical-striatal gene expression in neonatal hippocampal lesion (NVHL)-amplified cocaine sensitization</article-title>
        </element-citation>
      </ref>
      <ref id="ref72">
        <label>72</label>
        <element-citation publication-type="journal">
          <issue>23-24</issue>
          <page-range>3933-3945</page-range>
          <volume>233</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1007/s00213-016-4421-8</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Rao</surname>
              <given-names>Kalyan N.</given-names>
            </name>
            <name>
              <surname>Sentir</surname>
              <given-names>Alena M.</given-names>
            </name>
            <name>
              <surname>Engleman</surname>
              <given-names>Eric A.</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>Richard L.</given-names>
            </name>
            <name>
              <surname>Hulvershorn</surname>
              <given-names>Leslie A.</given-names>
            </name>
            <name>
              <surname>Breier</surname>
              <given-names>Alan</given-names>
            </name>
            <name>
              <surname>Chambers</surname>
              <given-names>R. Andrew</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>Toward early estimation and treatment of addiction vulnerability: radial arm maze and N-acetyl cysteine before cocaine sensitization or nicotine self-administration in neonatal ventral hippocampal lesion rats</article-title>
        </element-citation>
      </ref>
      <ref id="ref73">
        <label>73</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>45-51</page-range>
          <volume>226</volume>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.1007/s00213-012-2882-y</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Karlsson</surname>
              <given-names>Rose-Marie</given-names>
            </name>
            <name>
              <surname>Kircher</surname>
              <given-names>Daniel M.</given-names>
            </name>
            <name>
              <surname>Shaham</surname>
              <given-names>Yavin</given-names>
            </name>
            <name>
              <surname>OâDonnell</surname>
              <given-names>Patricio</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>Exaggerated cue-induced reinstatement of cocaine seeking but not incubation of cocaine craving in a developmental rat model of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref74">
        <label>74</label>
        <element-citation publication-type="journal">
          <issue>6</issue>
          <page-range>1020-1031</page-range>
          <volume>19</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1111/adb.12082</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Berg</surname>
              <given-names>Sarah A.</given-names>
            </name>
            <name>
              <surname>Sentir</surname>
              <given-names>Alena M.</given-names>
            </name>
            <name>
              <surname>Cooley</surname>
              <given-names>Benjamin S.</given-names>
            </name>
            <name>
              <surname>Engleman</surname>
              <given-names>Eric A.</given-names>
            </name>
            <name>
              <surname>Chambers</surname>
              <given-names>R. Andrew</given-names>
            </name>
          </person-group>
          <source>Addiction Biology</source>
          <article-title>Nicotine is more addictive, not more cognitively therapeutic in a neurodevelopmental model of schizophrenia produced by neonatal ventral hippocampal lesions</article-title>
        </element-citation>
      </ref>
      <ref id="ref75">
        <label>75</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <volume>25</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1111/adb.12704</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Sentir</surname>
              <given-names>Alena M.</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>Richard L.</given-names>
            </name>
            <name>
              <surname>Engleman</surname>
              <given-names>Eric A.</given-names>
            </name>
            <name>
              <surname>Chambers</surname>
              <given-names>R. Andrew</given-names>
            </name>
          </person-group>
          <source>Addiction Biology</source>
          <article-title>Polysubstance addiction vulnerability in mental illness: Concurrent alcohol and nicotine selfâadministration in the neurodevelopmental hippocampal lesion rat model of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref76">
        <label>76</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>39-48</page-range>
          <volume>49</volume>
          <year>1997</year>
          <pub-id pub-id-type="doi">10.1016/s0376-8716(97)00137-3</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Duncan</surname>
              <given-names>Susan C</given-names>
            </name>
            <name>
              <surname>Alpert</surname>
              <given-names>Anthony</given-names>
            </name>
            <name>
              <surname>Duncan</surname>
              <given-names>Terry E</given-names>
            </name>
            <name>
              <surname>Hops</surname>
              <given-names>Hyman</given-names>
            </name>
          </person-group>
          <source>Drug and Alcohol Dependence</source>
          <article-title>Adolescent alcohol use development and young adult outcomes</article-title>
        </element-citation>
      </ref>
      <ref id="ref77">
        <label>77</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>490-499</page-range>
          <volume>20</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1111/adb.12146</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Jeanblanc</surname>
              <given-names>JÃ©rÃ´me</given-names>
            </name>
            <name>
              <surname>Balguerie</surname>
              <given-names>Kevin</given-names>
            </name>
            <name>
              <surname>Coune</surname>
              <given-names>Fabien</given-names>
            </name>
            <name>
              <surname>Legastelois</surname>
              <given-names>RÃ©mi</given-names>
            </name>
            <name>
              <surname>Jeanblanc</surname>
              <given-names>Virginie</given-names>
            </name>
            <name>
              <surname>Naassila</surname>
              <given-names>MickaÃ«l</given-names>
            </name>
          </person-group>
          <source>Addiction Biology</source>
          <article-title>Light alcohol intake during adolescence induces alcohol addiction in a neurodevelopmental model of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref78">
        <label>78</label>
        <element-citation publication-type="journal">
          <page-range>91-97</page-range>
          <volume>194</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.schres.2017.02.029</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Khokhar</surname>
              <given-names>Jibran Y.</given-names>
            </name>
            <name>
              <surname>Todd</surname>
              <given-names>Travis P.</given-names>
            </name>
          </person-group>
          <source>Schizophrenia Research</source>
          <article-title>Behavioral predictors of alcohol drinking in a neurodevelopmental rat model of schizophrenia and co-occurring alcohol use disorder</article-title>
        </element-citation>
      </ref>
      <ref id="ref79">
        <label>79</label>
        <element-citation publication-type="journal">
          <issue>9</issue>
          <page-range>1268-1281</page-range>
          <volume>176</volume>
          <year>2019</year>
          <pub-id pub-id-type="doi">10.1111/bph.14625</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Spiller</surname>
              <given-names>Krista J.</given-names>
            </name>
            <name>
              <surname>Bi</surname>
              <given-names>Guoâhua</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>Yi</given-names>
            </name>
            <name>
              <surname>Galaj</surname>
              <given-names>Ewa</given-names>
            </name>
            <name>
              <surname>Gardner</surname>
              <given-names>Eliot L.</given-names>
            </name>
            <name>
              <surname>Xi</surname>
              <given-names>ZhengâXiong</given-names>
            </name>
          </person-group>
          <source>British Journal of Pharmacology</source>
          <article-title>Cannabinoid CB
            1
            and CB
            2
            receptor mechanisms underlie cannabis reward and aversion in rats</article-title>
        </element-citation>
      </ref>
      <ref id="ref80">
        <label>80</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <volume>18</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1007/s11920-015-0657-y</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Ksir</surname>
              <given-names>Charles</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>Carl L.</given-names>
            </name>
          </person-group>
          <source>Current Psychiatry Reports</source>
          <article-title>Cannabis and Psychosis: a Critical Overview of the Relationship</article-title>
        </element-citation>
      </ref>
      <ref id="ref81">
        <label>81</label>
        <element-citation publication-type="journal">
          <issue>9</issue>
          <page-range>1653-1657</page-range>
          <volume>112</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1111/add.13826</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Hamilton</surname>
              <given-names>Ian</given-names>
            </name>
          </person-group>
          <source>Addiction</source>
          <article-title>Cannabis, psychosis and schizophrenia: unravelling a complex interaction</article-title>
        </element-citation>
      </ref>
      <ref id="ref82">
        <label>82</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>436-438</page-range>
          <volume>147</volume>
          <year>2000</year>
          <pub-id pub-id-type="doi">10.1007/s002130050013</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Valjent</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Maldonado</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>A behavioural model to reveal place preference to Î9-tetrahydrocannabinol in mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref83">
        <label>83</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>311-319</page-range>
          <volume>18</volume>
          <year>2007</year>
          <pub-id pub-id-type="doi">10.1097/fbp.0b013e3282186cf2</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Vlachou</surname>
              <given-names>Styliani</given-names>
            </name>
            <name>
              <surname>Nomikos</surname>
              <given-names>George G.</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>David N.</given-names>
            </name>
            <name>
              <surname>Panagis</surname>
              <given-names>George</given-names>
            </name>
          </person-group>
          <source>Behavioural Pharmacology</source>
          <article-title>Lack of evidence for appetitive effects of ??9-tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents</article-title>
        </element-citation>
      </ref>
      <ref id="ref84">
        <label>84</label>
        <element-citation publication-type="journal">
          <page-range>1-6</page-range>
          <volume>144</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1016/j.pbb.2016.02.007</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Hempel</surname>
              <given-names>Briana J.</given-names>
            </name>
            <name>
              <surname>Wakeford</surname>
              <given-names>Alison G.P.</given-names>
            </name>
            <name>
              <surname>Clasen</surname>
              <given-names>Matthew M.</given-names>
            </name>
            <name>
              <surname>Friar</surname>
              <given-names>Mary A.</given-names>
            </name>
            <name>
              <surname>Riley</surname>
              <given-names>Anthony L.</given-names>
            </name>
          </person-group>
          <source>Pharmacology Biochemistry and Behavior</source>
          <article-title>Delta-9-tetrahydrocannabinol (THC) history fails to affect THC's ability to induce place preferences in rats</article-title>
        </element-citation>
      </ref>
      <ref id="ref85">
        <label>85</label>
        <element-citation publication-type="journal">
          <page-range>202-212</page-range>
          <volume>268</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1016/j.bbr.2014.04.020</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Gallo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bouchard</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>RomprÃ©</surname>
              <given-names>P.-P.</given-names>
            </name>
          </person-group>
          <source>Behavioural Brain Research</source>
          <article-title>Animals with a schizophrenia-like phenotype are differentially sensitive to the motivational effects of cannabinoid agonists in conditioned place preference</article-title>
        </element-citation>
      </ref>
      <ref id="ref86">
        <label>86</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>233-243</page-range>
          <volume>23</volume>
          <year>2004</year>
          <pub-id pub-id-type="doi">10.1016/j.ejps.2004.07.013</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Govaerts</surname>
              <given-names>Sophie J.</given-names>
            </name>
            <name>
              <surname>Hermans</surname>
              <given-names>Emmanuel</given-names>
            </name>
            <name>
              <surname>Lambert</surname>
              <given-names>Didier M.</given-names>
            </name>
          </person-group>
          <source>European Journal of Pharmaceutical Sciences</source>
          <article-title>Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors</article-title>
        </element-citation>
      </ref>
      <ref id="ref87">
        <label>87</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>307-315</page-range>
          <volume>75</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1016/j.biopsych.2013.07.011</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Meyer</surname>
              <given-names>Urs</given-names>
            </name>
          </person-group>
          <source>Biological Psychiatry</source>
          <article-title>Prenatal Poly(I:C) Exposure and Other Developmental Immune Activation Models in Rodent Systems</article-title>
        </element-citation>
      </ref>
      <ref id="ref88">
        <label>88</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>241-256</page-range>
          <volume>13</volume>
          <year>2007</year>
          <pub-id pub-id-type="doi">10.1177/1073858406296401</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Meyer</surname>
              <given-names>Urs</given-names>
            </name>
            <name>
              <surname>Yee</surname>
              <given-names>Benjamin K.</given-names>
            </name>
            <name>
              <surname>Feldon</surname>
              <given-names>Joram</given-names>
            </name>
          </person-group>
          <source>The Neuroscientist</source>
          <article-title>The Neurodevelopmental Impact of Prenatal Infections at Different Times of Pregnancy: The Earlier the Worse?</article-title>
        </element-citation>
      </ref>
      <ref id="ref89">
        <label>89</label>
        <element-citation publication-type="journal">
          <page-range>63-69</page-range>
          <volume>63</volume>
          <year>2015</year>
          <pub-id pub-id-type="doi">10.1016/j.pnpbp.2015.05.015</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>BorÃ§oi</surname>
              <given-names>Aline R.</given-names>
            </name>
            <name>
              <surname>Patti</surname>
              <given-names>Camilla L.</given-names>
            </name>
            <name>
              <surname>Zanin</surname>
              <given-names>Karina A.</given-names>
            </name>
            <name>
              <surname>Hollais</surname>
              <given-names>AndrÃ© W.</given-names>
            </name>
            <name>
              <surname>Santos-Baldaia</surname>
              <given-names>Renan</given-names>
            </name>
            <name>
              <surname>Ceccon</surname>
              <given-names>Liliane M.B.</given-names>
            </name>
            <name>
              <surname>Berro</surname>
              <given-names>LaÃ­s F.</given-names>
            </name>
            <name>
              <surname>Wuo-Silva</surname>
              <given-names>Raphael</given-names>
            </name>
            <name>
              <surname>Grapiglia</surname>
              <given-names>Stephanie B.</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>Luciana T.C.</given-names>
            </name>
            <name>
              <surname>Lopes-Silva</surname>
              <given-names>Leonardo B.</given-names>
            </name>
            <name>
              <surname>Frussa-Filho</surname>
              <given-names>Roberto</given-names>
            </name>
          </person-group>
          <source>Progress in Neuro-Psychopharmacology and Biological Psychiatry</source>
          <article-title>Effects of prenatal immune activation on amphetamine-induced addictive behaviors: Contributions from animal models</article-title>
        </element-citation>
      </ref>
      <ref id="ref90">
        <label>90</label>
        <element-citation publication-type="journal">
          <issue>9</issue>
          <page-range>907-917</page-range>
          <volume>74</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1002/dneu.22172</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Li</given-names>
            </name>
            <name>
              <surname>Perez</surname>
              <given-names>Stephanie M.</given-names>
            </name>
            <name>
              <surname>Lodge</surname>
              <given-names>Daniel J.</given-names>
            </name>
          </person-group>
          <source>Developmental Neurobiology</source>
          <article-title>An augmented dopamine system function is present prior to puberty in the methylazoxymethanol acetate rodent model of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref91">
        <label>91</label>
        <element-citation publication-type="journal">
          <issue>9</issue>
          <page-range>e637-e637</page-range>
          <volume>5</volume>
          <year>2015</year>
          <pub-id pub-id-type="doi">10.1038/tp.2015.129</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Labouesse</surname>
              <given-names>M A</given-names>
            </name>
            <name>
              <surname>Langhans</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <source>Translational Psychiatry</source>
          <article-title>Abnormal contextâreward associations in an immune-mediated neurodevelopmental mouse model with relevance to schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref92">
        <label>92</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>69-73</page-range>
          <volume>59</volume>
          <year>2005</year>
          <pub-id pub-id-type="doi">10.1002/syn.20217</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Carelli</surname>
              <given-names>Regina M.</given-names>
            </name>
            <name>
              <surname>Wondolowski</surname>
              <given-names>Joyce</given-names>
            </name>
          </person-group>
          <source>Synapse</source>
          <article-title>Anatomic distribution of reinforcer selective cell firing in the core and shell of the nucleus accumbens</article-title>
        </element-citation>
      </ref>
      <ref id="ref93">
        <label>93</label>
        <element-citation publication-type="journal">
          <page-range>57-67</page-range>
          <volume>8</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.ynstr.2018.01.002</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Bolton</surname>
              <given-names>Jessica L.</given-names>
            </name>
            <name>
              <surname>Ruiz</surname>
              <given-names>Christina M.</given-names>
            </name>
            <name>
              <surname>Rismanchi</surname>
              <given-names>Neggy</given-names>
            </name>
            <name>
              <surname>Sanchez</surname>
              <given-names>Gissell A.</given-names>
            </name>
            <name>
              <surname>Castillo</surname>
              <given-names>Erik</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Jeff</given-names>
            </name>
            <name>
              <surname>Cross</surname>
              <given-names>Christopher</given-names>
            </name>
            <name>
              <surname>Baram</surname>
              <given-names>Tallie Z.</given-names>
            </name>
            <name>
              <surname>Mahler</surname>
              <given-names>Stephen V.</given-names>
            </name>
          </person-group>
          <source>Neurobiology of Stress</source>
          <article-title>Early-life adversity facilitates acquisition of cocaine self-administration and induces persistent anhedonia</article-title>
        </element-citation>
      </ref>
      <ref id="ref94">
        <label>94</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>382-390</page-range>
          <volume>93</volume>
          <year>2009</year>
          <pub-id pub-id-type="doi">10.1016/j.pbb.2009.05.010</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Featherstone</surname>
              <given-names>Robert E.</given-names>
            </name>
            <name>
              <surname>Burton</surname>
              <given-names>Christie L.</given-names>
            </name>
            <name>
              <surname>Coppa-Hopman</surname>
              <given-names>Romina</given-names>
            </name>
            <name>
              <surname>Rizos</surname>
              <given-names>ZoÃ«</given-names>
            </name>
            <name>
              <surname>Sinyard</surname>
              <given-names>Judy</given-names>
            </name>
            <name>
              <surname>Kapur</surname>
              <given-names>Shitij</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>Paul J.</given-names>
            </name>
          </person-group>
          <source>Pharmacology Biochemistry and Behavior</source>
          <article-title>Gestational treatment with methylazoxymethanol (MAM) that disrupts hippocampal-dependent memory does not alter behavioural response to cocaine</article-title>
        </element-citation>
      </ref>
      <ref id="ref95">
        <label>95</label>
        <element-citation publication-type="journal">
          <page-range>38-48</page-range>
          <volume>69</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1016/j.pnpbp.2016.04.008</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Santos-Toscano</surname>
              <given-names>Raquel</given-names>
            </name>
            <name>
              <surname>Borcel</surname>
              <given-names>Ãrika</given-names>
            </name>
            <name>
              <surname>Ucha</surname>
              <given-names>Marcos</given-names>
            </name>
            <name>
              <surname>Orihuel</surname>
              <given-names>Javier</given-names>
            </name>
            <name>
              <surname>CapellÃ¡n</surname>
              <given-names>Roberto</given-names>
            </name>
            <name>
              <surname>Roura-MartÃ­nez</surname>
              <given-names>David</given-names>
            </name>
            <name>
              <surname>Ambrosio</surname>
              <given-names>Emilio</given-names>
            </name>
            <name>
              <surname>Higuera-Matas</surname>
              <given-names>Alejandro</given-names>
            </name>
          </person-group>
          <source>Progress in Neuro-Psychopharmacology and Biological Psychiatry</source>
          <article-title>Unaltered cocaine self-administration in the prenatal LPS rat model of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref96">
        <label>96</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>129-142</page-range>
          <volume>18</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1080/15622975.2016.1190032</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Ruda-Kucerova</surname>
              <given-names>Jana</given-names>
            </name>
            <name>
              <surname>Babinska</surname>
              <given-names>Zuzana</given-names>
            </name>
            <name>
              <surname>Amchova</surname>
              <given-names>Petra</given-names>
            </name>
            <name>
              <surname>Stark</surname>
              <given-names>Tibor</given-names>
            </name>
            <name>
              <surname>Drago</surname>
              <given-names>Filippo</given-names>
            </name>
            <name>
              <surname>Sulcova</surname>
              <given-names>Alexandra</given-names>
            </name>
            <name>
              <surname>Micale</surname>
              <given-names>Vincenzo</given-names>
            </name>
          </person-group>
          <source>The World Journal of Biological Psychiatry</source>
          <article-title>Reactivity to addictive drugs in the methylazoxymethanol (MAM) model of schizophrenia in male and female rats</article-title>
        </element-citation>
      </ref>
      <ref id="ref97">
        <label>97</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>121-133</page-range>
          <volume>32</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1007/s12640-017-9718-9</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Ruda-Kucerova</surname>
              <given-names>Jana</given-names>
            </name>
            <name>
              <surname>Babinska</surname>
              <given-names>Zuzana</given-names>
            </name>
            <name>
              <surname>Stark</surname>
              <given-names>Tibor</given-names>
            </name>
            <name>
              <surname>Micale</surname>
              <given-names>Vincenzo</given-names>
            </name>
          </person-group>
          <source>Neurotoxicity Research</source>
          <article-title>Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref98">
        <label>98</label>
        <element-citation publication-type="journal">
          <page-range>279-285</page-range>
          <volume>304</volume>
          <year>2015</year>
          <pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.07.029</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Said</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Lakehayli</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>El Khachibi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>El Ouahli</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Nadifi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hakkou</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Tazi</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <source>Neuroscience</source>
          <article-title>Prenatal stress induces vulnerability to nicotine addiction and alters D2 receptorsâ expression in the nucleus accumbens in adult rats</article-title>
        </element-citation>
      </ref>
      <ref id="ref99">
        <label>99</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>64-72</page-range>
          <volume>40</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1159/000486391</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>RussellÂ W.</given-names>
            </name>
            <name>
              <surname>Schlitt</surname>
              <given-names>MarjorieÂ A.</given-names>
            </name>
            <name>
              <surname>Owens</surname>
              <given-names>AlexÂ S.</given-names>
            </name>
            <name>
              <surname>DePreter</surname>
              <given-names>CaitlynnÂ C.</given-names>
            </name>
            <name>
              <surname>Cummins</surname>
              <given-names>ElizabethÂ D.</given-names>
            </name>
            <name>
              <surname>Kirby</surname>
              <given-names>SethÂ L.</given-names>
            </name>
            <name>
              <surname>Gill</surname>
              <given-names>W.Â Drew</given-names>
            </name>
            <name>
              <surname>Burgess</surname>
              <given-names>KatherineÂ C.</given-names>
            </name>
          </person-group>
          <source>Developmental Neuroscience</source>
          <article-title>Effects of Environmental Enrichment on Nicotine Sensitization in Rats Neonatally Treated with Quinpirole: Analyses of Glial Cell Line-Derived Neurotrophic Factor and Implications towards Schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref100">
        <label>100</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>620-630</page-range>
          <volume>23</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1111/adb.12517</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Waterhouse</surname>
              <given-names>Uta</given-names>
            </name>
            <name>
              <surname>Brennan</surname>
              <given-names>Katharine A.</given-names>
            </name>
            <name>
              <surname>Ellenbroek</surname>
              <given-names>Bart A.</given-names>
            </name>
          </person-group>
          <source>Addiction Biology</source>
          <article-title>Nicotine self-administration reverses cognitive deficits in a rat model for schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref101">
        <label>101</label>
        <element-citation publication-type="journal">
          <year>2019</year>
          <pub-id pub-id-type="doi">10.1093/ntr/ntz048</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Weeks</surname>
              <given-names>Jillian J</given-names>
            </name>
            <name>
              <surname>Rupprecht</surname>
              <given-names>Laura E</given-names>
            </name>
            <name>
              <surname>Grace</surname>
              <given-names>Anthony A</given-names>
            </name>
            <name>
              <surname>Donny</surname>
              <given-names>Eric C</given-names>
            </name>
            <name>
              <surname>Sved</surname>
              <given-names>Alan F</given-names>
            </name>
          </person-group>
          <source>Nicotine &amp; Tobacco Research</source>
          <article-title>Nicotine Self-administration Is Not Increased in the Methylazoxymethanol Acetate Rodent Model of Schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref102">
        <label>102</label>
        <element-citation publication-type="journal">
          <issue>43</issue>
          <page-range>14502-14512</page-range>
          <volume>30</volume>
          <year>2010</year>
          <pub-id pub-id-type="doi">10.1523/jneurosci.3909-10.2010</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Carnicella</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ahmadiantehrani</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>D.-Y.</given-names>
            </name>
            <name>
              <surname>Barak</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kharazia</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Ben Hamida</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Zapata</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Shippenberg</surname>
              <given-names>T. S.</given-names>
            </name>
            <name>
              <surname>Ron</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <source>Journal of Neuroscience</source>
          <article-title>Nucleus Accumbens-Derived Glial Cell Line-Derived Neurotrophic Factor Is a Retrograde Enhancer of Dopaminergic Tone in the Mesocorticolimbic System</article-title>
        </element-citation>
      </ref>
      <ref id="ref103">
        <label>103</label>
        <element-citation publication-type="journal">
          <page-range>S92-S105</page-range>
          <volume>25</volume>
          <year>2011</year>
          <pub-id pub-id-type="doi">10.1016/j.bbi.2011.01.008</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Blednov</surname>
              <given-names>Y.A.</given-names>
            </name>
            <name>
              <surname>Benavidez</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Geil</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Perra</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Morikawa</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>R.A.</given-names>
            </name>
          </person-group>
          <source>Brain, Behavior, and Immunity</source>
          <article-title>Activation of inflammatory signaling by lipopolysaccharide produces a prolonged increase of voluntary alcohol intake in mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref104">
        <label>104</label>
        <element-citation publication-type="journal">
          <page-range>E394-E403</page-range>
          <volume>37</volume>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.1111/j.1530-0277.2012.01926.x</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Chappell</surname>
              <given-names>Ann M.</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>Eugenia</given-names>
            </name>
            <name>
              <surname>McCool</surname>
              <given-names>Brian A.</given-names>
            </name>
            <name>
              <surname>Weiner</surname>
              <given-names>Jeff L.</given-names>
            </name>
          </person-group>
          <source>Alcoholism: Clinical and Experimental Research</source>
          <article-title>Adolescent Rearing Conditions Influence the Relationship Between Initial Anxiety-Like Behavior and Ethanol Drinking in Male Long Evans Rats</article-title>
        </element-citation>
      </ref>
      <ref id="ref105">
        <label>105</label>
        <element-citation publication-type="journal">
          <page-range>149-159</page-range>
          <volume>97</volume>
          <year>2015</year>
          <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.05.025</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Skelly</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Chappell</surname>
              <given-names>A.E.</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Weiner</surname>
              <given-names>J.L.</given-names>
            </name>
          </person-group>
          <source>Neuropharmacology</source>
          <article-title>Adolescent social isolation increases anxiety-like behavior and ethanol intake and impairs fear extinction in adulthood: Possible role of disrupted noradrenergic signaling</article-title>
        </element-citation>
      </ref>
      <ref id="ref106">
        <label>106</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>355-364</page-range>
          <volume>45</volume>
          <year>2011</year>
          <pub-id pub-id-type="doi">10.1016/j.alcohol.2010.08.017</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Lopez</surname>
              <given-names>Marcelo F.</given-names>
            </name>
            <name>
              <surname>Doremus-Fitzwater</surname>
              <given-names>Tamara L.</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>Howard C.</given-names>
            </name>
          </person-group>
          <source>Alcohol</source>
          <article-title>Chronic social isolation and chronic variable stress during early development induce later elevated ethanol intake in adult C57BL/6J mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref107">
        <label>107</label>
        <element-citation publication-type="journal">
          <issue>8</issue>
          <page-range>e00767</page-range>
          <volume>7</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1002/brb3.767</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Holgate</surname>
              <given-names>Joan Y.</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>Hilary</given-names>
            </name>
            <name>
              <surname>Chatterjee</surname>
              <given-names>Susmita</given-names>
            </name>
            <name>
              <surname>Bartlett</surname>
              <given-names>Selena E.</given-names>
            </name>
          </person-group>
          <source>Brain and Behavior</source>
          <article-title>Social and environmental enrichment has different effects on ethanol and sucrose consumption in mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref108">
        <label>108</label>
        <element-citation publication-type="journal">
          <fpage>147</fpage>
          <issue>2</issue>
          <lpage>159</lpage>
          <page-range>147-159</page-range>
          <volume>39</volume>
          <year>2018</year>
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>R. S.</given-names>
            </name>
            <name>
              <surname>Oswald</surname>
              <given-names>L. M.</given-names>
            </name>
            <name>
              <surname>Wand</surname>
              <given-names>G. S.</given-names>
            </name>
          </person-group>
          <source>Alcohol Research</source>
          <article-title>Early Life Stress as a Predictor of Co-Occurring Alcohol Use Disorder and Post-Traumatic Stress Disorder</article-title>
        </element-citation>
      </ref>
      <ref id="ref109">
        <label>109</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>17-31</page-range>
          <volume>214</volume>
          <year>2010</year>
          <pub-id pub-id-type="doi">10.1007/s00213-010-1916-6</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Enoch</surname>
              <given-names>Mary-Anne</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>The role of early life stress as a predictor for alcohol and drug dependence</article-title>
        </element-citation>
      </ref>
      <ref id="ref110">
        <label>110</label>
        <element-citation publication-type="journal">
          <page-range>98-106</page-range>
          <volume>194</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.schres.2017.02.028</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Fletcher</surname>
              <given-names>Paul J.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Zhaoxia</given-names>
            </name>
            <name>
              <surname>Coen</surname>
              <given-names>Kathleen M.</given-names>
            </name>
            <name>
              <surname>LÃª</surname>
              <given-names>Anh D.</given-names>
            </name>
          </person-group>
          <source>Schizophrenia Research</source>
          <article-title>Acquisition of nicotine self-administration in amphetamine and phencyclidine models of schizophrenia: A role for stress?</article-title>
        </element-citation>
      </ref>
      <ref id="ref111">
        <label>111</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>272-279</page-range>
          <volume>88</volume>
          <year>2008</year>
          <pub-id pub-id-type="doi">10.1016/j.pbb.2007.08.011</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Baird</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Turgeon</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wallman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hulick</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <source>Pharmacology Biochemistry and Behavior</source>
          <article-title>Behavioral processes mediating phencyclidine-induced decreases in voluntary sucrose consumption</article-title>
        </element-citation>
      </ref>
      <ref id="ref112">
        <label>112</label>
        <element-citation publication-type="journal">
          <issue>6</issue>
          <page-range>1106-1116</page-range>
          <volume>28</volume>
          <year>2002</year>
          <pub-id pub-id-type="doi">10.1038/sj.npp.1300124</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Spielewoy</surname>
              <given-names>Cecile</given-names>
            </name>
            <name>
              <surname>Markou</surname>
              <given-names>Athina</given-names>
            </name>
          </person-group>
          <source>Neuropsychopharmacology</source>
          <article-title>Withdrawal from Chronic Phencyclidine Treatment Induces Long-Lasting Depression in Brain Reward Function</article-title>
        </element-citation>
      </ref>
      <ref id="ref113">
        <label>113</label>
        <element-citation publication-type="journal">
          <page-range>26-31</page-range>
          <volume>194</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.schres.2017.05.004</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Chiappelli</surname>
              <given-names>Joshua</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Shuo</given-names>
            </name>
            <name>
              <surname>Hackman</surname>
              <given-names>Ann</given-names>
            </name>
            <name>
              <surname>Elliot Hong</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <source>Schizophrenia Research</source>
          <article-title>Evidence for differential opioid use disorder in schizophrenia in an addiction treatment population</article-title>
        </element-citation>
      </ref>
      <ref id="ref114">
        <label>114</label>
        <element-citation publication-type="chapter">
          <fpage>153</fpage>
          <lpage>195</lpage>
          <page-range>153-195</page-range>
          <publisher-loc>Amsterdam</publisher-loc>
          <publisher-name>Academic Press</publisher-name>
          <volume>104</volume>
          <year>2017</year>
          <pub-id pub-id-type="isbn">9780128122631</pub-id>
          <pub-id pub-id-type="doi">10.1016/bs.vh.2016.10.004</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Leal</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Bramham</surname>
              <given-names>C. R.</given-names>
            </name>
            <name>
              <surname>Duarte</surname>
              <given-names>C. B.</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Litwack</surname>
              <given-names>Gerald</given-names>
            </name>
          </person-group>
          <source>Neurotrophins</source>
          <chapter-title>BDNF and Hippocampal Synaptic Plasticity</chapter-title>
        </element-citation>
      </ref>
      <ref id="ref115">
        <label>115</label>
        <element-citation publication-type="journal">
          <page-range>677-683</page-range>
          <volume>76</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.04.024</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Bekinschtein</surname>
              <given-names>Pedro</given-names>
            </name>
            <name>
              <surname>Cammarota</surname>
              <given-names>Martin</given-names>
            </name>
            <name>
              <surname>Medina</surname>
              <given-names>Jorge H.</given-names>
            </name>
          </person-group>
          <source>Neuropharmacology</source>
          <article-title>BDNF and memory processing</article-title>
        </element-citation>
      </ref>
      <ref id="ref116">
        <label>116</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>375-380</page-range>
          <volume>207</volume>
          <year>2009</year>
          <pub-id pub-id-type="doi">10.1007/s00213-009-1665-6</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Da Chun</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Jing</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Bo</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Sheng Chang</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Chong Xi</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>You Lan</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Yan Li</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Ning</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Ke Bing</given-names>
            </name>
            <name>
              <surname>Xiu</surname>
              <given-names>Mei Hong</given-names>
            </name>
            <name>
              <surname>Kosten</surname>
              <given-names>Thomas R.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Xiang Yang</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>Decreased levels of serum brain-derived neurotrophic factor in drug-naÃ¯ve first-episode schizophrenia: relationship to clinical phenotypes</article-title>
        </element-citation>
      </ref>
      <ref id="ref117">
        <label>117</label>
        <element-citation publication-type="journal">
          <page-range>1-6</page-range>
          <volume>263</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.psychres.2018.02.034</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Man</surname>
              <given-names>Lijuan</given-names>
            </name>
            <name>
              <surname>Lv</surname>
              <given-names>Xiaoli</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>Xiang-Dong</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>Guangzhong</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>Xiaomin</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Yingyang</given-names>
            </name>
            <name>
              <surname>Soares</surname>
              <given-names>Jair C.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Xu-Na</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Xingshi</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Xiang Yang</given-names>
            </name>
          </person-group>
          <source>Psychiatry Research</source>
          <article-title>Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref118">
        <label>118</label>
        <element-citation publication-type="journal">
          <page-range>1-6</page-range>
          <volume>112</volume>
          <year>2019</year>
          <pub-id pub-id-type="doi">10.1016/j.jpsychires.2019.02.007</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Jena</surname>
              <given-names>Monalisa</given-names>
            </name>
            <name>
              <surname>Ranjan</surname>
              <given-names>Rajeev</given-names>
            </name>
            <name>
              <surname>Mishra</surname>
              <given-names>Biswa Ranjan</given-names>
            </name>
            <name>
              <surname>Mishra</surname>
              <given-names>Archana</given-names>
            </name>
            <name>
              <surname>Nath</surname>
              <given-names>Santanu</given-names>
            </name>
            <name>
              <surname>Sahu</surname>
              <given-names>Pallabi</given-names>
            </name>
            <name>
              <surname>Meher</surname>
              <given-names>Bikash Ranjan</given-names>
            </name>
            <name>
              <surname>Srinivasan</surname>
              <given-names>Anand</given-names>
            </name>
            <name>
              <surname>Maiti</surname>
              <given-names>Rituparna</given-names>
            </name>
          </person-group>
          <source>Journal of Psychiatric Research</source>
          <article-title>Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial</article-title>
        </element-citation>
      </ref>
      <ref id="ref119">
        <label>119</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>372-383</page-range>
          <volume>25</volume>
          <year>2005</year>
          <pub-id pub-id-type="doi">10.1523/jneurosci.4035-04.2005</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Hashimoto</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <source>Journal of Neuroscience</source>
          <article-title>Relationship of Brain-Derived Neurotrophic Factor and Its Receptor TrkB to Altered Inhibitory Prefrontal Circuitry in Schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref120">
        <label>120</label>
        <element-citation publication-type="journal">
          <issue>8</issue>
          <page-range>906-914</page-range>
          <volume>7</volume>
          <year>2008</year>
          <pub-id pub-id-type="doi">10.1111/j.1601-183x.2008.00430.x</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Saylor</surname>
              <given-names>A. J.</given-names>
            </name>
            <name>
              <surname>McGinty</surname>
              <given-names>J. F.</given-names>
            </name>
          </person-group>
          <source>Genes, Brain and Behavior</source>
          <article-title>Amphetamine-induced locomotion and gene expression are altered in BDNF heterozygous mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref121">
        <label>121</label>
        <element-citation publication-type="journal">
          <volume>7</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.3389/fncel.2013.00092</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Manning</surname>
              <given-names>Elizabeth E.</given-names>
            </name>
            <name>
              <surname>van den Buuse</surname>
              <given-names>Maarten</given-names>
            </name>
          </person-group>
          <source>Frontiers in Cellular Neuroscience</source>
          <article-title>BDNF deficiency and young-adult methamphetamine induce sex-specific effects on prepulse inhibition regulation</article-title>
        </element-citation>
      </ref>
      <ref id="ref122">
        <label>122</label>
        <element-citation publication-type="journal">
          <issue>2-3</issue>
          <page-range>234-258</page-range>
          <volume>156</volume>
          <year>2001</year>
          <pub-id pub-id-type="doi">10.1007/s002130100810</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Braff</surname>
              <given-names>David L.</given-names>
            </name>
            <name>
              <surname>Geyer</surname>
              <given-names>Mark A.</given-names>
            </name>
            <name>
              <surname>Swerdlow</surname>
              <given-names>Neal R.</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies</article-title>
        </element-citation>
      </ref>
      <ref id="ref123">
        <label>123</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>pyv116</page-range>
          <volume>19</volume>
          <year>2015</year>
          <pub-id pub-id-type="doi">10.1093/ijnp/pyv116</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Manning</surname>
              <given-names>Elizabeth E.</given-names>
            </name>
            <name>
              <surname>Halberstadt</surname>
              <given-names>Adam L.</given-names>
            </name>
            <name>
              <surname>van den Buuse</surname>
              <given-names>Maarten</given-names>
            </name>
          </person-group>
          <source>International Journal of Neuropsychopharmacology</source>
          <article-title>BDNF-Deficient Mice Show Reduced Psychosis-Related Behaviors Following Chronic Methamphetamine</article-title>
        </element-citation>
      </ref>
      <ref id="ref124">
        <label>124</label>
        <element-citation publication-type="journal">
          <page-range>181-185</page-range>
          <volume>305</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1016/j.bbr.2016.03.014</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Manning</surname>
              <given-names>Elizabeth E.</given-names>
            </name>
            <name>
              <surname>van den Buuse</surname>
              <given-names>Maarten</given-names>
            </name>
          </person-group>
          <source>Behavioural Brain Research</source>
          <article-title>Altered social cognition in male BDNF heterozygous mice and following chronic methamphetamine exposure</article-title>
        </element-citation>
      </ref>
      <ref id="ref125">
        <label>125</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>45</page-range>
          <volume>10</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1186/1744-9081-10-45</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Arime</surname>
              <given-names>Yosefu</given-names>
            </name>
            <name>
              <surname>Fukumura</surname>
              <given-names>Ryutaro</given-names>
            </name>
            <name>
              <surname>Miura</surname>
              <given-names>Ikuo</given-names>
            </name>
            <name>
              <surname>Mekada</surname>
              <given-names>Kazuyuki</given-names>
            </name>
            <name>
              <surname>Yoshiki</surname>
              <given-names>Atsushi</given-names>
            </name>
            <name>
              <surname>Wakana</surname>
              <given-names>Shigeharu</given-names>
            </name>
            <name>
              <surname>Gondo</surname>
              <given-names>Yoichi</given-names>
            </name>
            <name>
              <surname>Akiyama</surname>
              <given-names>Kazufumi</given-names>
            </name>
          </person-group>
          <source>Behavioral and Brain Functions</source>
          <article-title>Effects of background mutations and single nucleotide polymorphisms (SNPs) on the Disc1 L100P behavioral phenotype associated with schizophrenia in mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref126">
        <label>126</label>
        <element-citation publication-type="journal">
          <page-range>85-98</page-range>
          <volume>1532</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1016/j.brainres.2013.08.012</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Baca</surname>
              <given-names>Michael</given-names>
            </name>
            <name>
              <surname>Allan</surname>
              <given-names>Andrea M.</given-names>
            </name>
            <name>
              <surname>Partridge</surname>
              <given-names>L. Donald</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>Michael C.</given-names>
            </name>
          </person-group>
          <source>Brain Research</source>
          <article-title>Gene-environment interactions affect long-term depression (LTD) through changes in dopamine receptor affinity in Snap25 deficient mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref127">
        <label>127</label>
        <element-citation publication-type="journal">
          <issue>5</issue>
          <page-range>441-447</page-range>
          <volume>42</volume>
          <year>2010</year>
          <pub-id pub-id-type="doi">10.1038/ng.571</pub-id>
          <person-group person-group-type="author" />
          <source>Nature Genetics</source>
          <article-title>Genome-wide meta-analyses identify multiple loci associated with smoking behavior</article-title>
        </element-citation>
      </ref>
      <ref id="ref128">
        <label>128</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>347-354</page-range>
          <volume>23</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1038/nm.4274</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Koukouli</surname>
              <given-names>Fani</given-names>
            </name>
            <name>
              <surname>Rooy</surname>
              <given-names>Marie</given-names>
            </name>
            <name>
              <surname>Tziotis</surname>
              <given-names>Dimitrios</given-names>
            </name>
            <name>
              <surname>Sailor</surname>
              <given-names>Kurt A</given-names>
            </name>
            <name>
              <surname>O'Neill</surname>
              <given-names>Heidi C</given-names>
            </name>
            <name>
              <surname>Levenga</surname>
              <given-names>Josien</given-names>
            </name>
            <name>
              <surname>Witte</surname>
              <given-names>Mirko</given-names>
            </name>
            <name>
              <surname>Nilges</surname>
              <given-names>Michael</given-names>
            </name>
            <name>
              <surname>Changeux</surname>
              <given-names>Jean-Pierre</given-names>
            </name>
            <name>
              <surname>Hoeffer</surname>
              <given-names>Charles A</given-names>
            </name>
            <name>
              <surname>Stitzel</surname>
              <given-names>Jerry A</given-names>
            </name>
            <name>
              <surname>Gutkin</surname>
              <given-names>Boris S</given-names>
            </name>
            <name>
              <surname>DiGregorio</surname>
              <given-names>David A</given-names>
            </name>
            <name>
              <surname>Maskos</surname>
              <given-names>Uwe</given-names>
            </name>
          </person-group>
          <source>Nature Medicine</source>
          <article-title>Nicotine reverses hypofrontality in animal models of addiction and schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref129">
        <label>129</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>169-176</page-range>
          <volume>56</volume>
          <year>2004</year>
          <pub-id pub-id-type="doi">10.1016/j.biopsych.2004.04.006</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Korostishevsky</surname>
              <given-names>Michael</given-names>
            </name>
            <name>
              <surname>Kaganovich</surname>
              <given-names>Miryam</given-names>
            </name>
            <name>
              <surname>Cholostoy</surname>
              <given-names>Alina</given-names>
            </name>
            <name>
              <surname>Ashkenazi</surname>
              <given-names>Maya</given-names>
            </name>
            <name>
              <surname>Ratner</surname>
              <given-names>Yael</given-names>
            </name>
            <name>
              <surname>Dahary</surname>
              <given-names>Dvir</given-names>
            </name>
            <name>
              <surname>Bernstein</surname>
              <given-names>Jeanne</given-names>
            </name>
            <name>
              <surname>Bening-Abu-Shach</surname>
              <given-names>Ullrike</given-names>
            </name>
            <name>
              <surname>Ben-Asher</surname>
              <given-names>Edna</given-names>
            </name>
            <name>
              <surname>Lancet</surname>
              <given-names>Doron</given-names>
            </name>
            <name>
              <surname>Ritsner</surname>
              <given-names>Michael</given-names>
            </name>
            <name>
              <surname>Navon</surname>
              <given-names>Ruth</given-names>
            </name>
          </person-group>
          <source>Biological Psychiatry</source>
          <article-title>Is the G72/G30 locus associated with schizophrenia? single nucleotide polymorphisms, haplotypes, and gene expression analysis</article-title>
        </element-citation>
      </ref>
      <ref id="ref130">
        <label>130</label>
        <element-citation publication-type="journal">
          <issue>7</issue>
          <page-range>1758-1771</page-range>
          <volume>171</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1111/bph.12578</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Hambsch</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Keyworth</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lind</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Otte</surname>
              <given-names>D M</given-names>
            </name>
            <name>
              <surname>Racz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kitchen</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zimmer</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <source>British Journal of Pharmacology</source>
          <article-title>Chronic nicotine improves short-term memory selectively in a G72 mouse model of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref131">
        <label>131</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>2255-2263</page-range>
          <volume>50</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1111/ejn.14155</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Zanos</surname>
              <given-names>Panos</given-names>
            </name>
            <name>
              <surname>Keyworth</surname>
              <given-names>Helen</given-names>
            </name>
            <name>
              <surname>Georgiou</surname>
              <given-names>Polymnia</given-names>
            </name>
            <name>
              <surname>Hambsch</surname>
              <given-names>Boris</given-names>
            </name>
            <name>
              <surname>Otte</surname>
              <given-names>David M.</given-names>
            </name>
            <name>
              <surname>Kitchen</surname>
              <given-names>Ian</given-names>
            </name>
            <name>
              <surname>Zimmer</surname>
              <given-names>Andreas</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>Alexis</given-names>
            </name>
          </person-group>
          <source>European Journal of Neuroscience</source>
          <article-title>Chronic nicotine administration restores brain region specific upregulation of oxytocin receptor binding levels in a G72 mouse model of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref132">
        <label>132</label>
        <element-citation publication-type="journal">
          <issue>26</issue>
          <page-range>9341-9346</page-range>
          <volume>102</volume>
          <year>2005</year>
          <pub-id pub-id-type="doi">10.1073/pnas.0503736102</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Grayson</surname>
              <given-names>D. R.</given-names>
            </name>
            <name>
              <surname>Jia</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>R. P.</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>C. P.</given-names>
            </name>
            <name>
              <surname>Guidotti</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <source>Proceedings of the National Academy of Sciences</source>
          <article-title>Reelin promoter hypermethylation in schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref133">
        <label>133</label>
        <element-citation publication-type="journal">
          <issue>6</issue>
          <page-range>1329-1334</page-range>
          <volume>10</volume>
          <year>1999</year>
          <pub-id pub-id-type="doi">10.1097/00001756-199904260-00032</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Tueting</surname>
              <given-names>Patricia</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>Erminio</given-names>
            </name>
            <name>
              <surname>Dwivedi</surname>
              <given-names>Yogesh</given-names>
            </name>
            <name>
              <surname>Guidotti</surname>
              <given-names>Alessandro</given-names>
            </name>
            <name>
              <surname>Impagnatiello</surname>
              <given-names>Francesco</given-names>
            </name>
            <name>
              <surname>Manev</surname>
              <given-names>Radmila</given-names>
            </name>
            <name>
              <surname>Pesold</surname>
              <given-names>Christine</given-names>
            </name>
          </person-group>
          <source>NeuroReport</source>
          <article-title>The phenotypic characteristics of heterozygous reeler mouse</article-title>
        </element-citation>
      </ref>
      <ref id="ref134">
        <label>134</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>228-242</page-range>
          <volume>85</volume>
          <year>2006</year>
          <pub-id pub-id-type="doi">10.1016/j.nlm.2005.11.001</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Qiu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Korwek</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Prattdavis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bergman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weeber</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <source>Neurobiology of Learning and Memory</source>
          <article-title>Cognitive disruption and altered hippocampus synaptic function in Reelin haploinsufficient mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref135">
        <label>135</label>
        <element-citation publication-type="journal">
          <issue>9</issue>
          <page-range>1374-1387</page-range>
          <volume>35</volume>
          <year>2010</year>
          <pub-id pub-id-type="doi">10.1016/j.psyneuen.2010.03.012</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>MacrÃ¬</surname>
              <given-names>Simone</given-names>
            </name>
            <name>
              <surname>Biamonte</surname>
              <given-names>Filippo</given-names>
            </name>
            <name>
              <surname>Romano</surname>
              <given-names>Emilia</given-names>
            </name>
            <name>
              <surname>Marino</surname>
              <given-names>Ramona</given-names>
            </name>
            <name>
              <surname>Keller</surname>
              <given-names>Flavio</given-names>
            </name>
            <name>
              <surname>Laviola</surname>
              <given-names>Giovanni</given-names>
            </name>
          </person-group>
          <source>Psychoneuroendocrinology</source>
          <article-title>Perseverative responding and neuroanatomical alterations in adult heterozygous reeler mice are mitigated by neonatal estrogen administration</article-title>
        </element-citation>
      </ref>
      <ref id="ref136">
        <label>136</label>
        <element-citation publication-type="journal">
          <issue>9</issue>
          <page-range>4407-4411</page-range>
          <volume>107</volume>
          <year>2010</year>
          <pub-id pub-id-type="doi">10.1073/pnas.0914483107</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Maloku</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Covelo</surname>
              <given-names>I. R.</given-names>
            </name>
            <name>
              <surname>Hanbauer</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Guidotti</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kadriu</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>J. M.</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <source>Proceedings of the National Academy of Sciences</source>
          <article-title>Lower number of cerebellar Purkinje neurons in psychosis is associated with reduced reelin expression</article-title>
        </element-citation>
      </ref>
      <ref id="ref137">
        <label>137</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>103-115</page-range>
          <volume>36</volume>
          <year>2009</year>
          <pub-id pub-id-type="doi">10.1016/j.nbd.2009.07.001</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Biamonte</surname>
              <given-names>Filippo</given-names>
            </name>
            <name>
              <surname>Assenza</surname>
              <given-names>Giovanni</given-names>
            </name>
            <name>
              <surname>Marino</surname>
              <given-names>Ramona</given-names>
            </name>
            <name>
              <surname>D'Amelio</surname>
              <given-names>Marcello</given-names>
            </name>
            <name>
              <surname>Panteri</surname>
              <given-names>Roger</given-names>
            </name>
            <name>
              <surname>Caruso</surname>
              <given-names>Donatella</given-names>
            </name>
            <name>
              <surname>Scurati</surname>
              <given-names>Samuele</given-names>
            </name>
            <name>
              <surname>Yague</surname>
              <given-names>Josue Garcia</given-names>
            </name>
            <name>
              <surname>Garcia-Segura</surname>
              <given-names>Luis Miguel</given-names>
            </name>
            <name>
              <surname>Cesa</surname>
              <given-names>Roberta</given-names>
            </name>
            <name>
              <surname>Strata</surname>
              <given-names>Piergiorgio</given-names>
            </name>
            <name>
              <surname>Melcangi</surname>
              <given-names>Roberto Cosimo</given-names>
            </name>
            <name>
              <surname>Keller</surname>
              <given-names>Flavio</given-names>
            </name>
          </person-group>
          <source>Neurobiology of Disease</source>
          <article-title>Interactions between neuroactive steroids and reelin haploinsufficiency in Purkinje cell survival</article-title>
        </element-citation>
      </ref>
      <ref id="ref138">
        <label>138</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>205-215</page-range>
          <volume>24</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1007/s12640-013-9378-3</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Romano</surname>
              <given-names>Emilia</given-names>
            </name>
            <name>
              <surname>Fuso</surname>
              <given-names>Andrea</given-names>
            </name>
            <name>
              <surname>Laviola</surname>
              <given-names>Giovanni</given-names>
            </name>
          </person-group>
          <source>Neurotoxicity Research</source>
          <article-title>Nicotine Restores Wt-Like Levels of Reelin and GAD67 Gene Expression in Brain of Heterozygous Reeler Mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref139">
        <label>139</label>
        <element-citation publication-type="journal">
          <issue>8</issue>
          <page-range>1775-1787</page-range>
          <volume>231</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1007/s00213-013-3388-y</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Romano</surname>
              <given-names>Emilia</given-names>
            </name>
            <name>
              <surname>De Angelis</surname>
              <given-names>Federica</given-names>
            </name>
            <name>
              <surname>Ulbrich</surname>
              <given-names>Lisa</given-names>
            </name>
            <name>
              <surname>De Jaco</surname>
              <given-names>Antonella</given-names>
            </name>
            <name>
              <surname>Fuso</surname>
              <given-names>Andrea</given-names>
            </name>
            <name>
              <surname>Laviola</surname>
              <given-names>Giovanni</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>Nicotine exposure during adolescence: cognitive performance and brain gene expression in adult heterozygous reeler mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref140">
        <label>140</label>
        <element-citation publication-type="journal">
          <page-range>387-409</page-range>
          <volume>68</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1016/j.neubiorev.2016.06.001</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Mostaid</surname>
              <given-names>Md Shaki</given-names>
            </name>
            <name>
              <surname>Lloyd</surname>
              <given-names>David</given-names>
            </name>
            <name>
              <surname>Liberg</surname>
              <given-names>Benny</given-names>
            </name>
            <name>
              <surname>Sundram</surname>
              <given-names>Suresh</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>Avril</given-names>
            </name>
            <name>
              <surname>Pantelis</surname>
              <given-names>Christos</given-names>
            </name>
            <name>
              <surname>Karl</surname>
              <given-names>Tim</given-names>
            </name>
            <name>
              <surname>Weickert</surname>
              <given-names>Cynthia Shannon</given-names>
            </name>
            <name>
              <surname>Everall</surname>
              <given-names>Ian P.</given-names>
            </name>
            <name>
              <surname>Bousman</surname>
              <given-names>Chad A.</given-names>
            </name>
          </person-group>
          <source>Neuroscience &amp; Biobehavioral Reviews</source>
          <article-title>Neuregulin-1 and schizophrenia in the genome-wide association study era</article-title>
        </element-citation>
      </ref>
      <ref id="ref141">
        <label>141</label>
        <element-citation publication-type="journal">
          <issue>6</issue>
          <page-range>437-452</page-range>
          <volume>9</volume>
          <year>2008</year>
          <pub-id pub-id-type="doi">10.1038/nrn2392</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Mei</surname>
              <given-names>Lin</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>Wen-Cheng</given-names>
            </name>
          </person-group>
          <source>Nature Reviews Neuroscience</source>
          <article-title>Neuregulin 1 in neural development, synaptic plasticity and schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref142">
        <label>142</label>
        <element-citation publication-type="journal">
          <issue>23</issue>
          <page-range>9655-9666</page-range>
          <volume>33</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1523/jneurosci.2888-12.2013</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Jiang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Emmetsberger</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Talmage</surname>
              <given-names>D. A.</given-names>
            </name>
            <name>
              <surname>Role</surname>
              <given-names>L. W.</given-names>
            </name>
          </person-group>
          <source>Journal of Neuroscience</source>
          <article-title>Type III Neuregulin 1 Is Required for Multiple Forms of Excitatory Synaptic Plasticity of Mouse Cortico-Amygdala Circuits</article-title>
        </element-citation>
      </ref>
      <ref id="ref143">
        <label>143</label>
        <element-citation publication-type="journal">
          <issue>27</issue>
          <page-range>6872-6883</page-range>
          <volume>28</volume>
          <year>2008</year>
          <pub-id pub-id-type="doi">10.1523/jneurosci.1815-08.2008</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Y.-J. J.</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>M. A.</given-names>
            </name>
            <name>
              <surname>Lieberman</surname>
              <given-names>M. D.</given-names>
            </name>
            <name>
              <surname>Goodchild</surname>
              <given-names>R. E.</given-names>
            </name>
            <name>
              <surname>Schobel</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lewandowski</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Rosoklija</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>R.-C.</given-names>
            </name>
            <name>
              <surname>Gingrich</surname>
              <given-names>J. A.</given-names>
            </name>
            <name>
              <surname>Small</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Dwork</surname>
              <given-names>A. J.</given-names>
            </name>
            <name>
              <surname>Talmage</surname>
              <given-names>D. A.</given-names>
            </name>
            <name>
              <surname>Role</surname>
              <given-names>L. W.</given-names>
            </name>
          </person-group>
          <source>Journal of Neuroscience</source>
          <article-title>Type III Neuregulin-1 Is Required for Normal Sensorimotor Gating, Memory-Related Behaviors, and Corticostriatal Circuit Components</article-title>
        </element-citation>
      </ref>
      <ref id="ref144">
        <label>144</label>
        <element-citation publication-type="journal">
          <issue>5</issue>
          <page-range>843-850</page-range>
          <volume>142</volume>
          <year>2004</year>
          <pub-id pub-id-type="doi">10.1038/sj.bjp.0705855</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Suemaru</surname>
              <given-names>Katsuya</given-names>
            </name>
            <name>
              <surname>Yasuda</surname>
              <given-names>Kayo</given-names>
            </name>
            <name>
              <surname>Umeda</surname>
              <given-names>Kenta</given-names>
            </name>
            <name>
              <surname>Araki</surname>
              <given-names>Hiroaki</given-names>
            </name>
            <name>
              <surname>Shibata</surname>
              <given-names>Kazuhiko</given-names>
            </name>
            <name>
              <surname>Choshi</surname>
              <given-names>Tominari</given-names>
            </name>
            <name>
              <surname>Hibino</surname>
              <given-names>Satoshi</given-names>
            </name>
            <name>
              <surname>Gomita</surname>
              <given-names>Yutaka</given-names>
            </name>
          </person-group>
          <source>British Journal of Pharmacology</source>
          <article-title>Nicotine blocks apomorphine-induced disruption of prepulse inhibition of the acoustic startle in rats: possible involvement of central nicotinicÎ±7receptors</article-title>
        </element-citation>
      </ref>
      <ref id="ref145">
        <label>145</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>511-521</page-range>
          <volume>181</volume>
          <year>2008</year>
          <pub-id pub-id-type="doi">10.1083/jcb.200710037</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Hancock</surname>
              <given-names>Melissa L.</given-names>
            </name>
            <name>
              <surname>Canetta</surname>
              <given-names>Sarah E.</given-names>
            </name>
            <name>
              <surname>Role</surname>
              <given-names>Lorna W.</given-names>
            </name>
            <name>
              <surname>Talmage</surname>
              <given-names>David A.</given-names>
            </name>
          </person-group>
          <source>The Journal of Cell Biology</source>
          <article-title>Presynaptic Type III Neuregulin1-ErbB signaling targets Î±7 nicotinic acetylcholine receptors to axons</article-title>
        </element-citation>
      </ref>
      <ref id="ref146">
        <label>146</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>e104-e104</page-range>
          <volume>2</volume>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.1038/tp.2012.25</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Weickert</surname>
              <given-names>C S</given-names>
            </name>
            <name>
              <surname>Tiwari</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Schofield</surname>
              <given-names>P R</given-names>
            </name>
            <name>
              <surname>Mowry</surname>
              <given-names>B J</given-names>
            </name>
            <name>
              <surname>Fullerton</surname>
              <given-names>J M</given-names>
            </name>
          </person-group>
          <source>Translational Psychiatry</source>
          <article-title>Schizophrenia-associated HapICE haplotype is associated with increased NRG1 type III expression and high nucleotide diversity</article-title>
        </element-citation>
      </ref>
      <ref id="ref147">
        <label>147</label>
        <element-citation publication-type="journal">
          <page-range>227-235</page-range>
          <volume>353</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.bbr.2018.03.026</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Olaya</surname>
              <given-names>Juan C</given-names>
            </name>
            <name>
              <surname>Heusner</surname>
              <given-names>Carrie L</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>Mitsuyuki</given-names>
            </name>
            <name>
              <surname>Shannon Weickert</surname>
              <given-names>Cynthia</given-names>
            </name>
            <name>
              <surname>Karl</surname>
              <given-names>Tim</given-names>
            </name>
          </person-group>
          <source>Behavioural Brain Research</source>
          <article-title>Schizophrenia-relevant behaviours of female mice overexpressing neuregulin 1 type III</article-title>
        </element-citation>
      </ref>
      <ref id="ref148">
        <label>148</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>865-875</page-range>
          <volume>44</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1093/schbul/sbx122</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Olaya</surname>
              <given-names>Juan C</given-names>
            </name>
            <name>
              <surname>Heusner</surname>
              <given-names>Carrie L</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>Mitsuyuki</given-names>
            </name>
            <name>
              <surname>Sinclair</surname>
              <given-names>Duncan</given-names>
            </name>
            <name>
              <surname>Kondo</surname>
              <given-names>Mari A</given-names>
            </name>
            <name>
              <surname>Karl</surname>
              <given-names>Tim</given-names>
            </name>
            <name>
              <surname>Shannon Weickert</surname>
              <given-names>Cynthia</given-names>
            </name>
          </person-group>
          <source>Schizophrenia Bulletin</source>
          <article-title>Overexpression of Neuregulin 1 Type III Confers Hippocampal mRNA Alterations and Schizophrenia-Like Behaviors in Mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref149">
        <label>149</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>15-22</page-range>
          <volume>225</volume>
          <year>2011</year>
          <pub-id pub-id-type="doi">10.1016/j.bbr.2011.06.026</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Calzavara</surname>
              <given-names>Mariana Bendlin</given-names>
            </name>
            <name>
              <surname>Levin</surname>
              <given-names>Raquel</given-names>
            </name>
            <name>
              <surname>Medrano</surname>
              <given-names>Wladimir Agostini</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>ValÃ©ria</given-names>
            </name>
            <name>
              <surname>Sampaio</surname>
              <given-names>AntÃ´nio Pereira FrÃ³is</given-names>
            </name>
            <name>
              <surname>Barone</surname>
              <given-names>Lucas Cerqueira</given-names>
            </name>
            <name>
              <surname>Frussa-Filho</surname>
              <given-names>Roberto</given-names>
            </name>
            <name>
              <surname>AbÃ­lio</surname>
              <given-names>Vanessa Costhek</given-names>
            </name>
          </person-group>
          <source>Behavioural Brain Research</source>
          <article-title>Effects of antipsychotics and amphetamine on social behaviors in spontaneously hypertensive rats</article-title>
        </element-citation>
      </ref>
      <ref id="ref150">
        <label>150</label>
        <element-citation publication-type="journal">
          <issue>20</issue>
          <page-range>4790-4805</page-range>
          <volume>172</volume>
          <year>2015</year>
          <pub-id pub-id-type="doi">10.1111/bph.13250</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Laprairie</surname>
              <given-names>R B</given-names>
            </name>
            <name>
              <surname>Bagher</surname>
              <given-names>A M</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>M E M</given-names>
            </name>
            <name>
              <surname>Denovan-Wright</surname>
              <given-names>E M</given-names>
            </name>
          </person-group>
          <source>British Journal of Pharmacology</source>
          <article-title>Cannabidiol is a negative allosteric modulator of the cannabinoid CB1
 receptor</article-title>
        </element-citation>
      </ref>
      <ref id="ref151">
        <label>151</label>
        <element-citation publication-type="journal">
          <issue>32</issue>
          <page-range>5131-5140</page-range>
          <volume>18</volume>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.2174/138161212802884681</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Waldo Zuardi</surname>
              <given-names>Antonio</given-names>
            </name>
            <name>
              <surname>Alexandre S. Crippa</surname>
              <given-names>Jose</given-names>
            </name>
            <name>
              <surname>E.C. Hallak</surname>
              <given-names>Jaime</given-names>
            </name>
            <name>
              <surname>Bhattacharyya</surname>
              <given-names>Sagnik</given-names>
            </name>
            <name>
              <surname>Atakan</surname>
              <given-names>Zerrin</given-names>
            </name>
            <name>
              <surname>Martin-Santos</surname>
              <given-names>Rocio</given-names>
            </name>
            <name>
              <surname>K. McGuire</surname>
              <given-names>Philip</given-names>
            </name>
            <name>
              <surname>Silveira Guimaraes</surname>
              <given-names>Francisco</given-names>
            </name>
          </person-group>
          <source>Current Pharmaceutical Design</source>
          <article-title>A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation</article-title>
        </element-citation>
      </ref>
      <ref id="ref152">
        <label>152</label>
        <element-citation publication-type="journal">
          <page-range>30-35</page-range>
          <volume>41</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1016/j.pnpbp.2012.10.024</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Almeida</surname>
              <given-names>ValÃ©ria</given-names>
            </name>
            <name>
              <surname>Levin</surname>
              <given-names>Raquel</given-names>
            </name>
            <name>
              <surname>Peres</surname>
              <given-names>Fernanda Fiel</given-names>
            </name>
            <name>
              <surname>Niigaki</surname>
              <given-names>Suzy T.</given-names>
            </name>
            <name>
              <surname>Calzavara</surname>
              <given-names>Mariana B.</given-names>
            </name>
            <name>
              <surname>Zuardi</surname>
              <given-names>AntÃ´nio W.</given-names>
            </name>
            <name>
              <surname>Hallak</surname>
              <given-names>Jaime E.</given-names>
            </name>
            <name>
              <surname>Crippa</surname>
              <given-names>JosÃ© A.</given-names>
            </name>
            <name>
              <surname>AbÃ­lio</surname>
              <given-names>Vanessa C.</given-names>
            </name>
          </person-group>
          <source>Progress in Neuro-Psychopharmacology and Biological Psychiatry</source>
          <article-title>Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test</article-title>
        </element-citation>
      </ref>
      <ref id="ref153">
        <label>153</label>
        <element-citation publication-type="journal">
          <volume>9</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.3389/fphar.2018.00901</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Peres</surname>
              <given-names>Fernanda F.</given-names>
            </name>
            <name>
              <surname>Diana</surname>
              <given-names>Mariana C.</given-names>
            </name>
            <name>
              <surname>Levin</surname>
              <given-names>Raquel</given-names>
            </name>
            <name>
              <surname>Suiama</surname>
              <given-names>Mayra A.</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>ValÃ©ria</given-names>
            </name>
            <name>
              <surname>Vendramini</surname>
              <given-names>Ana M.</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>Camila M.</given-names>
            </name>
            <name>
              <surname>Zuardi</surname>
              <given-names>AntÃ´nio W.</given-names>
            </name>
            <name>
              <surname>Hallak</surname>
              <given-names>Jaime E. C.</given-names>
            </name>
            <name>
              <surname>Crippa</surname>
              <given-names>JosÃ© A.</given-names>
            </name>
            <name>
              <surname>AbÃ­lio</surname>
              <given-names>Vanessa C.</given-names>
            </name>
          </person-group>
          <source>Frontiers in Pharmacology</source>
          <article-title>Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref154">
        <label>154</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>327-335</page-range>
          <volume>27</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1017/s2045796018000239</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Mandolini</surname>
              <given-names>G. M.</given-names>
            </name>
            <name>
              <surname>Lazzaretti</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Pigoni</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Oldani</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Delvecchio</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Brambilla</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <source>Epidemiology and Psychiatric Sciences</source>
          <article-title>Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview</article-title>
        </element-citation>
      </ref>
      <ref id="ref155">
        <label>155</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>336-341</page-range>
          <volume>223</volume>
          <year>2011</year>
          <pub-id pub-id-type="doi">10.1016/j.bbr.2011.04.051</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Karl</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Burne</surname>
              <given-names>T.H.J.</given-names>
            </name>
            <name>
              <surname>Van den Buuse</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Chesworth</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <source>Behavioural Brain Research</source>
          <article-title>Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit?</article-title>
        </element-citation>
      </ref>
      <ref id="ref156">
        <label>156</label>
        <element-citation publication-type="journal">
          <issue>7</issue>
          <page-range>677-687</page-range>
          <volume>6</volume>
          <year>2007</year>
          <pub-id pub-id-type="doi">10.1111/j.1601-183x.2006.00298.x</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Karl</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Duffy</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Scimone</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Harvey</surname>
              <given-names>R. P.</given-names>
            </name>
            <name>
              <surname>Schofield</surname>
              <given-names>P. R.</given-names>
            </name>
          </person-group>
          <source>Genes, Brain and Behavior</source>
          <article-title>Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref157">
        <label>157</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>e34129</page-range>
          <volume>7</volume>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0034129</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Long</surname>
              <given-names>Leonora E.</given-names>
            </name>
            <name>
              <surname>Chesworth</surname>
              <given-names>Rose</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Xu-Feng</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>Alexander</given-names>
            </name>
            <name>
              <surname>Spiro</surname>
              <given-names>Adena</given-names>
            </name>
            <name>
              <surname>McGregor</surname>
              <given-names>Iain S.</given-names>
            </name>
            <name>
              <surname>Arnold</surname>
              <given-names>Jonathon C.</given-names>
            </name>
            <name>
              <surname>Karl</surname>
              <given-names>Tim</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Hashimoto</surname>
              <given-names>Kenji</given-names>
            </name>
          </person-group>
          <source>PLoS ONE</source>
          <article-title>Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref158">
        <label>158</label>
        <element-citation publication-type="journal">
          <issue>13</issue>
          <page-range>2462-2471</page-range>
          <volume>26</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1093/hmg/ddx139</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Segal-Gavish</surname>
              <given-names>Hadar</given-names>
            </name>
            <name>
              <surname>Gazit</surname>
              <given-names>Neta</given-names>
            </name>
            <name>
              <surname>Barhum</surname>
              <given-names>Yael</given-names>
            </name>
            <name>
              <surname>Ben-Zur</surname>
              <given-names>Tali</given-names>
            </name>
            <name>
              <surname>Taler</surname>
              <given-names>Michal</given-names>
            </name>
            <name>
              <surname>Hornfeld</surname>
              <given-names>Shay Henry</given-names>
            </name>
            <name>
              <surname>Gil-Ad</surname>
              <given-names>Irit</given-names>
            </name>
            <name>
              <surname>Weizman</surname>
              <given-names>Abraham</given-names>
            </name>
            <name>
              <surname>Slutsky</surname>
              <given-names>Inna</given-names>
            </name>
            <name>
              <surname>Niwa</surname>
              <given-names>Minae</given-names>
            </name>
            <name>
              <surname>Kamiya</surname>
              <given-names>Atsushi</given-names>
            </name>
            <name>
              <surname>Sawa</surname>
              <given-names>Akira</given-names>
            </name>
            <name>
              <surname>Offen</surname>
              <given-names>Daniel</given-names>
            </name>
            <name>
              <surname>Barzilay</surname>
              <given-names>Ran</given-names>
            </name>
          </person-group>
          <source>Human Molecular Genetics</source>
          <article-title>BDNF overexpression prevents cognitive deficit elicited by adolescent cannabis exposure and host susceptibility interaction</article-title>
        </element-citation>
      </ref>
      <ref id="ref159">
        <label>159</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>325-336</page-range>
          <volume>192</volume>
          <year>2007</year>
          <pub-id pub-id-type="doi">10.1007/s00213-007-0721-3</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Boucher</surname>
              <given-names>A. A.</given-names>
            </name>
            <name>
              <surname>Arnold</surname>
              <given-names>J. C.</given-names>
            </name>
            <name>
              <surname>Duffy</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Schofield</surname>
              <given-names>P. R.</given-names>
            </name>
            <name>
              <surname>Micheau</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Karl</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Î9-tetrahydrocannabinol</article-title>
        </element-citation>
      </ref>
      <ref id="ref160">
        <label>160</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>277-289</page-range>
          <volume>211</volume>
          <year>2010</year>
          <pub-id pub-id-type="doi">10.1007/s00213-010-1896-6</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Long</surname>
              <given-names>Leonora E.</given-names>
            </name>
            <name>
              <surname>Chesworth</surname>
              <given-names>Rose</given-names>
            </name>
            <name>
              <surname>Arnold</surname>
              <given-names>Jonathon C.</given-names>
            </name>
            <name>
              <surname>Karl</surname>
              <given-names>Tim</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>A follow-up study: acute behavioural effects of Î9-THC in female heterozygous Neuregulin 1 transmembrane domain mutant mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref161">
        <label>161</label>
        <element-citation publication-type="journal">
          <page-range>64-70</page-range>
          <volume>170</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.pbb.2018.05.003</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Lloyd</surname>
              <given-names>David</given-names>
            </name>
            <name>
              <surname>Talmage</surname>
              <given-names>David</given-names>
            </name>
            <name>
              <surname>Shannon Weickert</surname>
              <given-names>Cynthia</given-names>
            </name>
            <name>
              <surname>Karl</surname>
              <given-names>Tim</given-names>
            </name>
          </person-group>
          <source>Pharmacology Biochemistry and Behavior</source>
          <article-title>Reduced type III neuregulin 1 expression does not modulate the behavioural sensitivity of mice to acute Î 9 -tetrahydrocannabinol (D 9 -THC)</article-title>
        </element-citation>
      </ref>
      <ref id="ref162">
        <label>162</label>
        <element-citation publication-type="journal">
          <issue>01</issue>
          <page-range>163-175</page-range>
          <volume>16</volume>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.1017/s1461145711001854</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Long</surname>
              <given-names>Leonora E.</given-names>
            </name>
            <name>
              <surname>Chesworth</surname>
              <given-names>Rose</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Xu-Feng</given-names>
            </name>
            <name>
              <surname>McGregor</surname>
              <given-names>Iain S.</given-names>
            </name>
            <name>
              <surname>Arnold</surname>
              <given-names>Jonathon C.</given-names>
            </name>
            <name>
              <surname>Karl</surname>
              <given-names>Tim</given-names>
            </name>
          </person-group>
          <source>The International Journal of Neuropsychopharmacology</source>
          <article-title>Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence</article-title>
        </element-citation>
      </ref>
      <ref id="ref163">
        <label>163</label>
        <element-citation publication-type="journal">
          <volume>7</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.3389/fncel.2013.00015</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Spencer</surname>
              <given-names>Jarrah R.</given-names>
            </name>
            <name>
              <surname>Darbyshire</surname>
              <given-names>Keturah M. E.</given-names>
            </name>
            <name>
              <surname>Boucher</surname>
              <given-names>Aurelie A.</given-names>
            </name>
            <name>
              <surname>Kashem</surname>
              <given-names>Mohammed A.</given-names>
            </name>
            <name>
              <surname>Long</surname>
              <given-names>Leonora E.</given-names>
            </name>
            <name>
              <surname>McGregor</surname>
              <given-names>Iain S.</given-names>
            </name>
            <name>
              <surname>Karl</surname>
              <given-names>Tim</given-names>
            </name>
            <name>
              <surname>Arnold</surname>
              <given-names>Jonathon C.</given-names>
            </name>
          </person-group>
          <source>Frontiers in Cellular Neuroscience</source>
          <article-title>Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref164">
        <label>164</label>
        <element-citation publication-type="journal">
          <issue>5</issue>
          <page-range>442-455</page-range>
          <volume>15</volume>
          <year>1996</year>
          <pub-id pub-id-type="doi">10.1016/s0893-133x(96)00053-x</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Burnet</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <source>Neuropsychopharmacology</source>
          <article-title>5-HT1A and 5-HT2A Receptor mRNAs and Binding Site Densities Are Differentially Altered in Schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref165">
        <label>165</label>
        <element-citation publication-type="journal">
          <issue>5</issue>
          <page-range>867-871</page-range>
          <volume>33</volume>
          <year>2009</year>
          <pub-id pub-id-type="doi">10.1016/j.pnpbp.2009.04.010</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Kang</surname>
              <given-names>Kai</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Xu-Feng</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Qing</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>Chao</given-names>
            </name>
          </person-group>
          <source>Progress in Neuro-Psychopharmacology and Biological Psychiatry</source>
          <article-title>Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia-a postmortem study</article-title>
        </element-citation>
      </ref>
      <ref id="ref166">
        <label>166</label>
        <element-citation publication-type="journal">
          <issue>11</issue>
          <page-range>1251-1257</page-range>
          <volume>166</volume>
          <year>2009</year>
          <pub-id pub-id-type="doi">10.1176/appi.ajp.2009.09030311</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Compton</surname>
              <given-names>Michael T.</given-names>
            </name>
            <name>
              <surname>Kelley</surname>
              <given-names>Mary E.</given-names>
            </name>
            <name>
              <surname>Ramsay</surname>
              <given-names>Claire E.</given-names>
            </name>
            <name>
              <surname>Pringle</surname>
              <given-names>Makenya</given-names>
            </name>
            <name>
              <surname>Goulding</surname>
              <given-names>Sandra M.</given-names>
            </name>
            <name>
              <surname>Esterberg</surname>
              <given-names>Michelle L.</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>Tarianna</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>Elaine F.</given-names>
            </name>
          </person-group>
          <source>American Journal of Psychiatry</source>
          <article-title>Association of Pre-Onset Cannabis, Alcohol, and Tobacco Use With Age at Onset of Prodrome and Age at Onset of Psychosis in First-Episode Patients</article-title>
        </element-citation>
      </ref>
      <ref id="ref167">
        <label>167</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>363-369</page-range>
          <volume>156</volume>
          <year>2011</year>
          <pub-id pub-id-type="doi">10.1002/ajmg.b.31174</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Decoster</surname>
              <given-names>Jeroen</given-names>
            </name>
            <name>
              <surname>van Os</surname>
              <given-names>Jim</given-names>
            </name>
            <name>
              <surname>Kenis</surname>
              <given-names>Gunter</given-names>
            </name>
            <name>
              <surname>Henquet</surname>
              <given-names>Cecile</given-names>
            </name>
            <name>
              <surname>Peuskens</surname>
              <given-names>Joseph</given-names>
            </name>
            <name>
              <surname>De Hert</surname>
              <given-names>Marc</given-names>
            </name>
            <name>
              <surname>van Winkel</surname>
              <given-names>Ruud</given-names>
            </name>
          </person-group>
          <source>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</source>
          <article-title>Age at onset of psychotic disorder: Cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction</article-title>
        </element-citation>
      </ref>
      <ref id="ref168">
        <label>168</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>528-532</page-range>
          <volume>215</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1016/j.psychres.2013.12.038</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Donoghue</surname>
              <given-names>Kim</given-names>
            </name>
            <name>
              <surname>Doody</surname>
              <given-names>Gillian A.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>Robin M.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>Peter B.</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>Craig</given-names>
            </name>
            <name>
              <surname>Dazzan</surname>
              <given-names>Paola</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>Jozella</given-names>
            </name>
            <name>
              <surname>Mazzoncini</surname>
              <given-names>Rodolfo</given-names>
            </name>
            <name>
              <surname>MacCabe</surname>
              <given-names>James H.</given-names>
            </name>
          </person-group>
          <source>Psychiatry Research</source>
          <article-title>Cannabis use, gender and age of onset of schizophrenia: Data from the ÃSOP study</article-title>
        </element-citation>
      </ref>
      <ref id="ref169">
        <label>169</label>
        <element-citation publication-type="journal">
          <issue>6</issue>
          <page-range>1115-1130</page-range>
          <volume>36</volume>
          <year>2009</year>
          <pub-id pub-id-type="doi">10.1093/schbul/sbp031</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Koskinen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lohonen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Koponen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Isohanni</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Miettunen</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <source>Schizophrenia Bulletin</source>
          <article-title>Rate of Cannabis Use Disorders in Clinical Samples of Patients With Schizophrenia: A Meta-analysis</article-title>
        </element-citation>
      </ref>
      <ref id="ref170">
        <label>170</label>
        <element-citation publication-type="journal">
          <issue>10</issue>
          <page-range>1681-1692</page-range>
          <volume>232</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1007/s00213-014-3800-2</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Berg</surname>
              <given-names>Sarah A.</given-names>
            </name>
            <name>
              <surname>Sentir</surname>
              <given-names>Alena M.</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>Richard L.</given-names>
            </name>
            <name>
              <surname>Engleman</surname>
              <given-names>Eric A.</given-names>
            </name>
            <name>
              <surname>Chambers</surname>
              <given-names>R. Andrew</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>Nicotine effects in adolescence and adulthood on cognition and Î±4Î²2-nicotinic receptors in the neonatal ventral hippocampal lesion rat model of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref171">
        <label>171</label>
        <element-citation publication-type="journal">
          <page-range>21-34</page-range>
          <volume>63</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1016/j.bbi.2016.06.002</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Straley</surname>
              <given-names>Megan E.</given-names>
            </name>
            <name>
              <surname>Van Oeffelen</surname>
              <given-names>Wesley</given-names>
            </name>
            <name>
              <surname>Theze</surname>
              <given-names>Sarah</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>Aideen M.</given-names>
            </name>
            <name>
              <surname>OâMahony</surname>
              <given-names>Siobhain M.</given-names>
            </name>
            <name>
              <surname>Cryan</surname>
              <given-names>John F.</given-names>
            </name>
            <name>
              <surname>OâKeeffe</surname>
              <given-names>Gerard W.</given-names>
            </name>
          </person-group>
          <source>Brain, Behavior, and Immunity</source>
          <article-title>Distinct alterations in motor &amp; reward seeking behavior are dependent on the gestational age of exposure to LPS-induced maternal immune activation</article-title>
        </element-citation>
      </ref>
      <ref id="ref172">
        <label>172</label>
        <element-citation publication-type="journal">
          <page-range>40-46</page-range>
          <volume>299</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.toxlet.2018.09.002</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Alkhattabi</surname>
              <given-names>Nuha</given-names>
            </name>
            <name>
              <surname>Todd</surname>
              <given-names>Ian</given-names>
            </name>
            <name>
              <surname>Negm</surname>
              <given-names>Ola</given-names>
            </name>
            <name>
              <surname>Tighe</surname>
              <given-names>Patrick J.</given-names>
            </name>
            <name>
              <surname>Fairclough</surname>
              <given-names>Lucy C.</given-names>
            </name>
          </person-group>
          <source>Toxicology Letters</source>
          <article-title>Tobacco smoke and nicotine suppress expression of activating signaling molecules in human dendritic cells</article-title>
        </element-citation>
      </ref>
      <ref id="ref173">
        <label>173</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>61-72</page-range>
          <volume>83</volume>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.1124/mol.112.081497</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Cui</surname>
              <given-names>Wen-Yan</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Shufang</given-names>
            </name>
            <name>
              <surname>Polanowska-Grabowska</surname>
              <given-names>Renata</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Ju</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>Jinxue</given-names>
            </name>
            <name>
              <surname>Dash</surname>
              <given-names>Bhagirathi</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>Sulie L.</given-names>
            </name>
            <name>
              <surname>Saucerman</surname>
              <given-names>Jeffrey J.</given-names>
            </name>
            <name>
              <surname>Gu</surname>
              <given-names>Jun</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Ming D.</given-names>
            </name>
          </person-group>
          <source>Molecular Pharmacology</source>
          <article-title>Identification and Characterization of Poly(I:C)-induced Molecular Responses Attenuated by Nicotine in Mouse Macrophages</article-title>
        </element-citation>
      </ref>
      <ref id="ref174">
        <label>174</label>
        <element-citation publication-type="journal">
          <issue>7</issue>
          <page-range>1447-1457</page-range>
          <volume>42</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1038/npp.2017.40</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Osborne</surname>
              <given-names>Ashleigh L</given-names>
            </name>
            <name>
              <surname>Solowij</surname>
              <given-names>Nadia</given-names>
            </name>
            <name>
              <surname>Babic</surname>
              <given-names>Ilijana</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Xu-Feng</given-names>
            </name>
            <name>
              <surname>Weston-Green</surname>
              <given-names>Katrina</given-names>
            </name>
          </person-group>
          <source>Neuropsychopharmacology</source>
          <article-title>Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model</article-title>
        </element-citation>
      </ref>
      <ref id="ref175">
        <label>175</label>
        <element-citation publication-type="journal">
          <page-range>109666</page-range>
          <volume>95</volume>
          <year>2019</year>
          <pub-id pub-id-type="doi">10.1016/j.pnpbp.2019.109666</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Osborne</surname>
              <given-names>Ashleigh L.</given-names>
            </name>
            <name>
              <surname>Solowij</surname>
              <given-names>Nadia</given-names>
            </name>
            <name>
              <surname>Babic</surname>
              <given-names>Ilijana</given-names>
            </name>
            <name>
              <surname>Lum</surname>
              <given-names>Jeremy S.</given-names>
            </name>
            <name>
              <surname>Newell</surname>
              <given-names>Kelly A.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Xu-Feng</given-names>
            </name>
            <name>
              <surname>Weston-Green</surname>
              <given-names>Katrina</given-names>
            </name>
          </person-group>
          <source>Progress in Neuro-Psychopharmacology and Biological Psychiatry</source>
          <article-title>Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref176">
        <label>176</label>
        <element-citation publication-type="journal">
          <page-range>574-587</page-range>
          <volume>81</volume>
          <year>2019</year>
          <pub-id pub-id-type="doi">10.1016/j.bbi.2019.07.018</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Osborne</surname>
              <given-names>Ashleigh L.</given-names>
            </name>
            <name>
              <surname>Solowij</surname>
              <given-names>Nadia</given-names>
            </name>
            <name>
              <surname>Babic</surname>
              <given-names>Ilijana</given-names>
            </name>
            <name>
              <surname>Lum</surname>
              <given-names>Jeremy S.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Xu-Feng</given-names>
            </name>
            <name>
              <surname>Newell</surname>
              <given-names>Kelly A.</given-names>
            </name>
            <name>
              <surname>Weston-Green</surname>
              <given-names>Katrina</given-names>
            </name>
          </person-group>
          <source>Brain, Behavior, and Immunity</source>
          <article-title>Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders</article-title>
        </element-citation>
      </ref>
      <ref id="ref177">
        <label>177</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <volume>18</volume>
          <year>2015</year>
          <pub-id pub-id-type="doi">10.1093/ijnp/pyu018</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Gomes</surname>
              <given-names>Felipe V.</given-names>
            </name>
            <name>
              <surname>GuimarÃ£es</surname>
              <given-names>Francisco S.</given-names>
            </name>
            <name>
              <surname>Grace</surname>
              <given-names>Anthony A.</given-names>
            </name>
          </person-group>
          <source>International Journal of Neuropsychopharmacology</source>
          <article-title>Effects of Pubertal Cannabinoid Administration on Attentional Set-Shifting and Dopaminergic Hyper-Responsivity in a Developmental Disruption Model of Schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref178">
        <label>178</label>
        <element-citation publication-type="journal">
          <issue>7</issue>
          <page-range>413-431</page-range>
          <volume>259</volume>
          <year>2009</year>
          <pub-id pub-id-type="doi">10.1007/s00406-009-0024-2</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>DâSouza</surname>
              <given-names>Deepak Cyril</given-names>
            </name>
            <name>
              <surname>Sewell</surname>
              <given-names>Richard Andrew</given-names>
            </name>
            <name>
              <surname>Ranganathan</surname>
              <given-names>Mohini</given-names>
            </name>
          </person-group>
          <source>European Archives of Psychiatry and Clinical Neuroscience</source>
          <article-title>Cannabis and psychosis/schizophrenia: human studies</article-title>
        </element-citation>
      </ref>
      <ref id="ref179">
        <label>179</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>393-403</page-range>
          <volume>21</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1093/ijnp/pyy003</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Aguilar</surname>
              <given-names>David D</given-names>
            </name>
            <name>
              <surname>Giuffrida</surname>
              <given-names>Andrea</given-names>
            </name>
            <name>
              <surname>Lodge</surname>
              <given-names>Daniel J</given-names>
            </name>
          </person-group>
          <source>International Journal of Neuropsychopharmacology</source>
          <article-title>Adolescent Synthetic Cannabinoid Exposure Produces Enduring Changes in Dopamine Neuron Activity in a Rodent Model of Schizophrenia Susceptibility</article-title>
        </element-citation>
      </ref>
      <ref id="ref180">
        <label>180</label>
        <element-citation publication-type="journal">
          <issue>10</issue>
          <page-range>1117-1127</page-range>
          <volume>57</volume>
          <year>2005</year>
          <pub-id pub-id-type="doi">10.1016/j.biopsych.2005.01.026</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Caspi</surname>
              <given-names>Avshalom</given-names>
            </name>
            <name>
              <surname>Moffitt</surname>
              <given-names>Terrie E.</given-names>
            </name>
            <name>
              <surname>Cannon</surname>
              <given-names>Mary</given-names>
            </name>
            <name>
              <surname>McClay</surname>
              <given-names>Joseph</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>Robin</given-names>
            </name>
            <name>
              <surname>Harrington</surname>
              <given-names>HonaLee</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>Alan</given-names>
            </name>
            <name>
              <surname>Arseneault</surname>
              <given-names>Louise</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>Ben</given-names>
            </name>
            <name>
              <surname>Braithwaite</surname>
              <given-names>Antony</given-names>
            </name>
            <name>
              <surname>Poulton</surname>
              <given-names>Richie</given-names>
            </name>
            <name>
              <surname>Craig</surname>
              <given-names>Ian W.</given-names>
            </name>
          </person-group>
          <source>Biological Psychiatry</source>
          <article-title>Moderation of the Effect of Adolescent-Onset Cannabis Use on Adult Psychosis by a Functional Polymorphism in the Catechol-O-Methyltransferase Gene: Longitudinal Evidence of a Gene X Environment Interaction</article-title>
        </element-citation>
      </ref>
      <ref id="ref181">
        <label>181</label>
        <element-citation publication-type="journal">
          <issue>7481</issue>
          <page-range>11</page-range>
          <volume>330</volume>
          <year>2004</year>
          <pub-id pub-id-type="doi">10.1136/bmj.38267.664086.63</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Henquet</surname>
              <given-names>CÃ©cile</given-names>
            </name>
            <name>
              <surname>Krabbendam</surname>
              <given-names>Lydia</given-names>
            </name>
            <name>
              <surname>Spauwen</surname>
              <given-names>Janneke</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>Charles</given-names>
            </name>
            <name>
              <surname>Lieb</surname>
              <given-names>Roselind</given-names>
            </name>
            <name>
              <surname>Wittchen</surname>
              <given-names>Hans-Ulrich</given-names>
            </name>
            <name>
              <surname>van Os</surname>
              <given-names>Jim</given-names>
            </name>
          </person-group>
          <source>BMJ</source>
          <article-title>Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people</article-title>
        </element-citation>
      </ref>
      <ref id="ref182">
        <label>182</label>
        <element-citation publication-type="journal">
          <issue>10</issue>
          <page-range>1002</page-range>
          <volume>72</volume>
          <year>2015</year>
          <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2015.1131</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>French</surname>
              <given-names>Leon</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>Courtney</given-names>
            </name>
            <name>
              <surname>Leonard</surname>
              <given-names>Gabriel</given-names>
            </name>
            <name>
              <surname>Perron</surname>
              <given-names>Michel</given-names>
            </name>
            <name>
              <surname>Pike</surname>
              <given-names>G. Bruce</given-names>
            </name>
            <name>
              <surname>Richer</surname>
              <given-names>Louis</given-names>
            </name>
            <name>
              <surname>SÃ©guin</surname>
              <given-names>Jean R.</given-names>
            </name>
            <name>
              <surname>Veillette</surname>
              <given-names>Suzanne</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>C. John</given-names>
            </name>
            <name>
              <surname>Artiges</surname>
              <given-names>Eric</given-names>
            </name>
            <name>
              <surname>Banaschewski</surname>
              <given-names>Tobias</given-names>
            </name>
            <name>
              <surname>Bokde</surname>
              <given-names>Arun W. L.</given-names>
            </name>
            <name>
              <surname>Bromberg</surname>
              <given-names>Uli</given-names>
            </name>
            <name>
              <surname>Bruehl</surname>
              <given-names>Ruediger</given-names>
            </name>
            <name>
              <surname>Buchel</surname>
              <given-names>Christian</given-names>
            </name>
            <name>
              <surname>Cattrell</surname>
              <given-names>Anna</given-names>
            </name>
            <name>
              <surname>Conrod</surname>
              <given-names>Patricia J.</given-names>
            </name>
            <name>
              <surname>Flor</surname>
              <given-names>Herta</given-names>
            </name>
            <name>
              <surname>Frouin</surname>
              <given-names>Vincent</given-names>
            </name>
            <name>
              <surname>Gallinat</surname>
              <given-names>Jurgen</given-names>
            </name>
            <name>
              <surname>Garavan</surname>
              <given-names>Hugh</given-names>
            </name>
            <name>
              <surname>Gowland</surname>
              <given-names>Penny</given-names>
            </name>
            <name>
              <surname>Heinz</surname>
              <given-names>Andreas</given-names>
            </name>
            <name>
              <surname>Lemaitre</surname>
              <given-names>Herve</given-names>
            </name>
            <name>
              <surname>Martinot</surname>
              <given-names>Jean-Luc</given-names>
            </name>
            <name>
              <surname>Nees</surname>
              <given-names>Frauke</given-names>
            </name>
            <name>
              <surname>Orfanos</surname>
              <given-names>Dimitri Papadopoulos</given-names>
            </name>
            <name>
              <surname>Pangelinan</surname>
              <given-names>Melissa Marie</given-names>
            </name>
            <name>
              <surname>Poustka</surname>
              <given-names>Luise</given-names>
            </name>
            <name>
              <surname>Rietschel</surname>
              <given-names>Marcella</given-names>
            </name>
            <name>
              <surname>Smolka</surname>
              <given-names>Michael N.</given-names>
            </name>
            <name>
              <surname>Walter</surname>
              <given-names>Henrik</given-names>
            </name>
            <name>
              <surname>Whelan</surname>
              <given-names>Robert</given-names>
            </name>
            <name>
              <surname>Timpson</surname>
              <given-names>Nic J.</given-names>
            </name>
            <name>
              <surname>Schumann</surname>
              <given-names>Gunter</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>George Davey</given-names>
            </name>
            <name>
              <surname>Pausova</surname>
              <given-names>Zdenka</given-names>
            </name>
            <name>
              <surname>Paus</surname>
              <given-names>TomÃ¡Å¡</given-names>
            </name>
          </person-group>
          <source>JAMA Psychiatry</source>
          <article-title>Early Cannabis Use, Polygenic Risk Score for Schizophrenia and Brain Maturation in Adolescence</article-title>
        </element-citation>
      </ref>
      <ref id="ref183">
        <label>183</label>
        <element-citation publication-type="journal">
          <issue>6</issue>
          <page-range>1248-1259</page-range>
          <volume>36</volume>
          <year>2011</year>
          <pub-id pub-id-type="doi">10.1038/npp.2011.10</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>BÃ©dard</surname>
              <given-names>Anne-Marie</given-names>
            </name>
            <name>
              <surname>Maheux</surname>
              <given-names>JÃ©rÃ´me</given-names>
            </name>
            <name>
              <surname>LÃ©vesque</surname>
              <given-names>Daniel</given-names>
            </name>
            <name>
              <surname>Samaha</surname>
              <given-names>Anne-NoÃ«l</given-names>
            </name>
          </person-group>
          <source>Neuropsychopharmacology</source>
          <article-title>Continuous, but not Intermittent, Antipsychotic Drug Delivery Intensifies the Pursuit of Reward Cues</article-title>
        </element-citation>
      </ref>
      <ref id="ref184">
        <label>184</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>692-702</page-range>
          <volume>39</volume>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.1093/schbul/sbs077</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>BÃ©dard</surname>
              <given-names>Anne-Marie</given-names>
            </name>
            <name>
              <surname>Maheux</surname>
              <given-names>JÃ©rÃ´me</given-names>
            </name>
            <name>
              <surname>LÃ©vesque</surname>
              <given-names>Daniel</given-names>
            </name>
            <name>
              <surname>Samaha</surname>
              <given-names>Anne-NoÃ«l</given-names>
            </name>
          </person-group>
          <source>Schizophrenia Bulletin</source>
          <article-title>Prior Haloperidol, but not Olanzapine, Exposure Augments the Pursuit of Reward Cues: Implications for Substance Abuse in Schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref185">
        <label>185</label>
        <element-citation publication-type="journal">
          <page-range>715-725</page-range>
          <volume>99</volume>
          <year>2015</year>
          <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.03.012</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>El Hage</surname>
              <given-names>Cynthia</given-names>
            </name>
            <name>
              <surname>BÃ©dard</surname>
              <given-names>Anne-Marie</given-names>
            </name>
            <name>
              <surname>Samaha</surname>
              <given-names>Anne-NoÃ«l</given-names>
            </name>
          </person-group>
          <source>Neuropharmacology</source>
          <article-title>Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function</article-title>
        </element-citation>
      </ref>
      <ref id="ref186">
        <label>186</label>
        <element-citation publication-type="journal">
          <issue>11</issue>
          <page-range>1231-1240</page-range>
          <volume>60</volume>
          <year>2006</year>
          <pub-id pub-id-type="doi">10.1016/j.biopsych.2006.03.055</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Light</surname>
              <given-names>Gregory A.</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>Jung Lung</given-names>
            </name>
            <name>
              <surname>Hsieh</surname>
              <given-names>Ming H.</given-names>
            </name>
            <name>
              <surname>Meyer-Gomes</surname>
              <given-names>Katrin</given-names>
            </name>
            <name>
              <surname>Sprock</surname>
              <given-names>Joyce</given-names>
            </name>
            <name>
              <surname>Swerdlow</surname>
              <given-names>Neal R.</given-names>
            </name>
            <name>
              <surname>Braff</surname>
              <given-names>David L.</given-names>
            </name>
          </person-group>
          <source>Biological Psychiatry</source>
          <article-title>Gamma Band Oscillations Reveal Neural Network Cortical Coherence Dysfunction in Schizophrenia Patients</article-title>
        </element-citation>
      </ref>
      <ref id="ref187">
        <label>187</label>
        <element-citation publication-type="journal">
          <page-range>1-9</page-range>
          <volume>73</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.05.006</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Sivarao</surname>
              <given-names>Digavalli V.</given-names>
            </name>
            <name>
              <surname>Frenkel</surname>
              <given-names>Mikhail</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Ping</given-names>
            </name>
            <name>
              <surname>Healy</surname>
              <given-names>Francine L.</given-names>
            </name>
            <name>
              <surname>Lodge</surname>
              <given-names>Nicholas J.</given-names>
            </name>
            <name>
              <surname>Zaczek</surname>
              <given-names>Robert</given-names>
            </name>
          </person-group>
          <source>Neuropharmacology</source>
          <article-title>MK-801 disrupts and nicotine augments 40Â Hz auditory steady state responses in the auditory cortex of the urethane-anesthetized rat</article-title>
        </element-citation>
      </ref>
      <ref id="ref188">
        <label>188</label>
        <element-citation publication-type="journal">
          <page-range>41-62</page-range>
          <volume>142</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.11.045</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Cadinu</surname>
              <given-names>Daniela</given-names>
            </name>
            <name>
              <surname>Grayson</surname>
              <given-names>Ben</given-names>
            </name>
            <name>
              <surname>Podda</surname>
              <given-names>Giovanni</given-names>
            </name>
            <name>
              <surname>Harte</surname>
              <given-names>Michael K.</given-names>
            </name>
            <name>
              <surname>Doostdar</surname>
              <given-names>Nazanin</given-names>
            </name>
            <name>
              <surname>Neill</surname>
              <given-names>Joanna C.</given-names>
            </name>
          </person-group>
          <source>Neuropharmacology</source>
          <article-title>NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update</article-title>
        </element-citation>
      </ref>
      <ref id="ref189">
        <label>189</label>
        <element-citation publication-type="journal">
          <page-range>53-62</page-range>
          <volume>49</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1016/j.pnpbp.2013.11.008</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>Jordan W.</given-names>
            </name>
            <name>
              <surname>Rueter</surname>
              <given-names>Lynne E.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Min</given-names>
            </name>
          </person-group>
          <source>Progress in Neuro-Psychopharmacology and Biological Psychiatry</source>
          <article-title>Predictive validity of a MK-801-induced cognitive impairment model in mice: Implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically</article-title>
        </element-citation>
      </ref>
      <ref id="ref190">
        <label>190</label>
        <element-citation publication-type="journal">
          <page-range>164-173</page-range>
          <volume>259</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1016/j.bbr.2013.11.009</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Scott</surname>
              <given-names>Daniel</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>Jane R.</given-names>
            </name>
          </person-group>
          <source>Behavioural Brain Research</source>
          <article-title>Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task</article-title>
        </element-citation>
      </ref>
      <ref id="ref191">
        <label>191</label>
        <element-citation publication-type="journal">
          <issue>50</issue>
          <page-range>12570-12585</page-range>
          <volume>36</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1523/jneurosci.1628-16.2016</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Cloke</surname>
              <given-names>Jacob M.</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>Robin</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>Beryl Y.T.</given-names>
            </name>
            <name>
              <surname>Wasserman</surname>
              <given-names>David I.</given-names>
            </name>
            <name>
              <surname>De Lisio</surname>
              <given-names>Stephanie</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>Jun Chul</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>Craig D.C.</given-names>
            </name>
            <name>
              <surname>Winters</surname>
              <given-names>Boyer D.</given-names>
            </name>
          </person-group>
          <source>The Journal of Neuroscience</source>
          <article-title>A Novel Multisensory Integration Task Reveals Robust Deficits in Rodent Models of Schizophrenia: Converging Evidence for Remediation via Nicotinic Receptor Stimulation of Inhibitory Transmission in the Prefrontal Cortex</article-title>
        </element-citation>
      </ref>
      <ref id="ref192">
        <label>192</label>
        <element-citation publication-type="journal">
          <page-range>6-11</page-range>
          <volume>159</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1016/j.pbb.2017.06.010</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>RodrÃ­guez</surname>
              <given-names>Guadalupe</given-names>
            </name>
            <name>
              <surname>Neugebauer</surname>
              <given-names>Nichole M.</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>Katherine Lan</given-names>
            </name>
            <name>
              <surname>Meltzer</surname>
              <given-names>Herbert Y.</given-names>
            </name>
            <name>
              <surname>Csernansky</surname>
              <given-names>John G.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>Hongxin</given-names>
            </name>
          </person-group>
          <source>Pharmacology Biochemistry and Behavior</source>
          <article-title>Î9-tetrahydrocannabinol (Î9-THC) administration after neonatal exposure to phencyclidine potentiates schizophrenia-related behavioral phenotypes in mice</article-title>
        </element-citation>
      </ref>
      <ref id="ref193">
        <label>193</label>
        <element-citation publication-type="journal">
          <issue>2</issue>
          <page-range>169-181</page-range>
          <volume>30</volume>
          <year>2015</year>
          <pub-id pub-id-type="doi">10.1177/0269881115612239</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Aguilar</surname>
              <given-names>David D</given-names>
            </name>
            <name>
              <surname>Giuffrida</surname>
              <given-names>Andrea</given-names>
            </name>
            <name>
              <surname>Lodge</surname>
              <given-names>Daniel J</given-names>
            </name>
          </person-group>
          <source>Journal of Psychopharmacology</source>
          <article-title>THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref194">
        <label>194</label>
        <element-citation publication-type="journal">
          <issue>7</issue>
          <page-range>568-577</page-range>
          <volume>79</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.12.011</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Skosnik</surname>
              <given-names>Patrick D.</given-names>
            </name>
            <name>
              <surname>Cortes-Briones</surname>
              <given-names>Jose A.</given-names>
            </name>
            <name>
              <surname>HajÃ³s</surname>
              <given-names>MihÃ¡ly</given-names>
            </name>
          </person-group>
          <source>Biological Psychiatry</source>
          <article-title>Itâs All in the Rhythm: The Role of Cannabinoids in Neural Oscillations and Psychosis</article-title>
        </element-citation>
      </ref>
      <ref id="ref195">
        <label>195</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>531-542</page-range>
          <volume>225</volume>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.1007/s00213-012-2839-1</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Spano</surname>
              <given-names>Maria Sabrina</given-names>
            </name>
            <name>
              <surname>Fattore</surname>
              <given-names>Liana</given-names>
            </name>
            <name>
              <surname>Cadeddu</surname>
              <given-names>Francesca</given-names>
            </name>
            <name>
              <surname>Fratta</surname>
              <given-names>Walter</given-names>
            </name>
            <name>
              <surname>Fadda</surname>
              <given-names>Paola</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats</article-title>
        </element-citation>
      </ref>
      <ref id="ref196">
        <label>196</label>
        <element-citation publication-type="journal">
          <issue>9</issue>
          <page-range>1816-1824</page-range>
          <volume>38</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1038/npp.2013.81</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Seillier</surname>
              <given-names>Alexandre</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>Alex A</given-names>
            </name>
            <name>
              <surname>Giuffrida</surname>
              <given-names>Andrea</given-names>
            </name>
          </person-group>
          <source>Neuropsychopharmacology</source>
          <article-title>Phencyclidine-Induced Social Withdrawal Results from Deficient Stimulation of Cannabinoid CB1 Receptors: Implications for Schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref197">
        <label>197</label>
        <element-citation publication-type="journal">
          <page-range>49-58</page-range>
          <volume>110</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1016/j.neures.2016.04.004</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Matricon</surname>
              <given-names>Julien</given-names>
            </name>
            <name>
              <surname>Seillier</surname>
              <given-names>Alexandre</given-names>
            </name>
            <name>
              <surname>Giuffrida</surname>
              <given-names>Andrea</given-names>
            </name>
          </person-group>
          <source>Neuroscience Research</source>
          <article-title>Distinct neuronal activation patterns are associated with PCP-induced social withdrawal and its reversal by the endocannabinoid-enhancing drug URB597</article-title>
        </element-citation>
      </ref>
      <ref id="ref198">
        <label>198</label>
        <element-citation publication-type="journal">
          <page-range>87-93</page-range>
          <volume>633</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1016/j.neulet.2016.09.020</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>SzÅ±cs</surname>
              <given-names>Edina</given-names>
            </name>
            <name>
              <surname>DvorÃ¡cskÃ³</surname>
              <given-names>Szabolcs</given-names>
            </name>
            <name>
              <surname>TÃ¶mbÃ¶ly</surname>
              <given-names>Csaba</given-names>
            </name>
            <name>
              <surname>BÃ¼ki</surname>
              <given-names>Alexandra</given-names>
            </name>
            <name>
              <surname>KÃ©kesi</surname>
              <given-names>Gabriella</given-names>
            </name>
            <name>
              <surname>HorvÃ¡th</surname>
              <given-names>GyÃ¶ngyi</given-names>
            </name>
            <name>
              <surname>Benyhe</surname>
              <given-names>SÃ¡ndor</given-names>
            </name>
          </person-group>
          <source>Neuroscience Letters</source>
          <article-title>Decreased CB receptor binding and cannabinoid signaling in three brain regions of a rat model of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref199">
        <label>199</label>
        <element-citation publication-type="journal">
          <issue>7</issue>
          <page-range>772</page-range>
          <volume>65</volume>
          <year>2008</year>
          <pub-id pub-id-type="doi">10.1001/archpsyc.65.7.772</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Eggan</surname>
              <given-names>Stephen M.</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>Takanori</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>David A.</given-names>
            </name>
          </person-group>
          <source>Archives of General Psychiatry</source>
          <article-title>Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in Schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref200">
        <label>200</label>
        <element-citation publication-type="journal">
          <issue>10</issue>
          <page-range>2060-2071</page-range>
          <volume>35</volume>
          <year>2010</year>
          <pub-id pub-id-type="doi">10.1038/npp.2010.75</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Eggan</surname>
              <given-names>Stephen M</given-names>
            </name>
            <name>
              <surname>Stoyak</surname>
              <given-names>Samuel R</given-names>
            </name>
            <name>
              <surname>Verrico</surname>
              <given-names>Christopher D</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>David A</given-names>
            </name>
          </person-group>
          <source>Neuropsychopharmacology</source>
          <article-title>Cannabinoid CB1 Receptor Immunoreactivity in the Prefrontal Cortex: Comparison of Schizophrenia and Major Depressive Disorder</article-title>
        </element-citation>
      </ref>
      <ref id="ref201">
        <label>201</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>531-549</page-range>
          <volume>206</volume>
          <year>2009</year>
          <pub-id pub-id-type="doi">10.1007/s00213-009-1612-6</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Fernandez-Espejo</surname>
              <given-names>Emilio</given-names>
            </name>
            <name>
              <surname>Viveros</surname>
              <given-names>Maria-Paz</given-names>
            </name>
            <name>
              <surname>NÃºÃ±ez</surname>
              <given-names>Luis</given-names>
            </name>
            <name>
              <surname>Ellenbroek</surname>
              <given-names>Bart A.</given-names>
            </name>
            <name>
              <surname>Rodriguez de Fonseca</surname>
              <given-names>Fernando</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>Role of cannabis and endocannabinoids in the genesis of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref202">
        <label>202</label>
        <element-citation publication-type="journal">
          <issue>7</issue>
          <page-range>1037-1048</page-range>
          <volume>8</volume>
          <year>2008</year>
          <pub-id pub-id-type="doi">10.1586/14737175.8.7.1037</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>MÃ¼ller-Vahl</surname>
              <given-names>Kirsten R</given-names>
            </name>
            <name>
              <surname>Emrich</surname>
              <given-names>Hinderk M</given-names>
            </name>
          </person-group>
          <source>Expert Review of Neurotherapeutics</source>
          <article-title>Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref203">
        <label>203</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>789-802</page-range>
          <volume>235</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1007/s00213-017-4794-3</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Moran</surname>
              <given-names>Lauren V.</given-names>
            </name>
            <name>
              <surname>Stoeckel</surname>
              <given-names>Luke E.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Kristina</given-names>
            </name>
            <name>
              <surname>Caine</surname>
              <given-names>Carolyn E.</given-names>
            </name>
            <name>
              <surname>Villafuerte</surname>
              <given-names>Rosemond</given-names>
            </name>
            <name>
              <surname>Calderon</surname>
              <given-names>Vanessa</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>Justin T.</given-names>
            </name>
            <name>
              <surname>Ongur</surname>
              <given-names>Dost</given-names>
            </name>
            <name>
              <surname>Janes</surname>
              <given-names>Amy C.</given-names>
            </name>
            <name>
              <surname>Evins</surname>
              <given-names>A. Eden</given-names>
            </name>
            <name>
              <surname>Pizzagalli</surname>
              <given-names>Diego A.</given-names>
            </name>
          </person-group>
          <source>Psychopharmacology</source>
          <article-title>Nicotine-induced activation of caudate and anterior cingulate cortex in response to errors in schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref204">
        <label>204</label>
        <element-citation publication-type="journal">
          <issue>7</issue>
          <page-range>801-811</page-range>
          <volume>31</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1177/0269881117705071</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Smucny</surname>
              <given-names>Jason</given-names>
            </name>
            <name>
              <surname>Tregellas</surname>
              <given-names>Jason R</given-names>
            </name>
          </person-group>
          <source>Journal of Psychopharmacology</source>
          <article-title>Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging</article-title>
        </element-citation>
      </ref>
      <ref id="ref205">
        <label>205</label>
        <element-citation publication-type="journal">
          <issue>12</issue>
          <page-range>2513-2521</page-range>
          <volume>44</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1017/s0033291714000191</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Manrique-Garcia</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Zammit</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Dalman</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Hemmingsson</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Andreasson</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Allebeck</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <source>Psychological Medicine</source>
          <article-title>Prognosis of schizophrenia in persons with and without a history of cannabis use</article-title>
        </element-citation>
      </ref>
      <ref id="ref206">
        <label>206</label>
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>e94-e94</page-range>
          <volume>2</volume>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.1038/tp.2012.15</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Leweke</surname>
              <given-names>F M</given-names>
            </name>
            <name>
              <surname>Piomelli</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pahlisch</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Muhl</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gerth</surname>
              <given-names>C W</given-names>
            </name>
            <name>
              <surname>Hoyer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>KlosterkÃ¶tter</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hellmich</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Koethe</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <source>Translational Psychiatry</source>
          <article-title>Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia</article-title>
        </element-citation>
      </ref>
      <ref id="ref207">
        <label>207</label>
        <element-citation publication-type="journal">
          <issue>4</issue>
          <page-range>708-717</page-range>
          <volume>43</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1038/npp.2017.285</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Swerdlow</surname>
              <given-names>Neal R</given-names>
            </name>
            <name>
              <surname>Bhakta</surname>
              <given-names>Savita G</given-names>
            </name>
            <name>
              <surname>Talledo</surname>
              <given-names>Jo A</given-names>
            </name>
            <name>
              <surname>Franz</surname>
              <given-names>Daniel M</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>Erica L</given-names>
            </name>
            <name>
              <surname>Rana</surname>
              <given-names>Brinda K</given-names>
            </name>
            <name>
              <surname>Light</surname>
              <given-names>Gregory A</given-names>
            </name>
          </person-group>
          <source>Neuropsychopharmacology</source>
          <article-title>Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients</article-title>
        </element-citation>
      </ref>
      <ref id="ref208">
        <label>208</label>
        <element-citation publication-type="journal">
          <page-range>97-107</page-range>
          <volume>157</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1016/j.bcp.2018.07.009</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Ibarra-Lecue</surname>
              <given-names>InÃ©s</given-names>
            </name>
            <name>
              <surname>Pilar-CuÃ©llar</surname>
              <given-names>Fuencisla</given-names>
            </name>
            <name>
              <surname>Muguruza</surname>
              <given-names>Carolina</given-names>
            </name>
            <name>
              <surname>Florensa-Zanuy</surname>
              <given-names>Eva</given-names>
            </name>
            <name>
              <surname>DÃ­az</surname>
              <given-names>Ãlvaro</given-names>
            </name>
            <name>
              <surname>UrigÃ¼en</surname>
              <given-names>Leyre</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>Elena</given-names>
            </name>
            <name>
              <surname>Pazos</surname>
              <given-names>Angel</given-names>
            </name>
            <name>
              <surname>Callado</surname>
              <given-names>Luis F.</given-names>
            </name>
          </person-group>
          <source>Biochemical Pharmacology</source>
          <article-title>The endocannabinoid system in mental disorders: Evidence from human brain studies</article-title>
        </element-citation>
      </ref>
      <ref id="ref209">
        <label>209</label>
        <element-citation publication-type="journal">
          <issue>1</issue>
          <page-range>20-29</page-range>
          <volume>19</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1038/mp.2013.136</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Poels</surname>
              <given-names>E M P</given-names>
            </name>
            <name>
              <surname>Kegeles</surname>
              <given-names>L S</given-names>
            </name>
            <name>
              <surname>Kantrowitz</surname>
              <given-names>J T</given-names>
            </name>
            <name>
              <surname>Slifstein</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Javitt</surname>
              <given-names>D C</given-names>
            </name>
            <name>
              <surname>Lieberman</surname>
              <given-names>J A</given-names>
            </name>
            <name>
              <surname>Abi-Dargham</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Girgis</surname>
              <given-names>R R</given-names>
            </name>
          </person-group>
          <source>Molecular Psychiatry</source>
          <article-title>Imaging glutamate in schizophrenia: review of findings and implications for drug discovery</article-title>
        </element-citation>
      </ref>
      <ref id="ref210">
        <label>210</label>
        <element-citation publication-type="journal">
          <volume>8</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.3389/fpsyt.2017.00118</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>de Jonge</surname>
              <given-names>Jeroen C.</given-names>
            </name>
            <name>
              <surname>Vinkers</surname>
              <given-names>Christiaan H.</given-names>
            </name>
            <name>
              <surname>Hulshoff Pol</surname>
              <given-names>Hilleke E.</given-names>
            </name>
            <name>
              <surname>Marsman</surname>
              <given-names>Anouk</given-names>
            </name>
          </person-group>
          <source>Frontiers in Psychiatry</source>
          <article-title>GABAergic Mechanisms in Schizophrenia: Linking Postmortem and In Vivo Studies</article-title>
        </element-citation>
      </ref>
      <ref id="ref211">
        <label>211</label>
        <element-citation publication-type="journal">
          <page-range>233-245</page-range>
          <volume>45</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1016/j.neubiorev.2014.06.005</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Selvaraj</surname>
              <given-names>Sudhakar</given-names>
            </name>
            <name>
              <surname>Arnone</surname>
              <given-names>Danilo</given-names>
            </name>
            <name>
              <surname>Cappai</surname>
              <given-names>Alessandra</given-names>
            </name>
            <name>
              <surname>Howes</surname>
              <given-names>Oliver</given-names>
            </name>
          </person-group>
          <source>Neuroscience &amp; Biobehavioral Reviews</source>
          <article-title>Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies</article-title>
        </element-citation>
      </ref>
      <ref id="ref212">
        <label>212</label>
        <element-citation publication-type="journal">
          <issue>11</issue>
          <page-range>1036-1047</page-range>
          <volume>48</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1177/0004867414533838</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Sara</surname>
              <given-names>Grant E</given-names>
            </name>
            <name>
              <surname>Burgess</surname>
              <given-names>Philip M</given-names>
            </name>
            <name>
              <surname>Malhi</surname>
              <given-names>Gin S</given-names>
            </name>
            <name>
              <surname>Whiteford</surname>
              <given-names>Harvey A</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>Wayne C</given-names>
            </name>
          </person-group>
          <source>Australian &amp; New Zealand Journal of Psychiatry</source>
          <article-title>Stimulant and other substance use disorders in schizophrenia: Prevalence, correlates and impacts in a population sample</article-title>
        </element-citation>
      </ref>
      <ref id="ref213">
        <label>213</label>
        <element-citation publication-type="journal">
          <issue>6</issue>
          <page-range>515-520</page-range>
          <volume>190</volume>
          <year>2007</year>
          <pub-id pub-id-type="doi">10.1192/bjp.bp.106.024448</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Barnett</surname>
              <given-names>Jennifer H.</given-names>
            </name>
            <name>
              <surname>Werners</surname>
              <given-names>Ursula</given-names>
            </name>
            <name>
              <surname>Secher</surname>
              <given-names>Sandra M.</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>Katherine E.</given-names>
            </name>
            <name>
              <surname>Brazil</surname>
              <given-names>Rossa</given-names>
            </name>
            <name>
              <surname>Masson</surname>
              <given-names>Kim</given-names>
            </name>
            <name>
              <surname>Pernet</surname>
              <given-names>David E.</given-names>
            </name>
            <name>
              <surname>Kirkbride</surname>
              <given-names>James B.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>Graham K.</given-names>
            </name>
            <name>
              <surname>Bullmore</surname>
              <given-names>Ed. T.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>Peter B.</given-names>
            </name>
          </person-group>
          <source>British Journal of Psychiatry</source>
          <article-title>Substance use in a population-based clinic sample of people with first-episode psychosis</article-title>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>